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Abstract 
The most common method of vaccine delivery uses the needle and syringe, which 
was invented in the mid-1800s. This form of vaccine administration is effective but 
unpopular, requiring a liquid suspension be injected into the muscle, subcutaneous fat or 
skin. The limitations associated with needle and syringe administration are related to the 
risk of needle-stick injuries, needle reuse and needle phobia. In addition, the needle and 
syringe does not deliver the vaccine optimally to antigen presenting cells within the skin 
resulting in relatively poor immune responses when compared to intradermal delivery of 
vaccine.  
 
Alternate methods of delivery have been developed in an effort to accurately target 
specific cells in the skin without the limitations of the needle and syringe. These range 
from powdered and liquid jet injections to electroporation and ultrasound devices. A more 
recent area of trans/intra cutaneous drug/vaccine delivery is the use of patches containing 
arrays of micro-scale sized needles or projections. The microneedles/microprojections 
penetrate the upper layers of the skin resulting in perforations for drug delivery and 
diffusion. 
 
Designed in the Kendall Group, the Nanopatch (NP) differs significantly from current 
forms of microneedles in relation to size, spacing and density of projections in an array. 
The NP morphology was carefully designed based on a probability analysis to maximise 
direct targeting of deposited antigen to the abundant immune cells in the skin. In relation to 
immunogenicity, preliminary assessment within the mouse model has shown that NP 
immunisation with Fluvax2008® has achieved 100-fold dose reduction compared to the 
needle and syringe – this is also a factor of 10 greater than what has been achieved with 
the existing microneedles (up to 700 µm in length and less than 321 projections per cm2). 
 
In addition to solid microneedles/NPs, various sizes and compositions of dissolving 
microneedles have also been fabricated. In general, fabrication of dissolving / 
biodegradable microneedles utilise complex techniques and harsh conditions (high 
temperature, extreme pH, etc). In addition many of the dissolving microneedles are 
tailored for sow release (hours to days for complete dissolution). These conditions have 
limited dissolving microneedles to the delivery of drugs and robust biomolecules, instead 
of sensitive vaccines.  
 VIII 
 
This thesis aims to address the shortcomings of current dissolving microneedles in 
relation to their fabrication, dissolution and use as a delivery platform, by introducing a 
fabrication method for dissolving Nanopatches (dNPs) and analysing the mechanisms of 
administration, dissolution and diffusion of microstructures within skin. The data contains 
both applied and fundamental research. The applied focus relates to the development of 
an alternate vaccine/drug delivery platform (dNPs) for the targeted delivery of vaccines 
into the skin. Once a reproducible method is developed, the dNPs will be used to deliver 
selected antigens as test cases for the platform. 
 
The fundamental focus of this project is to provide information on the structure-
dependant diffusion characteristics of the skin and more specifically the diffusion of 
dNP/NP delivered payloads. The skin will be analysed using fluorescence confocal and 
multiphoton microscopy to assess the payload distribution within the stratum corneum, 
viable epidermis and dermis. Fluorescence microscopy will also be used to image and 
analyse important immune cells in the skin and their migration kinetics post dNP/NP 
delivery.  
 
The data obtained will benefit both direct (physically targeted) and indirect (topically 
applied without physical enhancement) drug delivery to the skin – providing insight into the 
distribution of payloads within the skin and also the impact of direct approaches on 
immune cell migration. Overall, the data in this project will benefit the microfabrication, 
micro-mechanics, pharmaceutical and dermatology fields, and more specifically cutaneous 
drug/vaccine delivery. 
 
Keywords 
Vaccine delivery, drug delivery, microneedles, transdermal, nanoindentation, solid 
formulation, microfabrication 
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CHAPTER 1 
Introduction 
1.1 Introduction and project summary 
Having been invented in 1853, the needle and syringe is used as the delivery 
device for approximately 16 billion injections annually (prophylactic and therapeutic [1]). 
Out of the 16 billion injections, 5% (0.8 billion [1]) are associated with prophylactic 
(vaccine) administration – for which injection is the most common method of vaccine 
administration globally. The needle and syringe is used to inject liquid suspensions of 
vaccines into the muscle subcutaneous fat or skin. However, this approach has several 
significant limitations, including:  
 accidental needle-stick injuries occurring in both developed and developing 
countries (resulting in more than 500,000 deaths annually [2]);  
 a large number of infections caused by the improper, unsterile re-use and disposal 
of needles and syringes (contributing to 21 million Hep B cases, 2 million Hep C 
cases and 260,000 HIV cases globally [1], with approximately 30% of unsafe 
injections in developing countries [3]); 
 the need for cold-chain transport and storage conditions (contributing up to 80% of 
cost in vaccination programs [4]);  
 poor compliance in vaccination programs due to needle phobia, and also; 
 multiple doses and relatively large quantities of vaccines may be required for lasting 
immunity. 
Even with just under one billion prophylactic injections, 17 million people die annually [5] 
from infectious diseases (most in developing countries), many of which could be prevented 
with vaccination. More specifically, in 2002 alone 2.5 million children died out of a total 
10.5 million child deaths globally from diseases for which vaccines are currently available 
[6] (summarised in Figure 1.1). 
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Figure 1.1. Causes of 2.5 million child deaths (where child is defined as 5 years or 
younger and the death is attributed to a disease where the vaccine is available) out of 10.5 
million child deaths globally in 2002. Figure adapted from WHO [6]. 
 
Researchers have overcome some of these disadvantages by fabricating arrays of 
micrometer-scale needles/projections that deliver vaccines to the densely packed antigen 
presenting cells (APCs) present in skin (Figure 1.2)[7, 8]. Microneedles penetrate the 
outer layers of the skin resulting in micro-perforations, increasing permeability and drug 
absorption. By coating vaccines onto the surface of microneedles, payloads can be 
delivered to specific immunogenic layers within the skin. Standard intramuscular injection 
consists of delivering the antigen to the muscle, often leading to limited uptake by APCs. In 
contrast, targeted delivery within the skin can increase the amount of vaccine uptake by 
antigen by APCs without the limitations of the needle and syringe. 
 
A recent development related to the microneedle field was the invention of the 
Nanopatch (NP) [9]. Designed in the Kendall Group, the NP differs significantly from 
current forms of microneedles in relation to size, spacing, density and the number of 
projections in an array (Figure 1.2). Current microneedles are up to 700 µm in length and 
contain less than 321 projections per cm2 [10]. By contrast, the NP consists of 
approximately 100 m projections in length that are 70 m apart with an array density 
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>20,000 projections/cm2. The NP morphology was carefully designed based on a 
probability analysis to maximise direct targeting of deposited antigen to thousands of 
immune cells in the skin [11]; without relying upon diffusion In relation to immunogenicity, 
preliminary assessment within the mouse model has shown that NP immunisation with 
Fluvax2008® has achieved 100-fold dose reduction compared to the needle and syringe – 
this is also a factor of 10 greater than what has been achieved with the current much 
larger, sparse microneedles. [11]. 
 
 
Figure 1.2. Schematic adapted from Hegde et al. 2011 [12],comparing traditional modes 
of needle injection of vaccines compared to recent microneedle and NP modes of delivery. 
 
In addition to solid microneedles/NPs, various sizes and compositions of dissolving 
microneedles have also been fabricated. In general, fabrication of dissolving / 
biodegradable microneedles requires complex techniques and harsh conditions (e.g. 
particle encapsulation and high temperatures ranging from 55oC to 230oC [13-17]). In 
addition many of the dissolving microneedles may require hours to days for complete 
dissolution once applied to the skin [18]. Overall, these conditions have limited dissolving 
microneedles to the delivery of drugs and robust biomolecules, instead of sensitive 
vaccines. This thesis aimed to address the shortcomings of current dissolving 
 4 
microneedles in relation to their fabrication, dissolution and use as a delivery platform. This 
was achieved by introducing a fabrication method for dissolving Nanopatches (dNPs) and 
analysing the mechanisms of administration, dissolution and diffusion of the 
microstructures within skin. 
 
This thesis commences with a literature review detailing current research on 
vaccines and their delivery to the skin, with an emphasis on microneedle delivery. The 
review highlights the importance of using alternate methods for the delivery of large 
biomolecules to the skin instead of the hypodermic needle and syringe. The review also 
highlights the limited progress made using dissolving microneedles in relation to vaccine 
delivery due to limitations in design and fabrication of current techniques. The literature 
review was followed by common materials and experimental procedures used throughout 
the project. This was followed by chapters containing data obtained during this project in 
context to the issues raised within the literature review. Finally, the thesis concludes with a 
chapter discussing potential future work and a conclusions chapter summarising the key 
findings of the project. 
 
In summary this thesis introduces a method of fabricating dNPs for specific, 
controlled and rapid release of payloads into the skin. The key advantages of the novel 
fabrication method designed that distinguish dNPs from the much larger dissolving 
microneedles are: 
 Ability to fabricate microstructures (< 200 m in size) with picolitre quantities of 
antigen potentially improving vaccine usage, 
 mild fabrication conditions that maintain vaccine integrity, 
 much finer control over payload deposition within moulds, 
 ability to layer multiple payloads in a single array, 
 enhanced immunogenicity, 
 dose-sparing and,  
 rapid dissolution and diffusion. 
The findings within this thesis would stem from both the applied and fundamental nature of 
the project contributing to the development, delivery and dissolution of biological payloads 
using dNPs as an alternate platform for vaccine delivery. It would also benefit direct 
(physically targeted) and indirect (topically applied) drug delivery to the skin providing 
insight into the distribution of payloads within the skin and also the impact of direct 
approaches on immune cell migration.  
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1.2 Scope of thesis  
This PhD project contains both applied and fundamental research. The applied 
focus was to develop an alternate vaccine/drug delivery platform (dNPs) for the targeted 
delivery of vaccines into the skin. This was achieved by first designing a fabrication 
method utilising the gold-coated silicon NP developed in the Kendall Group. The method 
was developed and improved with an emphasis on techniques suitable for encapsulation 
and delivery of sensitive biological. Once a reproducible method was developed, the dNPs 
were used to deliver selected antigens as test cases for the platform. Characterisation and 
optimisation was ongoing throughout the PhD project. The data obtained would provide 
valuable insight into the development, delivery and dissolution of biological payloads using 
dNPs as an alternate platform for vaccine delivery.  
 
The fundamental focus of this PhD project was to provide information on the 
structure-dependant diffusion characteristics of the skin and more specifically the diffusion 
of dNP/NP delivered payloads. The skin was analysed using fluorescence confocal and 
multiphoton microscopy to assess the payload distribution within the stratum corneum, 
viable epidermis and dermis. Fluorescence microscopy was used to image and analyse 
important immune cells in the skin and their migration kinetics post dNP/NP delivery. The 
data obtained would benefit both direct (physically targeted) and indirect (topically applied) 
drug delivery to the skin providing insight into the distribution of payloads within the skin 
and also the impact of direct approaches on immune cell migration. Overall the project can 
be divided into three core objectives as detailed in the resulting paragraphs. 
 
1.2.1 Objective One – development, fabrication and characterisation dNPs 
The key area of objective one encompasses the applied aspect of the project, which 
was the fabrication of dissolving microprojections using the gold-coated silicon NP as a 
template. The core question that defines objective one was: 
 
Could arrays of reproducible dissolving microstructures (<200 m) be produced in a 
manner, designed to incorporate and deliver sensitive biologicals? 
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Due to the scale (micron) and accuracy required to replicate the NP master 
structures, silicone microfluidic techniques was used in designing a moulding technique for 
dNPs. The moulds were then used to cast dNPs with excipients commonly used in the 
pharmaceutical/microneedle field (e.g. sugars and cellulose derivatives). The casting 
technique was developed to reproducibly fill the whole mould with emphasis on 
concentrating the payload within the projections and not within the backing of the dNP. 
The data obtained would aid in the improvement and design of delivery polymer/dissolving 
microstructures. 
 
1.2.2 Objective Two – administration of dNPs into skin 
For payloads to be delivered to skin using dNPs, the dNPs must be able to 
penetrate the stratum corneum and dissolve, releasing the payload. Research has shown 
much larger biodegradable structures capable of skin penetration. Firstly, administration 
and penetration characteristics of dNP scaled microstructures within skin are yet to be 
explored. Secondly, there have been no reports published on dissolving microstructures 
for the delivery of sensitive biological (protein, DNA, etc.). Therefore the question driving 
objective two was: 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
The initial focus of objective two was to develop an administration process for the 
dNPs. Once successful administration was achieved (i.e. the majority of microprojections 
penetrate the skin), the delivery was characterised and quantified. Histology and 
microscopy was an important tool for the characterisation of penetration depth and 
diffusion. Delivery was quantified in regards to the total payload delivered and percentage 
of penetrated projections.  
 
The overall aim of developing dNPs was for use as a platform for the delivery of 
vaccines to the skin. Therefore, assessing whether the dNPs can be used to deliver 
antigens for the generation of systemic immune responses was an important aspect of this 
project. Various antigens were used with initial test cases using ovalbumin protein – a 
simple model antigen. The dNPs were then used to deliver a commercial influenza vaccine 
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(Fluvax®) as a test case. This would provide a solid foundation for the use of dNPs for 
vaccine delivery. 
 
1.2.3 Objective Three – diffusion properties of skin and payload kinetics post NP 
administration 
As stated, this thesis contains both applied and fundamental aspects. The 
fundamental approach stems from the need to gain further understanding of the diffusive 
properties of the skin and the kinetics of payload/immune-cell diffusion/migration. The 
fundamental question at the core of objective three was: 
 
What governed the diffusion behaviour within the upper layers of the skin and how does 
this impact the distribution of skin delivered payloads?  
 
This objective utilises the minimally invasive nature of the NP design to deposit 
payloads in the skin followed by high resolution imaging and analysis using multiphoton 
and fluorescence confocal microscopy. The long term kinetics of payload deposition and 
preliminary analysis of immune cell migration post NP/dNP administration was 
investigated, providing important information on the mechanisms of microneedle 
intracutaneous delivery. 
 
1.2.4 Summary 
This PhD project has both applied and fundamental aspects. The application of this 
PhD project was in the development and characterisation of a novel platform for vaccine 
delivery. New fabrication techniques were developed, designed to encapsulate and deliver 
sensitive payloads rapidly into skin. Although the fabrication process was geared towards 
applied research, fundamental scientific data on the mechanical, crystalline and diffusion 
properties of various solid formulations was investigated. I also provided fundamental 
knowledge on the enhanced structure dependant diffusion properties within the skin and 
the local kinetics of immune cells following dNP/NP administration, which would benefit the 
dermatology field and more importantly cutaneous drug/vaccine delivery.  
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CHAPTER 2 
Literature review 
 
2.1 Overview of vaccine administration 
Vaccines are prophylactic treatments that stimulate the body’s ability to eliminate 
pathogens by antibody and cellular immune responses. The immune system of a 
vaccinated individual, when challenged by a pathogen, responds at a greater speed and 
magnitude than in a naïve person, thereby mitigating disease [19, 20]. The efficacy in 
disease prevention of vaccines led to the implementation of many vaccination programs – 
improving the health of individuals by shortening the duration or completely preventing an 
infection – ultimately saving lives.  This in turn led to significant decreases in cases of 
multiple diseases such as pertussis and diphtheria, with the eradication of smallpox from 
the world in 1980 [19]. More recently, the introduction of the first Human Papillomavirus 
vaccine on the market is expected to reduce the likelihood of cervical cancer cases by at 
least 30% in Australia alone [21].   
 
2.1.1 Types of vaccines 
One of the earliest forms of vaccine are live virus vaccines – where an individual is 
vaccinated with a non-virulent pathogen from another animal species or bacterium (e.g. 
Smallpox vaccine was a variant from cows [19, 20]) or by human pathogens, which have 
been attenuated. Live virus vaccines elicit strong cellular and humoral responses, which in 
some cases may confer long-lasting immunity with only one or two vaccinations [22]. 
However, not all pathogens have a non-virulent form in other animal species, therefore 
another approach is to attenuate (weaken) the pathogen for use as a vaccine [23]. 
Attenuated viral vaccines also elicit strong immune responses and one such example is 
the Measles, Mumps and Rubella vaccine (MMR). The use of live, attenuated viruses is 
subject in some cases to the possibility that the virus can mutate and become pathogenic. 
This limits its use in the very young, elderly, pregnant and individuals with compromised 
immune systems [24]. Another factor, not limited to live virus vaccines, is their costly 
manufacture process and transportation. 
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An alternate approach with the potential for fewer adverse events to attenuated viral 
vaccines is the use of killed viruses. In many cases, vaccines comprising inactivated 
viruses induce immune responses in individuals to a lesser extent than live attenuated viral 
vaccines. Their often lower immunogenicity sometimes requires a larger amount of antigen 
per dose and/or adjuvant. The increased dosage and adjuvant can lead to redness, pain 
and swelling localised to the site of injection [25]. 
 
Bacterial pathogens on the other hand can produce toxins that can be vaccinated 
against. Toxoid vaccines consist of an inactivated toxin secreted by a particular pathogen. 
The individual mounts an immune response to the inactivated toxin leading to the 
production of antibodies, which bind to the toxin. This assists in the removal of the toxin 
and also prevents the toxin binding to receptors within the body. Both diphtheria and 
tetanus vaccines consist of toxoids [23]. 
 
Instead of using whole pathogens, vaccines can be developed with the pathogens’ 
antigenic components, resulting in lower adverse reactions. The creation of subunit 
vaccines requires identification of specific antigens required for a potent immune 
response. In order to improve on the immune response to subunit vaccines, these 
antigens were attached to specific proteins through chemical conjugation. These 
‘conjugate’ vaccines were specifically developed to vaccinate against pathogens with a 
polysaccharide coating. Conjugate vaccines stemmed from early polysaccharide vaccines 
such as the first Haemophilus influenzae type b (Hib) vaccine. However, limitations in 
immunogenicity and lack of response in infants less than 18 months of age led to alternate 
Hib vaccines being developed and removal of the conjugate Hib vaccine from the market. 
Second generation Hib vaccines consisted of polysaccharides conjugated to carrier 
proteins, which led to protective immunity in young infants as well as protection from Hib 
carriage [26]. 
 
In an effort to address the limitations of conventional vaccines, DNA vaccines are 
emerging as promising candidates. In their simplest forms, DNA vaccines consist of 
circular plasmids with genes encoding an antigen and a promoter/terminator for 
expression in mammalian cells [27]. Advantages of DNA vaccines include the ability to 
induce cellular and humoral immune responses, safety and stability. These factors, 
coupled with the ease and cost of manufacturing DNA vaccines, make them a 
hypothetically ideal candidate for new vaccines. However, concerns regarding DNA 
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vaccines have risen due to early observations that in-vivo transfection was an inefficient 
process with muscle cells achieving greatest uptake and expression [27-29].   Low level 
antigen production, inefficient cellular delivery of DNA plasmids and poor stimulation of the 
innate immunity are believed to be causes of low potency of DNA vaccines in larger 
mammals preventing them from being a successful commercial option [30]. With this in 
mind many advances in DNA vaccines are being pursued in the areas of DNA vectors, 
DNA delivery and site of delivery [30-33]. 
 
It is clear that there are many challenges in creating and delivering vaccines, with 
diseases such as HIV, malaria and tuberculosis continuing to cause immense suffering 
worldwide, resulting in over six million related deaths annually [34]. The reasons for this 
are complex, including a lack of understanding of both the disease itself and mechanisms 
of the immune response. Current advances in research, in particular molecular biology and 
biotechnology are leading to improvements in both vaccine composition and delivery. 
 
Another key driving force for the development of new vaccines is the possibility of 
an epidemic or pandemic and its international impact. Influenza is one such example of an 
infectious virus that has killed millions of people with multiple outbreaks over the course of 
history. Three influenza pandemics have occurred in the 20th Century killing approximately 
40 million, 2 million and 1 million people in 1918, 1957 and 1968, respectively [35]. It is 
estimated that the economic cost associated with another influenza pandemic would be 
between US$71-166 billion [36]. This can be prevented with the possibility of economic 
returns if mass vaccination is conducted rapidly and effectively [36]. Even without 
considering the many other current and emerging infectious diseases, there is a clear 
need for efficient vaccination, not only for economic reasons but also to save lives. 
 
2.1.2 Vaccine administration 
Administration of vaccines has yet to significantly evolve, with standard application 
and route being intramuscular (IM) or subcutaneous injection using the needle and syringe 
– which was invented in 1853 [37]. This method has several limitations. Accidental needle-
stick injuries occur in both developed and developing countries with approximately 
400,000 needle-stick injuries occurring annually in USA hospitals alone [38]. A large 
number of infections are caused by the improper, unsafe use and disposal of needle and 
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syringes. Needle phobia, which can be attributed to reduced compliance in vaccination 
programs is another major drawback to the needle and syringe [39]. 
 
Due to the limitations of IM/SC injection, alternate delivery methods and routes are 
being explored (Figure 2.1 and Table 2.1.). Mucosal surfaces provide a physical barrier 
between the body cavities and the external environment. It can be found in literature that 
all mucosal surfaces have been investigated as possible routes for vaccination (oral [40, 
41], nasal [42], lung [43], rectal [44], conjunctival [45] and vaginal [41]). However, research 
has been largely focused on oral, nasal and respiratory (lung) administration. Currently, 
mucosal immunisation is the primary needle-free method of immunisation used in wide-
scale vaccination programs – i.e. oral vaccine delivery. 
 
 
Figure 2.1. Schematic showing a summary of vaccination sites and methods. 
Adapted from Mitragotri 2005 [46]. 
 
However there are still limitations in oral delivery with both the polio (Sabin oral 
polio vaccine) and rotavirus (Rotashield®) oral vaccine being removed in the 1990s from 
the US market due to complications (vaccine-associated paralytic poliomyelitis and 
intussusceptions respectively). A significant limitation is that in general oral vaccines often 
require multiple doses with large amounts of antigen to induce sufficient immune response 
due to vaccine degradation [47, 48]. 
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Nasal delivery of vaccines has also gained attention, especially in relation to 
respiratory based pathogens e.g. Influenza. However, it is limited to vaccine type, with only 
one live vaccine and one subunit viral vaccine ever reaching the market [47, 48]. 
Adjuvants have been explored to increase the immunogenicity, however this needs to be 
done with careful consideration and research. In the 2000/2001 influenza season a 
Switzerland licensed nasal vaccine – Nasalflu®, was taken off the market due to a strong 
correlation with increased risk of Bell’s palsy [49]. This association was related to the 
adsorption of the potent mucosal adjuvant LT (heat-labile enterotoxin) [47]. 
 
Like nasal delivery, lung delivery (aerosol delivery) of vaccines is an exciting route 
of interest especially in relation to respiratory based pathogens. The vaccine is delivered in 
particulate form (liquid or dry-powder) to the lungs and respiratory tract using devices such 
as nebulizers, metered-dose inhalers and dry-powder inhalers[50]. Aerosol delivery 
requires the generation of small microparticles (< 5 m) of well-defined sizes so as to be 
confident of targeted delivery [48, 51, 52]. Due to the location of the mucosal surface and 
immune response there is concern about stimulation of inflammatory responses in the 
lungs post vaccine delivery, especially in relation to individuals suffering from airway 
diseases [48]. This route has showed promise with a measles vaccine [48] and also dry-
powdered tuberculosis vaccines [53, 54], however there is a need for long-term clinical 
studies showing the effectiveness and safety of such vaccine delivery methods. 
 
Recently, a non-mucosal delivery route, receiving much interest is cutaneous 
delivery. Cutaneous delivery, unlike mucosal delivery has the advantage of being 
compatible with a wide range of delivery methods (as discussed later) and has a higher 
tolerance to adjuvants and vaccines than the mucosa. The skin, unlike muscle, contains 
an abundance of cells (APCs) capable of inducing high immune responses [55], (Figure 
2.2). This is unlike needle and syringe IM injections, which are shown to require larger 
amounts of vaccine to improve the likelihood of vaccine uptake by immunologically-
sensitive cells and hence an immune response [56]. In addition, improved immunogenicity 
over the IM route may be required to not only improve the use of current multi-dose 
vaccines but assist in the introduction of new vaccines against diseases such as Malaria, 
TB and HIV. In the case of pandemics the amount of vaccines produced may not be 
enough to cover the doses required to vaccinate the affected regions. Therefore, there is a 
great need to explore dose sparing methods of vaccinations.  
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Table 2.1: Summary of the advantages and disadvantages of different vaccination routes 
Vaccination route Advantages Disadvantages 
Intramuscular  Easy to administer 
 Socially acceptable 
 Most common route of 
delivery 
 Avoids first pass effects* 
 Invasive 
 Painful 
 Requires liquid suspensions 
 Cold chain 
 Some vaccines require adjuvants 
 Risk of cross-contamination 
 Risk of needle stick injuries 
 Requires skilled personnel 
Oral  Non-invasive 
 Easy to administer 
 Socially acceptable 
 Rapid administration 
 First pass effects (GI tract, liver) 
 Large vaccine amount required 
 Low immunogenicity due to 
degradation 
 
Nasal  Non-invasive 
 Easy to administer 
 Avoids first pass effects 
 Requires less vaccine 
than oral administration 
 Some vaccines require adjuvants 
 Relatively low immunogenicity 
compared to delivered antigen 
mass 
 Aerosol production complex 
 Infant delivery difficult 
Lung  Non-invasive 
 Avoids first pass effects 
 Can induce systemic 
responses 
 Aerosol production complex 
 Inflammation and safety concerns 
 Devices may be expensive 
 Infant delivery difficult 
 
Skin  Minimally invasive 
 Highly immunogenic 
 Versatile delivery 
approaches 
 Large target area 
 Avoids first pass effects 
 Stratum corneum barrier 
 Risk of pain, bleeding 
 Some devices are complex 
 Potentially expensive devices 
 Potential for cross contamination  
*Degradation of antigen within gastro-intestinal tract and liver. 
 
2.2 Structure and composition of skin 
The skin is the largest organ of the body and like mucosal surfaces is the primary 
barrier to the external environment and pathogens. Skin is a highly complex multilayered 
material comprising both epithelial (epidermis) and connective tissue (dermis). The layered 
epidermis consists of an outer physical barrier of dead cells arranged in a ‘brick and 
mortar’ structure known as the stratum corneum (SC) followed by a highly cellular aqueous 
region known as the viable epidermis (VE). The dermis however, contains relatively few 
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cells and is composed of the extracellular matrix (ECM), sensory nerve endings and blood 
vessels (Figure 2.1).  
 
 
Figure 2.2. Schematic images showing the layers of the skin with key immune cells – 
Langerhans cells in epidermis and dermal dendritic cells in dermis adapted from Kupper 
T.S. Nature Reviews Immunology 2004 [57, 58]. 
 
2.2.1 Stratum Corneum 
As stated, the skin is the primary defence to the external environment; more 
specifically this role is the responsibility of the stratum corneum (SC). As stated, the SC is 
known as a brick and mortar structure, with corneocytes (brick) being surrounded by a lipid 
(mortar) matrix [59]. Corneocytes are nonviable flat cells lacking cell nuclei and organelles 
derived from the keratinocytes in the lower epidermis. The skin is continuously 
regenerating, whereby keratinocytes move up from the lower epidermis changing in 
structure to become corneocytes (desquamation).  
 
The SC is the rate limiting barrier, with the lipids (approx. 20% of SC volume [60]) 
acting as a barrier for water and large proteins, and the corneocytes acting as the physical 
barrier against chemicals and mechanical damage. However, the SC relies on a critical 
balance of lipids, corneocytes and cellular regeneration to maintain adequate moisture 
content (15-30%) and flexibility [60-62]. Overall, in relation to transdermal/intra-cutaneous 
delivery, the SC is the barrier which must be overcome by either mechanical or chemical 
stimulus for successful administration.  
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2.2.2 Viable epidermis 
Directly below the SC is the VE. The VE is a highly cellular aqueous layer (approx. 
70% hydration [61]) consisting primarily of four main cell types – keratinocytes, 
melanocytes, Langerhans cells and Merkel cells [63]. Keratinocytes are responsible for the 
overall structural integrity of the epidermis and originate in the basal layer. As the skin 
regenerates in the desquamation process, keratinocytes migrate towards the surface of 
the skin becoming elongated and flat. There is also an increase in lipid synthesis and the 
amount of keratin structural protein produced by the keratinocytes. As mentioned in the 
previous section, once the keratinocytes lose their nuclei and organelles they are classified 
as corneocytes. 
 
The other important cell type in the viable epidermis is the Langerhans cells, which 
are a subset of important immunological dendritic cells. Although these APCs only 
represent 3-5% of cells in the epidermis, their surface area accounts for approximately 
27% of total cellular surface area [64]. The large surface area is attributed to the many 
long dendrites protruding from the cell body designed to recognise and internalise foreign 
bodies (pathogens). Langerhans cells are important immune cells in the skin acting as 
sentinels, regulating the immune system and even though there is still a debate over their 
exact role, there is no doubt that they play a role in intra-cutaneous vaccine delivery. 
 
2.2.3 Dermis 
The dermis, which is separated from the viable epidermis by the basal layer, is 
where the connective tissue layer in the skin begins. Unlike the epidermis which is highly 
cellular, there are relatively few cells in the dermis and instead it is composed of the ECM 
– structural protein fibres, (primarily collagen and elastin) as well as proteoglycans. 
Collagen accounts for approximately 77% of fat free dry weight of dermal tissue and 
approximately 90 % of all dermal protein [65, 66]. Besides the ECM, the dermis contains 
sensory nerve endings and blood capillaries responsible for nutrient supply to the 
epidermis. 
 
Like the epidermis, the dermis also contains important immunological cells. 
Discovered much later than Langerhans cells, dermal dendritic cells are believed to be a 
significant cell type in providing an immune response to invading pathogens [67, 68]. Even 
more recent is the discovery of dermal Langerin+ dendritic cells, which are also believed to 
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play an important role in the immune system, however further characterisation is needed 
[69]. 
 
2.3 Immunological significance of the skin 
The immune system can be divided into two main areas, known as the innate and 
adaptive immune systems (Figure 2.3). The innate immunity is a non-specific response of 
the body to invading antigens whereas the adaptive immunity is a highly specific response 
to invading antigens. An antigen is any foreign body that elicits an immune response. 
Adaptive immunity can be further divided into two main responses, being a humoral 
response, which is primarily by B-cells (antibody response) or a cell-mediated response, 
which is primarily controlled by T-cells (Figure 2.4). Humoral responses consist of the 
production of specific antibodies that bind specifically to antigens on the surface of the 
invaded pathogen. Antibodies inactivate antigens in the extracellular fluid by multiple 
mechanisms – tagging pathogens for destruction, binding pathogens to form aggregates 
and/or binding and blocking surface receptors on the pathogens [70]. Infected cells on the 
other hand, are not removed by antibodies and instead are destroyed by T-cells in a cell 
mediated response. T-cells specifically recognise and kill infected cells by binding to 
specific receptors on their surface as a result of infection. However, the immune response 
is as clear cut with T-cells being further divided into two main groups – cytolytic T-cells 
that, as described, target and kill infected cells, and CD4+ T-helper cells that interact with 
B-cells, assisting in their proliferation and antibody production. 
 18 
 
 
Figure 2.3. An overview of the two main sectors of the immune system – innate and 
adaptive immunity. a) Phagocytosis of a bacterial cell; b) bacterial cell killing by 
complement; c) apoptosis induced by a natural killer cell; d) induction of viral resistance by 
interferon-α; e) neutralisation by antibodies; f) antibody coating of bacterial cell; and g) 
apoptosis induced by T-cell. Adapted from Cell and Molecular Biology 4th Edition [70].  
 
As a result of an immune response to a particular antigen, the body produces 
memory cells which circulate the body long after the antigen has been removed. For 
example, if an individual previously mounted an immune response against Antigen X, it 
would produce memory cells that specifically recognise Antigen X. The memory cells 
circulate in the body and if in  future the individual comes in contact with Antigen X, the 
immune system ‘remembers’ the antigen and coordinates a rapid response, much faster 
than the original infection of Antigen X. This phenomenon is known as adaptive immunity 
and results in individuals being able to respond to an antigen in a rapid manner before 
serious symptoms, if any, develop [70].  
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Figure 2.4. An overview of the two main responses of the adaptive immunity – cellular and 
humoral (antibody) responses. Molecules released by T-cells aid proliferation (1 and 2); 
antibody production (3); and macrophage activation (4) [71]. 
 
IM and SC injections are the standard procedure for vaccine delivery and are 
painful, often requiring multiple vaccinations for a single vaccine. This leads to compliance 
issues due to needle phobia [72]. Accurately targeting specific layers within the skin can 
lead to delivery with minimal or no pain and bleeding compared to IM injections. This is 
because the pain receptors and blood vessels are located deep in the dermis and 
underlying tissue [70]. However as stated previously, the skin is an effective barrier to the 
external environment and administration of vaccines to/through the skin is limited [56]. 
 
Besides acting as a physical barrier against invading pathogens, the skin has a 
cellular component in the form of an abundance of immunologically potent cells – antigen 
presenting cells (APCs). These cells are called dendritic cells with three examples being, 
Langerhans Cells, which are located in the viable epidermis, and Dermal Dendritic Cells 
and dermal Langerin+ cells, which are in the dermis [55]. APCs are highly efficient at up-
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taking and presenting antigen to additional immune cells leading to strong immune 
responses in the body. Research has shown that accurately targeting the layers of the skin 
leads to the potential for improved immune responses with far less antigen than 
conventional needle and syringe injections, which target the muscle [73, 74]. As stated, the 
Kendall Group has shown a 100-fold dose reduction of influenza vaccine compared to IM 
by targeted delivery using the Nanopatch within mice with a single immunisation [11]. It is 
speculated that the reduction in the amount of vaccine required per dose may have 
downstream benefits, such as the potential for reduction in cost per administration and the 
possibility of achieving lasting immunity without requiring additional booster shots.  
 
2.4 Vaccine delivery to the skin 
It has been established in literature that skin is a very important delivery site for 
vaccination, and multiple methods are being developed to accurately deliver vaccines to 
the skin. Briefly, these are diffusion/permeation delivery, liquid jet injection, biolistic and 
microparticle injection to name a few [56] (summarised in Figure 2.5 and Table 2.2). 
These approaches still have disadvantages. For example, diffusion/permeation delivery is 
more suited for small molecules (<500Da) [75]; liquid jet injection is not pain-free and like 
biolistic microparticle injection, it is difficult to achieve accurate targeting of specific 
immunogenic cells. 
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Figure 2.5. Schematic adapted from Mitragotri 2005 [46],  showing a summary of skin 
delivery techniques in relation to the layers of the skin. A) Liquid jet injection: disrupts skin 
delivering vaccine, painful with past risk of cross-infection; B) biolistic injection of particles: 
Propels vaccine-particles into skin, dispersion of particles in layers and cell death and 
damage; Ca) administration via hair follicles: poor efficiency; Cb) tape stripping: removes 
stratum corneum allowing absorption of drug; Cc) thermal/radio-wave ablation of stratum 
corneum: creates micropores for vaccine absorption, complex and expensive; Cd) 
lipophilic colloidal carriers for topical application; Ce) ultrasound mediated delivery: 
increases vaccine absorption, complex and expensive; Cf) topically applied adjuvants: 
requires specific adjuvants to increase absorption; Cg) electroporation: uses high voltage 
pulses to disrupt skin and increase permeability.  
 
Researchers have overcome some disadvantages over previous intra-cutaneous 
devices by fabricating arrays of micrometer-scale projections. (Figure 2.5) Microneedles 
penetrate the skin causing micro-perforations leading to increased permeability and drug 
absorption. However, some of the limitations to current microneedle vaccine delivery are 
complex fabrication techniques, small payload capacity, single coating formulation and the 
possibility of needle re-use and needle stick injury. 
 
2.4.1 Needle and syringe 
Officially invented in 1853, the needle and syringe revolutionised vaccine and drug 
delivery by providing an accurate and reproducible method of administering payloads into 
the body [37]. It later on provided a sterile platform that could be utilised with many 
different therapeutic formulations.  Ideally suited for delivery of large payload volume deep 
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into the body, the needle and syringe is a relatively large instrument where highly accurate 
delivery of small quantities is required. Technological development has led to smaller and 
finer needles allowing for increased ease in delivery resulting in intradermal delivery 
(Mantoux Method [76]). However, controlled intradermal injection still requires time and a 
highly qualified practitioner.  
 
2.4.2 Electroporation and iontophoresis 
Two electrical methods of drug delivery to the skin are electroporation or 
iontophoresis. Both methods involve the use of an electric current to either disrupt the 
surface barrier of the skin or force the payload into the skin due to charge [77]. 
Electroporation uses high voltage pulses to disrupt the skin surface leading to transient 
pores and increased drug permeability. Iontophoresis utilises low levels of electric current 
resulting in increased drug permeability by various mechanisms: electrorepulsion, electro-
osmosis and/or electropertubation [77]. Limitations of these two methods relate to possible 
tissue damage, cost and complexity of design preventing it from being utilised in the home 
environment [78]. 
 
2.4.3 Liquid jet injection 
Jet injections were widely used in the mid twentieth century and were developed for 
mass immunisation campaigns for the developing world and military personnel [79] 
(Figure 2.6). They function by delivering a liquid payload at high velocity to the skin. The 
payload ‘bursts’ through the outer layer and is delivered to a range of tissue layers. 
Multiuse jet injector devices were withdrawn from use after an outbreak of Hepatitis B was 
linked with jet injector vaccination (splashback of blood and vaccine onto the surface of the 
injector) [47]. To reduce the risk of contamination fully disposable single-use injectors were 
developed [80]. However, even with advances in jet injector technology, the method itself 
disrupts relatively large regions within the skin causing pain and damage [81]. 
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Figure 2.6. Example high throughput liquid jet injector (Lectrajet® HS) with disposable 
cartridges [47, 82]. 
 
2.4.4 Biolistic injection 
Another form of ballistic delivery utilizes very high pressures to deliver a ‘shot gun’ 
burst of tiny particles into the skin – coined ‘biolistic injection’. Biolistic delivery is achieving 
much attention due to its success in DNA delivery to skin, which is highly significant for 
vaccine delivery [83]. Working on similar principle to liquid jet injectors, biolistic injection 
carries antigen in high-speed flow of gas to deliver the payload into the skin [84]. Due to 
the very small size and mass of the particles, very high velocity is required for delivery 
[72]. The sudden impact of the particles induces widespread cell death and damage [85], 
with a dispersion of particles delivered throughout different layers of tissue [72]. Other 
issues relate to high cost and complexity of apparatus, with wastage of payload ‘bouncing’ 
off the surface of the skin. 
 
2.5 Microneedles 
Advances in computers and electronics have led to the development of techniques 
for the fabrication of a variety of microneedles on a scale that was otherwise not thought 
possible.  The potential for microneedles to accurately deliver therapeutics into the skin 
was seen and in 1998 the first peer reviewed journal paper was published [86]. Since then 
much research has gone into optimising microneedles for drug and vaccine delivery with 
an example array shown in Figure 2.7. 
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2.5.1 Solid microneedles 
There are many variations of microneedle drug delivery with the simplest approach 
being microneedle array application either in conjunction with or followed by application of 
a drug formulation [87]. The microneedle array penetrates the tough barrier of the stratum 
corneum producing channels for drug diffusion. There are various ways to apply the patch 
with two common techniques being vertical insertion of the microneedles or a lateral 
‘scratching’ motion of the microneedles on the surface of the skin. It was shown in 2002 
that using the technique of ‘scratching’ the stratum corneum with microneedles in 
conjunction with drug formulation leads to a 1,000 – 2,800 fold increase in response 
compared to topical applications [74]. 
 
 
Figure 2.7. Example of solid microneedles approximately 330 µm compared to a 25-
gauge needle. Inset shows microneedle coated with protein antigen, Matriano J. A. et al. 
[88]. 
 
Another form of delivery with solid microneedles is by coating the drug formulation 
onto the surface of the needles and drying. Delivery of 1 µg coated ovalbumin showed a 
50-fold and 10-fold increase in antibody response compared to intramuscular and 
subcutaneous injections respectively [88]. As mentioned, the skin contains an abundance 
of immunologically potent cells and when accurately targeted a potent immune response 
can be achieved with minimal vaccine [89]. 
 
2.5.2 Hollow microneedles 
A more complicated method of microneedle drug delivery is the use of hollow 
microneedles to inject liquid drug formulation into the skin. Hollow microneedles deliver a 
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relatively larger quantity of drug over time compared to solid microneedles. During 
application of hollow microneedles there is the possibility of needle blockage upon entry 
into the skin as well as back pressure causing the payload fluid to leak onto the surface of 
the skin. This led to the fabrication of complex microneedle structures with hollow 
chambers that release drug from the sides of the microneedles instead of the tips like 
standard hypodermic needles [90] (Figure 2.8).  
 
 
Figure 2.8: Example of the complexity of fabricated hollow microneedles. Payload is 
released from the side of the microneedles post insertion, Roxhed N. et al. [90].  
 
As mentioned, a benefit of hollow microneedles is controlled drug release over time. 
Experiments using hollow microneedles for the delivery of insulin have shown promising 
results of controlled release with sustained glycaemic control over the application time 
period [91]. Another method of delivery is by modifying current syringes so that a small 
array of hollow microneedles are attached to the tip instead of a long needle. The drug 
formulation can then be applied using the same application method as a needle and 
syringe. Studies with an influenza vaccine showed an 80% dose-sparing immune 
response in healthy adults [92].  
 
2.6 Nanopatch 
Designed in the Kendall Group, the Nanopatch (NP) differs significantly from current 
forms of microneedles in relation to size, spacing and density of projections in an array 
(Figure 2.9). Current microneedles are up to 700 µm in length and less than 321 
projections per cm2 [10]. By contrast, the NP consists of approximately 100 m projections 
that are 70 m apart with an array density >20,000 projections/cm2. The NP morphology 
 26 
was carefully designed based on a probability analysis to maximise direct targeting of 
deposited antigen to thousands of immune cells in the skin [11]; without relying upon 
diffusion. 
 
 
Figure 2.9: Schematic of skin targeting using the Nanopatch compared to existing needle-
based delivery methods. Drawn to scale is the structure of human skin. The geometry of 
different needle-based delivery devices (a–c) and the Nanopatch (d) are also drawn to 
scale. (a) Intramuscular (IM) route directly inject a vaccine into muscle, which contains a 
low density of antigen presenting cells (APCs). (b) Intradermal (ID) injection delivers 
vaccine to the dermis of the skin, where there is an extensive network of resident 
professional APCs. (c) Generally, microneedle techniques might use sparsely packed 
needles with dimensions of hundreds of micrometers to deliver a liquid or dry form of the 
vaccine to the skin. (d) The Nanopatch technique uses a very small and densely packed 
array (over 20,000 projections/cm2) to directly deposit vaccine material into the immediate 
vicinity of a large population of APCs in a small area, Fernando G. J. P. et al. [11]. 
 
The NP is fabricated from silicon using a Deep Reactive Ion Etching (DRIE) process 
[93]. The surface of the NP is either silicon or sputter-coated with a thin layer of gold (400–
1500 nm in thickness). The array consists of 58 x 58 projections in a square grid layout 
(Figure 2.10). Two formulation coating methods have been reported with the NP, one 
being a jet coating technique using nitrogen gas and the other a dip coating technique 
whereby the formulation is localised to the tips of the projections [9, 10]. The jet coating 
method is quite versatile and has been used to coat simple protein antigens (ovalbumin) to 
more complex virus-like particles (Human Papillomavirus [HPV]).  
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Figure 2.10: (a) Prototype of Nanopatch, (b) uncoated Nanopatch and (c) HSV-2-gD2 
vaccine coated Nanopatch. The scale bar indicates 50 μm for (b) and (c), Chen X, et al. 
[41]. 
 
Currently five different vaccines have been used in animal-model vaccination with 
the NP (Fluvax2008® [11], Gardasil® [94], attenuated DNA West Nile virus vaccine [95], 
inactivated adjuvanted chikungunya whole virus vaccine [94] and herpes simplex DNA 
virus vaccine [41, 96]). Overall, in regards to immunogenicity within the mouse model,  NP 
immunisation with Fluvax2008® achieved 100-fold dose reduction compared to the 
syringe – this is also a factor of 10 greater than what has been achieved with the current 
much larger, sparse microneedles [11].  
 
2.7 Dissolving microneedles 
A major development in the microneedle field was the introduction of dissolving 
microneedles. Biodegradable polymer microneedles were first reported in 2003 with a 
more in depth report in 2005 [97, 98]. Since then, multiple journal articles have been 
published with various fabrication techniques and compositions of dissolving microneedles 
[14, 18, 99, 100] (Figure 2.11).  
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Figure 2.11. Various types of dissolving microneedles: a) long single dissolving splinters 
for delivery of heparin [101]; b) solid maltose microneedles used to penetrate skin followed 
by topical application of drug [102]; c) PLGA tips with PEG backing containing PLGA 
encapsulated vitamin B [14]; d) carboxymethylcellulose dissolving microneedles [18]; e) 
calcein encapsulated in the tips of tapered PLGA microneedles [13]; f) UV-crosslinked 
PVP microneedles encapsulating sulforhodamine [103]; g) calcein encapsulated in the tips 
of tapered PLGA microneedles [13]; h) PLA microparticles ultrasonically welded to form 
microneedles [14]. 
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Table 2.2: Advantages and disadvantages of skin delivery technologies 
Technique Advantages Disadvantages 
Needle and syringe (ID by 
Mantoux Method) 
 Effective 
 Cheap 
 Easy to manufacture 
 Payload versatility 
 Difficult, even with 
trained personnel 
required 
 Needle phobia 
 Cross contamination 
 Biohazard waste 
 Cold chain 
Electroporation  Potential for DNA 
vaccinations 
 
 Tissue damage 
 Complex devices 
 Expensive 
 Cold chain 
Liquid jet injector  Potential for rapid 
administration 
 High throughput 
 Painful 
 Possibility of cross 
contamination 
 Cold chain 
Biolistic injection  Stable solid formulations 
 Potential for DNA 
vaccinations 
 Complex device 
 Expensive 
 Cell death and tissue 
damage 
 Nanoparticle safety 
concern 
Microneedles  Minimally invasive 
 Low risk of cross 
contamination 
 Low risks of sharps 
 Stable solid formulations 
 Complex fabrication 
 Potential to be expensive 
 Risk of skin irritation from 
needle breakage 
 Limited by payload 
volume 
Dissolving microneedle  Minimally invasive 
 No risk of cross 
contamination 
 No sharps risk 
 Large volume of payload 
 Stable solid formulations 
 Mechanical strength of 
polymers 
 Sensitive to humidity 
 Complex/harsh 
fabrication techniques 
 Slow release profiles 
Nanopatch  Minimally invasive 
 Low risk of cross 
contamination 
 Low risks of sharps 
 Stable solid formulations 
 Highly immunogenic 
 Rapid release profiles 
 Complex fabrication 
 Risk of skin irritation from 
needle breakage 
 Complex coating 
technique 
 Limited by payload 
volume 
 
However, compared to the general microneedle field, there is only a small number 
of dissolving microneedle publications published annually (Figure 2.12 – Web of 
Knowledge search results using the terms ‘microneedle’ and ‘dissolving microneedle’). 
More specifically, there are even fewer papers published relating to 
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microneedles/dissolving microneedles and vaccine delivery. This emphasises the obvious 
need for a greater understanding and knowledge in the field of sensitive biomolecular 
delivery to the skin. Table 2.3 provides a summary of dissolving microneedle fabrication 
methods and applications published in 2008 and earlier. Current papers are discussed in 
detail within the introduction sections of the remaining thesis. 
 
 
Figure 2.12. Web of Knowledge publication results using the terms ‘microneedles’, 
‘dissolving microneedles’, ‘microneedles vaccine’ and ‘dissolving microneedles vaccine’. 
The search starts in 1998, which is the first reported microneedle array paper published 
and publications are limited to articles. 
 
Unlike solid and hollow microneedles, the biocompatible dissolving variety has the 
advantages of: 
 no possibility of needle re-use; 
 no possibility of needle-stick injuries; 
 no need for complex sharp disposal systems, and; 
 by controlling the composition and size, drugs and vaccines can be tailored 
for controlled delivery depending on their purpose. 
These advantages make dissolving microneedles an exciting alternative to the other 
previously mentioned skin delivery platforms.
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Table 2.3: Summary of fabrication methods and release assays of dissolving microneedles published 2008 and sooner 
Senior 
Author 
Year 
Microneedle 
Composition 
Microneedle 
Length 
Casting Procedure Model 
Payload 
Material 
Payload Delivered 
Takada 
[104] 
2006 
Dextrin needles 
mixed with 
varying 
concentrations of 
insulin weighing 
0.59 +/- 0.01mg  
3.24mm 
2.0g of dextrin was dissolved 
in 1.0mL DI water. 3.10mg, 
1.30mg and 0.6mg insulin 
was dissolved in 100µL DI 
water with 10µL insulin 
solution added to the dextrin 
glue. Threads were formed 
using plastic tips and dried in 
a desiccator.  
Male ddY 
mice 
Insulin 
Physiological availability of 
insulin was 97.7% (0.5IU/kg), 
93.3% (1.0IU/kg), and 91.3% 
(2.5IU/kg). 
Takada 
[100] 
2006 
Dextrin, 
chondroitin 
sulfate and 
albumin with 
varying 
concentrations of 
EPO weighing 
0.59 +/- 0.01mg  
~1.5mm 
(Actual data 
not given) 
200mg dextrin and 100mg 
chondroitin was dissolved in 
125µL DI water. 10µL EPO 
was added and mixed well. 
Threads were formed using 
plastic tips and dried in a 
desiccator. 300mg of 
chondroitin was mixed with 
90mg of L-Lysine and L-Glu 
or 11mg chondroitin and 
55mg albumin was dissolved 
in 160 or 30µL. 20 or 5µL of 
EPO was added to resulting 
mixture and needles were 
formed. 
Male ddY 
mice 
Erythropoietin 
Peak EPO level was obtained at 
7.5hrs (138.3+/- 16.1mIU/mL) 
AUC approx. 1240mIU/mL over 
24 hrs. S.C admin. - 99.4% BA. 
PC admin. – approx. 83% BA  
Takada 
[101] 
2008 
Dextrin, 
chondroitin and 
dextran with 
heparin weighing 
1.24 +/- 0.01mg 
and dose of 
100IU/kg 
1.52mm+/-
0.12mm 
20mg heparin dissolved in 
20µL DI water. Heparin 
solution mixed with dextrin, 
chondroitin or dextran to form 
glue. Threads were formed 
using plastic tips and dried in 
desiccator. After drying 
Male 
Wistar 
rats 
Low Molecular 
Weight Heparin 
Almost all released in 10min. 
Cmax was 0.40, 0.46, 
0.47IU/mL for dextrin, 
chondroitin and dextran 
respectively. 
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Senior 
Author 
Year 
Microneedle 
Composition 
Microneedle 
Length 
Casting Procedure Model 
Payload 
Material 
Payload Delivered 
threads cut to size. 
Kwon 
[105] 
2004 
Lidocaine/CMC 
mixture 
550µm to 
650µm 
Lidocaine and CMC were 
dissolved in DI water at 
varying ratios. Solution was 
cast into a mould and 
compressed followed by 
drying under ambient 
conditions. 
Excised 
Human 
skin 
Lidocaine 
hydrochloride 
22.4µg/cm2/h to 98.6µg/cm2/h 
over 24 hours 
Kwon 
[106] 
2005 
Lidocaine/CMC 
mixture 
1.5mm 
Lidocaine and CMC were 
dissolved in DI water at 
varying ratios to form a gel. 
The gel was cast into a 
mould by centrifugation and 
dried under ambient 
conditions. 
Excised 
Human 
skin 
Lidocaine 
hydrochloride 
99 +/- 20µg to 394 +/- 33µg over 
30min 
Kwon 
[107] 
2006 
Ascorbic acid and 
benzoyl peroxide 
and CMC mixture 
1.2mm 
Ascorbic acid, CMC and 
benzoyl peroxide were 
dissolved in DI water at 
predetermined ratios (1% 
BP). The gel was cast into a 
mould by centrifugation and 
dried under ambient 
conditions. 
Excised 
Human 
skin 
Ascorbic acid 
and benzoyl 
peroxide 
N/A 
Kwon 
[108] 
2006 
Fluzone 2004/05 
with dextrin and 
trehalose with 
CMC backing 
1.5mm 
Fluzone was dialyzed, 
concentrated, blended with 
dextrin and trehalose and 
lyophilized to formulations of 
2% and 10% hemagglutinin. 
Powder was reconstituted in 
Mouse 
Fluzone 
2004/05 
1µg to 25µg over 15min 
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Senior 
Author 
Year 
Microneedle 
Composition 
Microneedle 
Length 
Casting Procedure Model 
Payload 
Material 
Payload Delivered 
DI water and cast into a 
mould by centrifugation. 
CMC gel was added as 
backing. 
Kwon 
[109] 
2007 
0.5µm 
polystyrene 
beads and violet 
dye  concentrated 
in tips with CMC 
backing  
1.5mm 
Beads and violet dye was 
mixed with the CMC gel 
respectively and cast into a 
mould by centrifugation at 
3000rpm for 5min. Excess 
gel was removed from 
surface of mould and pure 
CMC gel was replaced and 
spun into mould.  
Excised 
Human 
skin - 
dermal 
layer 
0.5µm 
polystyrene 
beads and violet 
dye 
N/A 
Kwon 
[110] 
2007 
Human 
parathyroid 
hormone and 
CMC mixture 
1.5mm 
PTH and CMC were 
dissolved in DI water to form 
a gel and was cast into a 
mould by centrifugation and 
dried under ambient 
conditions. Total drug loading 
was 729µg+/-19. 33% in 
needles and 67% in backing. 
Polyester 
film 
laminate 
Human 
parathyroid 
hormone 
~718µg over 24 hours 
Hanada 
[99] 
2005 
Maltose melt 
containing 
ascorbate-2-
glicoside, sodium 
salicylate or 
calcein 
150µm to 
2mm 
(500µm 
tested) 
Powdered maltose is heated 
for one hour at 140oC, 
followed by addition of 
powdered drug and cooled. 
Drug candy was cast at 95oC 
and process is completed 
within a minute followed by 
removal at 55oC 
Human 
Ascorbate-2-
glucoside 
N/A, however assumed less 
than 10 wt% 
Konishi 
[111] 
2007 6000 MW PEG 
200µm to 
2mm (2mm 
tested) 
PEG was cast at 90oC and 
evacuated to a few Pa. After 
cooling to room temperature 
Cultured 
human 
skin 
N/A N/A 
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Senior 
Author 
Year 
Microneedle 
Composition 
Microneedle 
Length 
Casting Procedure Model 
Payload 
Material 
Payload Delivered 
mould is removed. model 
Prausnitz 
[98] 
2005 
Solid L-PLA, PGA 
and PLGA made 
from a polymer 
melt 
600µm to 
1.5mm 
Male moulds were 
constructed using SU-8 
photoresist and wet/dry 
etching techniques. PDMS 
was used to make female 
mastermoulds. The polymer 
was placed on mould and 
cast in an oven at -70 kPa for 
5min between 140 and 
230oC depending on 
polymer. Mould was placed 
in -20oC freezer for 30min 
followed by removal of 
needles. 
Excised 
Human 
skin 
Calcein and 
BSA 
N/A 
Prausnitz 
[13] 
2006 
Drug-CMC or 
drug-PLA 
particulates 
concentrated in 
tips with PLGA 
melt backing 
600µm to 
750µm 
Male moulds were 
constructed using SU-8 
photoresist and wet/dry 
etching techniques. PDMS 
was used to make female 
mastermoulds. Three 
different needle profiles were 
designed. Calcein or BSA 
was suspended in 
acetonitrile at 10% w/v and 
homogenized for 5min at 
10,000rpm followed by 
filtering and reconstitution in 
acetonotrile. Solution was 
poured into PDMS mould 
and vacuumed. Excess was 
Excised 
Human 
skin 
Calcein, BSA 
encapsulated in 
CMC or PLA 
100-needle patch with 2% drug 
loading released ~ 20µg. Rate 
dependent on formulation 
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Senior 
Author 
Year 
Microneedle 
Composition 
Microneedle 
Length 
Casting Procedure Model 
Payload 
Material 
Payload Delivered 
removed from surface and 
then mould was filled with a 
PLGA melt in a vacuum oven 
at 135oC for 10-20min. The 
other two formulations 
consisted similar protocol, 
however drugs were 
encapsulated in either CMC 
or PLA. 
Prausnitz 
[18] 
2008 
CMC/drug 
needles with 
CMC backing or 
CMC/drug 
backing 
600µm 
Male moulds were 
constructed using SU-8 
photoresist and wet/dry 
etching techniques. PDMS 
was used to make female 
mastermoulds. CMC, 
amylopectin and BSA were 
dissolved in DI water and 
concentrated either by 
vacuum or heat to ~27wt%. 
Three model drugs, 0.15-
30wt% sulforhodamine B, 
20wt% BSA or 5wt% 
lysozyme was hand mixed 
into the gel. 100-300mg of 
gel was placed on mould and 
spun at 3000g, 37oC for 2h. 
For drug only in tips 8-10mg 
was spun into mould followed 
by removal of excess. 100-
Excised 
pig skin, 
excised 
human 
skin 
Sulforhodamine 
B, BSA or 
Lysozyme 
1mg Sulforhodamine/CMC over 
at least 48 hours and 1mg 
Sulforhodamine/amylopectin 
over at least 120 hours 
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Senior 
Author 
Year 
Microneedle 
Composition 
Microneedle 
Length 
Casting Procedure Model 
Payload 
Material 
Payload Delivered 
200mg of pure gel was spun 
as backing.  
Prausnitz 
[103] 
2008 
UV Cross-linked 
PVP-MAA using 
AIBN initiator with 
model drug mixed 
in prior to 
polymerisation 
750µm 
Male moulds were 
constructed using SU-8 
photoresist and wet/dry 
etching techniques. PDMS 
was used to make female 
mastermoulds. Liquid 
monomer PVP and radical 
initiator AIBN were used to fill 
the mould via vacuum for 
2min. The filled mould was 
then placed under a UV lamp 
for 30min to induce 
photopolymerisation. Same 
process used for copolymer 
needles. 
Excised 
pig skin 
Sulforhodamine 
B, BSA and β-
galactosidase 
50µg β-galactosidase over 18 
hours 
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2.7.1 Common fabrication techniques of dissolving microneedles 
Multiple fabrication methods have been developed to produce dissolving 
microneedles under different conditions, as summarised in Table 2.3. However, I will 
discuss in detail a range of dissolving microneedle papers published to give a more 
detailed snapshot of the different approaches being used.  
 
Perhaps the simplest approach of fabricating dissolving microneedles is the use of 
mini ‘splinters’ designed to pierce and release the payload into the skin. The ‘splinters’ are 
constructed by forming threads out of a viscous drug solution and drying under ambient 
conditions [100, 101, 104] (Figure 2.11a). The threads formed are between 1.5 mm and 
3.2 mm in length. This method showed success in delivering insulin, erythropoietin and low 
molecular weight heparin. The physiological availability of insulin was over 90% per dose 
and it was found that insulin remained stable in the microneedle for up to one month at 
40oC [104]. The erythropoietin microneedles resulted in approximately 70% bioavailability 
[100]. Delivery of low molecular weight heparin resulted in the highest bioavailability – 
greater than 90%, with maximum blood concentrations approximately one hour after 
application [101]. The needles were composed of dextrin, a dissolving cellulose derivative 
mixed in with various concentrations of the drug. Dextran and chondroitin sulfate were also 
used as excipients with similar results to dextrin. 
 
An alternate approach for the fabrication of dissolving microneedles is the use of a 
microneedle array mould, which can then be filled with the desired payloads to form solid 
microneedles. One possible method is by etching a female mould into metal to produce 
inverse microneedles in a range from 150 µm to 2 mm [99]. A sugar such as maltose is 
then heated and melted into the mould (Figure 2.11b). Molten PEG has also been used in 
an effort to increase throughput of production [111]. This method can only produce a few 
arrays of microneedles and requires temperatures ranging from 65oC to 140oC depending 
on polymer/sugar. The application method used with these microneedles is a ‘poke and 
coat’ method, where the patch is first applied and removed followed by a topical 
application of the drug. Low molecular weight heparin, therapeutic antibodies and 
nicardipine hydrochloride all showed increase permeability into the skin post microneedle 
(~500 µm) application [102, 112, 113]. 
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Another method of producing a female mould is to use an inert polymer to construct 
moulds from microneedle master structures. Polydimethylsiloxsane (PDMS) is one such 
material and is a widely used silicon-based organic polymer. Its inert, hydrophobic and 
non-toxic properties, coupled with its ability to uniformly coat micron-sized structures, 
make PDMS an ideal polymer for moulds [18]. To fill the moulds, multiple techniques can 
be used depending on the formulation desired. Drugs, particles and robust biological 
payloads can be heated and compressed or vacuumed into the moulds followed by 
hardening and removal. Polylactic acid, polyglycolic acid and polylactic-co-glycolic acid 
biodegradable microneedles have all been developed in this manner. Polymer pellets are 
placed on the surface of the moulds and heated to 140oC, 230oC or 180oC respectively for 
5 minutes at -70kPa. Once the moulds are filled they are placed in a freezer at -20oC for 
30 minutes [98]. Due to the harsh conditions of production (extreme temperature 
variances), these polymer microneedles are more suited for the ‘poke and coat’ method 
mentioned previously, where the drug is applied separately after microneedle application. 
 
An alternate approach of producing polymer microneedles, which contain bioactive 
payloads, is to encapsulate the payloads in a polymer particle. The polymer particles can 
then be vacuumed or centrifuged into the mould so that they are focused towards the tips 
(Figure 2.11c, e, g). A polymer melt can then be forced into the mould and hardened. This 
method produced microneedles approximately 600 µm in height that penetrated and 
degraded in skin [13]. The polymer microneedles can be controlled to release over hours 
to months [13]. To avoid using high temperatures in the production process of polymer 
microneedles, particles can be ‘welded’ together using ultrasonic waves and compression. 
This method is limited to particle-based microneedles and is very useful if a large quantity 
of particles are required for delivery because the whole array can be made from the 
particles [14]. An approach to polymer microneedles without the use of high temperatures 
or particles uses polymer solutions mixed with desired payload. The polymer and payload 
is forced into the mould and UV-light is applied to cross-link the polymer forming solid 
microneedles (Figure 2.11f). This method has been used to produce 750 µm needles that 
were successful in delivering β-galactosidase to skin as a model enzyme [103]. 
 
Polymers have been utilized in the composition of biodegradable microneedles for 
controlled release over time. Fabrication methods often involve harsh processes including 
UV-light, cross-linking and ultrasonic waves, which may disrupt sensitive biological 
payloads. Rapid release dissolving microneedles are constructed from molten sugar and 
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hardened, however this approach uses high temperatures, for example 140oC for maltose. 
Techniques have been developed under physiological conditions using drug formulations 
containing sugar and cellulose derivatives. The formulations are cast into a mould by 
force, often by centrifugation. The loaded moulds are then dried at varying temperatures 
and conditions until the solvent has evaporated. Early reports show dissolving 
microneedles using this method with lengths ranging from 500 µm-1.5 mm [105, 106, 114]. 
One example uses lidocaine hydrochloride as a model drug with sodium 
carboxymethylcellulose as the excipient. It was shown that a 2.5 to 12 fold increase in 
transdermal delivery was achieved [105]. More recently, dissolving microneedles were 
fabricated with a similar technique and used to deliver  sulforhodamine B, bovine serum 
albumin and lysozyme [18]. Lysozyme was shown to maintain 96% activity after two 
months storage at room temperature when encapsulated within the microneedles [18]. 
 
Attempts have been made at fabricating dissolving microneedles with the payload 
concentrated in the tips of the needles [14, 18, 109]. This is useful in reducing the payload 
if required, and also preventing any wastage of excess vaccine. One common technique is 
to fill the microneedle mould with a payload followed by removal of excess  payload and 
then the addition of  a backing layer containing no payload [18] (Figure 2.11h). Another 
method is to use drug particulates or drug absorbed onto particles and force them into a 
microneedle mould [109]. This method is limited to larger particles with a higher density 
compared to the excipient and other payloads in the microneedle mould. Using vaccines 
encapsulated in different polymers having different melting points is another way to form 
layered microneedles. This process requires the production of a polymer microneedle 
array with a high melting point that is then inserted into a microneedle mould filled with a 
different polymer of lower melting point [14].  Due to the complexity of this method only 
larger microneedles can be developed of approximately 750 µm. 
 
More recently, two reports have been published showing successful immunisation 
using two different types of influenza vaccines [115, 116]. One report fabricated dissolving 
microneedles 650 µm tall with tips tapering to a 10 µm radius of curvature in a 100 needle 
array [115]. Each patch encapsulated 3 µg of inactivated influenza virus vaccine. The 
excipient was UV cross-linked polyvinylpyrrolidone and required the patch to be applied for 
15 minutes during application. The immune responses achieved were comparable to the 
needle and syringe; however the microneedle patch showed much greater viral lung 
clearance than the needle and syringe. The other, was a dNP paper (published from data 
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within this thesis), showing a dose-sparing ability of the dNPs, however the results are 
discussed in detail in Chapter 6. 
 
2.8 Summary of literature review 
It is clear that targeting of the skin for vaccine administration is important in 
producing a potent immune response. Skin targeting has the potential benefits of: 
 Enhanced immunogenicity, 
 dose-sparing, 
 minimal pain when compared to intramuscular needle and syringe injections and,  
 reduction in sharps risks such as needle-stick injuries. 
Many vaccine types and application techniques have been developed to overcome these 
limitations, however each approach has their own limitations. Dissolving microneedles and 
dNPs are an exciting new development in skin delivery, with benefits including but not 
limited to: 
 no possibility of needle re-use; 
 no possibility of needle-stick injuries; 
 no need for complex sharp disposal systems, and; 
 by controlling the composition and size, drugs and vaccines can be tailored for 
controlled delivery depending on their purpose. 
 
As discussed, the dissolving microneedle field is still in its infancy with development 
and optimisation of fabrication techniques still required. Layering of dissolving 
microneedles has potential for the delivery of multiple payloads per array, or the reduction 
of payload wastage on the surface of the skin. Also, fabrication under physiological 
conditions with minimal handling and wastage is required for vaccine delivery. Currently, 
many of the dissolving microneedles require hours to days for complete dissolution once 
applied to the skin. Overall, these conditions have limited dissolving microneedles to the 
delivery of drugs and robust biomolecules, instead of sensitive vaccines. This thesis aims 
to address the shortcomings discussed in the literature review of current skin delivery 
technologies, in particular dissolving microneedles. This will be achieved by introducing a 
fabrication method for dissolving Nanopatches (dNPs) and analysing the mechanisms of 
administration, dissolution and diffusion of the microstructures within skin. 
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CHAPTER 3 
Materials and Methods 
 
The materials and methods chapter of this thesis contains common procedures 
used throughout multiple chapters as well as in depth detail on the more common 
laboratory techniques such as the ELISA assay. The chapter starts with a list of the 
reagents used, followed by the core procedures. 
3.1 Reagents 
Following reagents ordered from Sigma-Aldrich (USA): ABTS (2,2′-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt [#A1888]), bovine serum albumin 
([BSA], #A2153), carboxymethylcellulose ([CMC] 90,000 MW, #419273), Evans Blue (85% 
dye, #206334), mannitol (#M9546), ovalbumin protein (#A5503), phosphate citrate buffer, 
pH5 tablets (#P4809), sodium bicarbonate (#S5761), sodium chloride (#S9888), sodium 
dodecyl sulphate 10% solution (#L4522), sorbitol (85529), sucrose (#84097), trehalose 
(#T0167), Tween-20 (#P1379) 
 
Following reagents ordered from Invitrogen (USA): FITC-dextran (2,000,000 MW), 
goat anti-mouse IgG horseradish peroxidise conjugate (#G21040) phosphate buffered 
saline (#3002), rhodamine-dextran (3,000 MW, 70,000 MW, 2,000,000 MW) 
Following reagents ordered from Perkin Elmer: Acetic acid, sodium salt, [1-14C] 
(#NEC084H001MC), Hionic-Fluor (#6013311), Ultima Gold (#6013321), Soluene 
(#6003038), Solvable (#6NE9100) 
 
Following reagents ordered from miscellaneous companies: Concentrator (Amicon 
Ultra 4, Millipore, #UFC801024, USA), Fluvax2008®/2010® (CSL Biotherapies, Australia), 
ketamine (Troy Laboratories, Australia), optimal cutting temperature compound ([OCT] 
Tissue-Tek, #4583, USA), ovalbumin [methyl-14C] methylated (Amer. Radio. Chem. #0431, 
USA), paraformaldehyde ([PFA] Electron Microscopy Sciences, #15710, USA), 
polydimethysiloxane ([PDMS] Dow Corning, Sylgard® 184, USA), polyethersulfone ([PES] 
Nalgene, #596-3320, USA), Quil-A (Brenntag Biosector, Denmark), tris-buffered saline 
(Amresco, #J640), Triton-X (AJAX Finechem, #A1552, USA), Ultrapure water (GIBCO 
#2562, USA), Xylazil (Troy Laboratories, Australia). 
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3.2 Methods 
3.2.1 Animal patching 
Due to the size of the NP and dNP, a novel applicator and administration technique 
was developed in the Kendall Group [117]. A general description of the apparatus used 
and method of administration will be given in this chapter with more detailed descriptions 
in relevant chapters. Six week old female C57BL/6 mice were anesthetised with an 
intraperitoneal injection of 150 L of 10 mg/mL ketamine and 2 mg/mL xylazil in saline. 
Mice were placed on a custom built stand designed in the Kendall Group. Application of 
the NP or dNP was with a custom spring applicator (designed in the Kendall Group) at a 
velocity of 2.6 ms-1 to the ventral side of each ear (Discussed in more detail in Chapter 5).  
 
The positive control consisted of a 30 L intramuscular injection of vaccine 
formulation into the caudal thigh muscle. The negative control was an NP/dNP with no 
projections coated or filled with vaccine formulation. The negative control was applied 
using the same protocol as the NP/dNP samples. After immunisation, approximately 50 L 
of blood was taken from each mouse at specified time points (eg. 21 days post 
immunisation). The blood samples were allowed to clot and then centrifuged at 5000 g for 
10 minutes to separate sera. The sera were removed and stored at -80oC for analysis by 
direct ELISA. 
 
3.2.2 Fixation and staining of ear tissue 
Step One: Fix ears 
A fresh solution of 2% paraformaldehyde was prepared in 0.1 M phosphate buffer. 
Whole or split ears were then fixed in this solution for 1 hour at room temperature without 
agitation. The tissue was then washed 3 times in 0.1 M phosphate buffer for 10 minute 
intervals on a rotary. Excess and waste PFA were collected in appropriate hazardous 
waste containers. 
 
Step Two: Permeabilisation and blocking 
Whole ears were split under the stereo microscope to separate the side of interest 
(patched ventral side of ear) from the cartilage and dorsal side of ear. The tissue was then 
placed in 0.25% Triton X in 1x TBS for 30 minutes on a rotary. After permeabilisation the 
tissue was then washed 3 times in 1x TBS buffer for 10 minute intervals on a rotary 
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shaker. The tissue was then blocked with sterile filtered 5% BSA in 1x TBS for 1.5 hours at 
room temperature on a rotary. 
 
 
Step Three: Staining 
Following permeabilisation the tissue can be stained with many different antibody-
dye conjugates. The method for MHC-II FITC staining will be described as an example. 
MHC-II FITC was diluted 1:50 in 1% BSA/TBS. The tissue was submerged in the solution 
for 2-4 hours at room temperature or overnight at 4oC on a rotary. The tissue was then 
washed 3 times in 1x TBS buffer for 10 minute intervals on a rotary and then stored in 1x 
TBS at 4oC prior to imaging. 
 
3.2.3 Histology 
Protocol adapted from procedure within the Kendall Group [117]. If fixing was 
required: A fresh solution of 2% paraformaldehyde was prepared in 0.1 M phosphate 
buffer. Whole or split ears were then fixed in this solution for 1 hour at room temperature 
without agitation. The tissue was then washed 3 times in 0.1 M phosphate buffer for 10 
minute intervals on a rotary. Excess and waste PFA were collected in appropriate 
hazardous waste containers. Following either fixing or excision the tissue was placed in a 
cryo-mould. Tissue mounting media was then added (OCT), which was then frozen with 
either liquid nitrogen or dry-ice. Once frozen, 10 to 50 m thick slices were cut on a 
cryostat. 
 
3.2.4 CryoSEM 
CryoSEM protocol adapted from procedure within the Kendall Group [117].CMC 
dNPs were applied to the ventral side of excised female C57BL/6 mouse ears. Application 
was with a spring applicator at a velocity of 1.9 ms-1. Following administration the 
combined dNPs and ear were frozen in liquid nitrogen slush, within 60 seconds or 2 
minutes depending on application. The dNP array was then removed in a cryo-preparation 
chamber under vacuum (Cryo-SEM analysis). A Philips XL30 instrument with Oxford 
CT1500 Cryo-preparation system was used to examine the ears. For histology analysis, 
the dNP remained in the skin during sectioning and sliced at 30 m slices using a cryostat.  
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3.2.5 Multiphoton/Fluorescence confocal  
Microscopy was done using a Zeiss LSM510 Meta confocal microscope (Carl Zeiss, 
Inc., Germany). Fluorescence confocal microscopy consisted of single photon excitation of 
a fluorophore with a specific wavelength (eg. FITC – 488 nm, rhodamine – 543 nm) 
followed by collection using specific filters. Multiphoton microscopy consisted of two-
photon excitation of a fluorophore using a titanium-sapphire solid laser (highly tuneable 
short pulse laser). Second harmonic generation of collagen in the dermis was achieved 
using with an excitation of 840 nm and collection below 490 nm. 
  
3.2.6 14C Ovalbumin experiment to determine the Fluvax dose delivered by dNPs 
To determine the delivery efficiency of the dNPs, 14C radiolabelled ovalbumin 
protein was used as a tracer in dNP formulations. This technique was designed within the 
Kendall Laboratory because it was a much more sensitive and accurate technique than the 
Dotblot method. The dNP mould was placed in the well of a standard biological 28-well 
plate. A stock solution of 1% CMC and Fluvax was prepared so that each mould received 
10 l of Fluvax solution spiked with a minimum of 25 nCi 14C Ovalbumin. The plates were 
then placed in an enclosed plate carrier and centrifuged at specified time points (standard 
run time of 1 hour) at 3000 g at room temperature. Finally, 50 L to 100 L of 2.1 mM 
CMC was applied to the moulds to form the backing layer containing no payload. The 
moulds were then centrifuged at 3000 g for 30 minutes. The moulds were then placed in a 
sealed desiccator at 22oC containing dry-beads, until the dNPs had dried usually within 4 – 
6 hours. The dNP array was then removed from the moulds and stored in a sealed 
desiccator at 22oC in nitrogen gas.  
 
Six week old female C57BL/6 mice were anesthetised with an intraperitoneal 
injection of 150 L of 10 mg/mL ketamine and 2 mg/mL xylazil in saline. Each group 
contained three mice (total of 6 ears per group). A dNP array was applied to the ventral 
side of each ear. Application was with a spring applicator at a velocity of 1.9 ms-1 and held 
in place for a specified time (standard application time of 5 minutes). Post dNP 
administration, the patched side of the ear was swabbed with cotton buds soaked in 
saline. The swabs were then placed in scintillation vials with 1 mL of PBS. The used dNPs 
were also collected in separate scintillation vials with 1 mL of PBS. The mice were 
euthanized by cervical dislocation followed by removal of their ears. The ears were also 
placed in separate scintillation vials with the addition of 750 l of tissue solubiliser 
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(Solvable). The samples were placed in an oven at 55oC overnight or until the samples 
were solubilised. All samples were then vortexed thoroughly prior to the addition of 10 mL 
of scintillation liquid (Ultima Gold) and vortexed again. Samples were then counted using a 
beta counter (PerkinElmer TriCarb Model 2810TR). To determine if there was any 
chemiluminescence, the samples were stored in the dark overnight and recounted the 
following day. 
 
3.2.7 Tissue sample prep (homogenisation) 
Prior to protein quantification and analysis, the tissues (ears) were homogenised. 
Tissue samples were homogenised using a FastPrep Automated Homogeniser (MP Bio). 
Lysis buffer was prepared  by the addition of 50 mM (0.3 g) Tris, 150 mM (0.44 g) NaCl, 
0.01% SDS and 0.01% Triton X in 500 mL distilled water. Excised ears were placed in 
1000 L of lysis buffer in specified MP Bio lysis tubes. Samples were homogenised 
following the manufacturer’s standard protocol. In brief, each sample was homogenised at 
45 second intervals with a 1 minute resting period in ice and repeated until all the samples 
were completely homogenised. Samples were centrifuged briefly on the mini centrifuge 
followed by removal of the supernatant. Samples were then stored at -20oC.  
 
3.2.8 DotBlot quantitation for Ovalbumin protein/labelled Fluvax 
Quantification of specific protein concentrations in a heterogenous protein solution 
were analysed using dotblot. The Dotblot apparatus was washed thoroughly in distilled 
water. A nitrocellulose membrane was cut to fit the Dotblot apparatus. Prior to fitting the 
membrane onto the apparatus, the membrane was soaked in a 1x TBS solution for 30 
minutes. Samples prepared for a standard curve (eg. Labelled Fluvax, ovalbumin protein). 
Dilution factor based on stock concentration of protein of interest. The following example 
was based on a 20 mg/mL ovalbumin protein concentration: 
a. Stock OVA. Dilute 1:1000. 
b. Standard Curve 
i. 64ng = 640uL of 1:1000 + 1360uL TBS 
ii. 32ng = 1ml TBS and 1ml from (i) 
iii. 16ng = 1ml TBS and 1ml from (ii) 
iv. 8ng = 1ml TBS and 1ml from (iii) 
v. 4ng = 1ml TBS and 1ml from (iv) 
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The Dotblot apparatus was then assembled with the pre-soaked nitrocellulose 
membrane and vacuumed briefly to remove excess liquid. Vacuum was then turned off 
and standards and samples applied to the membrane (representative layout shown 
below). 
 
 
 
 
 
 
 
 
The samples were incubated for 30 minutes at room temperature in the dark. For 
fluorescently-tagged samples, the samples were vacuumed post incubation and washed 
twice with T-TBS. The membrane was removed from the apparatus and washed in 0.5% 
Tween-20 in 1x TBS (T-TBS) for 2 minutes followed by analysis using the Typhoon Laser 
Scanner. 
 
For non-tagged samples, the next step was adding the primary antibody. For 
ovalbumin protein, 1:10,000 mouse/rabbit anti-chicken ova diluted in 1% BSA in T-TBS. 
The antibody was then incubated for 1 hour at room temperature in the dark. The samples 
were washed 3 times in T-TBS for 5 minutes each wash. Subsequently, 1:2000 of 
secondary antibody either goat anti-mouse or goat anti-rabbit was added. Again the 
samples were incubated for 1 hour at room temperature in the dark. The samples were 
washed 3 times in T-TBS for 5 minutes each wash and then analysed on the Typhoon 
Scanner. 
 
3.2.9 Protein quantitation 
Total protein quantification of homogenised ear tissue was analysed on a Qubit 
Fluorometer (Invitrogen) using the manufacturer’s standard protocol. In brief, homogenised 
tissue samples were diluted 1/10 and 1/100 in 1x PBS. A working reagent of 200 L per 
sample/standard was made for the total number of samples and standards. Next, 190 L 
of working reagent was then added to 10 L of protein buffer and incubated for 15 minutes 
in the dark at room temperature. The working buffer contains fluorescent dyes that when 
 Stds Stds Samples          
             A 128ng 128ng 1A 1A 2A 2A 3A 3A 4A 4A 5A 5A 
             B 64ng 64ng 1B 1B 2B 2B 3B 3B 4B 4B 5B 5B 
             C 32ng 32ng 1C 1C 2C 2C 3C 3C 4C 4C 5C 5C 
             D 16ng 16ng 1D 1D 2D 2D 3D 3D 4D 4D 5D 5D 
             E 8ng 8ng 6A 6A 7A 7A 8A 8A 128ng 128ng 8ng 8ng 
             F 4ng 4ng 6B 6B 7B 7B 8B 8B 64ng 64ng 4ng 4ng 
            G 0ng 0ng 6C 6C 7C 7C 8C 8C 32ng 32ng 0ng 0ng 
            H NEG  NEG  6D 6D 7D 7D 8D 8D 16ng 16ng     
 1 2 3 4 5 6 7 8 9 10 11 12 
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bound to the protein fluoresce. Samples were then excited at either 460 or 635 nm and 
analysed on the Qubit. 
 
3.2.10 ELISA protocol for mouse serum antibody detection 
The ELISA protocol was performed based on a previously described method [118]. 
Coating of ELISA plates 
The protein of interest was diluted in binding buffer (0.1 M Sodium Bicarbonate 
filtered through 0.2 m filter) to give a final concentration of 3 g/ml Fluvax or 50 g/ml 
ovalbumin protein. Binding buffer solution (50 L) was added to each NUNC Maxisorp 
ELISA plate well. The plates were tapped gently so that the bottoms of the wells were 
completely covered with solution, followed by sealing in plastic wrap and incubation 
overnight at 4oC. 
Blocking of the plates 
The binding buffer was discarded and the plates washed once with wash buffer (1 L 
PBS containing 0.2ml Tween-20 (PBS-T)) using a squirt bottle. Next, 150 L of blocking 
buffer (4 mg/mL BSA in PBS) was added to each well followed by incubation of the plate at 
room temperature for 1-2 hours in the dark. The plates were then either used immediately 
or stored at -20oC for later use.  
Dilution and addition of sera samples 
Each sample of sera was serial diluted from 1:100 to 1:20480 in dilution buffer (4 
mg/mL BSA in PBS-T). The samples were diluted in a 96-well dilution plate. The blocking 
buffer was discarded from the previously blocked plates and washed once with wash 
buffer. Next, 50 L of each diluted sera sample was then transferred from the dilution plate 
to the ELISA plate following the example template. However this varied depending upon 
the number of samples: 
 
1, 2 3 etc were test sera samples (7 samples per plate).  
Dilution 100 200 400 800 1600 3200 6400 12800 25600 51200 102400 204800 
Sample1             
Sample2             
Sample3             
Sample4             
Sample5             
Sample6             
Sample7             
No Sera             
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The ELISA plates were then incubated at room temperature for 2 hours in the dark or 
overnight at 4oC. 
Addition of anti mouse IgG horseradish peroxidise (HRP) 
The secondary antibody was prepared by diluting HRP conjugated goat anti-mouse 
IgG antibody 1:600 in dilution buffer. After sample incubation, the samples were removed 
and the plates washed 4 times with wash buffer. After washing, 50 L or prepared 
secondary antibody solution was added to each well. The plates were incubated for 1.5 
hours at room temperature in the dark. 
Colour development and read out 
An ABTS developing solution was prepared by: 
1. Dissolution of 3.36 g citric acid in 200 mL distilled water, 
2. Addition of 6.3 g Na2HPO4.12H2O to the citric acid solution, 
3. Adjust solution to pH 4.1 using NaOH, 
4. 100 mg ABTS powder was then added to citric acid buffer, and 
5. Finally 72 L of 30% H2O2 was added. 
 The developing solution was tested by adding 0.5 L secondary antibody solution 
to 500 L. Excess solution was stored in 12ml aliquots at -20oC. The secondary antibody 
was removed and the plates washed 3 times with wash buffer. The plates were then 
washed for a fourth time using 1x PBS without Tween 20. After washing, 50 L of ABTS 
developing solution was added to each well. After 3 minutes the colour development was 
stopped by the addition of 1% SDS in water and then analysed using a BMG Labtech 
FLUOstar Omega spectrometer at OD 405nm. 
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CHAPTER 4 
Development, fabrication and characterisation of dissolving 
Nanopatches 
4.1 Summary 
As discussed in the literature review, multiple different fabrication techniques for 
dissolving microneedles have been developed. These fabrication techniques were 
designed for large (~ 600 m in length [18]), low density projection arrays (up to 200 
projections per cm2 [115] or just one needle [100])  with an end goal of payload delivery 
into systemic circulation. However, the emphasis of NP delivery (and hence dNP delivery) 
was on the intra-cutaneous delivery of large biologicals (vaccines). 
 
In this chapter, I report on the development and fabrication of a novel method for 
the production of dNPs – a method that I have both published and filed for patent, which 
addressed the key question of objective one: 
 
Could arrays of reproducible dissolving microstructures (<200 m) be produced in a 
manner, designed to incorporate and deliver sensitive biologicals? 
 
The dNP fabrication process developed was achieved without heating, or 
harsh/complex chemical processes (eg. encapsulation) and was performed at a neutral 
pH. These attributes were important in fabricating a platform for vaccine delivery – as 
vaccines could lose functionality when subjected to adverse conditions. The formulated 
densely-packed dNPs were two orders of magnitude smaller than the standard needle and 
syringe (which currently delivers most vaccines). By formulating the payload within the 
dNPs, with multiple layers and tight tolerances (e.g. ± 1.5 m) – I have achieved enhanced 
functional miniaturisation of the platform enabling vaccine to be delivered directly within 
skin strata rich in immunologically active cells. These results address the above question 
providing a versatile method of fabricating structures on a micron scale. 
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4.2 Introduction 
As discussed in Chapter 2, there have been a range of emerging physical targeting 
methods designed for cutaneous drug delivery (e.g. liquid jet injection [~100 µm diameter 
jets] [119], gene guns [~2 µm gold microparticles] [84], reviewed in Kendall, 2006) [81]. 
Another approach was to reduce the size of the needle used in vaccinations – and  as 
outlined in Chapter 2, there is a class of device called microneedles, which has achieved 
some degree of miniaturisation by reducing the needle length down to  600 µm [8, 120]. 
Vaccines and drugs have been successfully dry-coated onto the surface of these 
microneedles, facilitating delivery within the skin upon application [121-124]. However, 
these microneedles were limited to large sizes (of the same order of magnitude as the 
needle and syringe; with only modest size reductions), in sparsely packed arrays up to 200 
projections per cm2 [115] (or just one needle) [125] – and therefore might not target 
antigen directly to desired immune cell populations within thin skin layers for optimal 
immune responses. 
 
To help address this challenge, the Kendall Group conceived a new approach, of 
very small and densely packed microprojections (Nanopatch [NP]), designed to directly 
and precisely deposit vaccine to thousands of skin immune cells; without widespread cell 
death.  One example prototype NP consists of a density approximately 20,000 
projections/cm2[9]. These silicon projections, coated with vaccines in the dry form, were 
applied to the skin, piercing the stratum corneum with subsequent vaccine delivery to 
immunologically sensitive cells [9, 126, 127]. The high density of these projections 
significantly increases the probability of targeting vaccine directly to the skin’s immune 
cells in the viable epidermis and/or dermis within a given surface area of skin [128]. 
 
By utilising the unique morphology and scale of the NP, I developed a method of 
fabricating arrays of multi-layered dNPs, which avoids the disadvantages (high 
temperature, use of harsh chemicals) of the previously published methods of fabrication. 
This method was published in SMALL [116] and was filed for patent [129]. The core idea 
was to achieve improved vaccine efficiency and effectiveness – over the needle and 
syringe – through precise targeting of vaccines to skin strata and APCs, achieved by 
device miniaturisation based on theoretical calculations and predictions [127]. Functional 
miniaturisation was done in two ways.  First, I established a robust method of formulating 
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dissolving dNPs, that were two orders of magnitude smaller than the standard needle and 
syringe (which is currently used to deliver most vaccines).  Then, by formulating the dNPs 
with multiple layers with tight tolerances (of the order of a micron), I achieved further 
functional miniaturisation of the platform to enable vaccine to be delivered directly within 
skin strata rich in different types of immune active cells.  Beyond the unique device 
miniaturisation, another important consideration of the formulation approach was that I did 
not use harsh chemical conditions, or high temperatures – key attributes suited for vaccine 
stability [130, 131].  
 
4.3 Experimental procedures 
4.3.1 Preliminary PDMS moulding of NP template 
The NP, (which as discussed in Chapter 1, was designed and developed in the 
Kendall Group) was used as a moulding template for dNP fabrication that consisted of 
3364 projections uniformly spaced in a square grid formation (4 mm x 4 mm) 70 mm apart 
[9]. The NP template was washed in 70% ethanol and dried at ambient conditions followed 
by storage in a petri-dish with needles facing upwards. PDMS was then poured over the 
master structure until complete immersion to a depth of approximately 5 mm. The 
immersed template was then placed under vacuum for 2 hours. Following degassing the 
combined template was placed in an oven at 65oC overnight to cure. After the PDMS had 
cured, the moulds were removed and cut to fit a standard biological 96-well plate. In 
preparation for casting, the moulds were thoroughly washed in water followed by 70% 
ethanol and dried at 50oC. 
 
4.3.2 Standard PDMS moulding of NP template 
The NP used as the moulding template had the same configuration as described in 
the previous section. The NP template was washed in 70% ethanol and dried at ambient 
conditions. The NP templates were then adhered to the moulding/casting apparatus 
(described in detail in Chapter 4, Section 4.4.2) using double sided sticky-tape. PDMS 
was then poured into each well of the moulding apparatus until level with the top and 
placed under vacuum for 2 hours. Following degassing the combined template was placed 
in an oven at 65oC overnight to cure. After the PDMS had cured, the moulds were 
removed and thoroughly washed in water followed by 70% ethanol and dried at 50oC. The 
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clean moulds were then placed in a standard biological 24-well plate prior to casting and 
fabrication of dNPs.  
 
4.3.3 Single-layer dNP casting 
Rhodamine-dextran dNPs were fabricated by mixing 1 mL of 2.5 mM rhodamine-
dextran (70,000 MW) with 9 mL of 0.22 mM carboxymethylcellulose (CMC) (90,000 MW) 
solution, which was added to the surface of the moulds. The moulds were then centrifuged 
at 3000 g for 2 hours at 22oC to facilitate compaction and drying. The moulds were then 
placed in a sealed desiccator at 22oC containing silica gel dry-beads, until solution had 
dried usually within 4 – 6 hours. The dNP array was then removed from the moulds and 
stored in a sealed desiccator at 22oC. 
 
4.3.4 Multi-layer dNP casting 
Polyethersulfone (PES) membrane was cut to fit on the surface of the moulds in a 
96-well plate. A solution of 50 mM rhodamine-dextran and 0.22 mM CMC was prepared 
and 5 mL was pipetted onto the surface of PES. Moulds were then centrifuged at 3000 g 
for 5 minutes. The PES membrane was removed from the mould with any remaining 
excess solution. Moulds were then centrifuged at 3000 g for 5 minutes to allow for further 
compaction and drying. For additional layers, fresh PES was placed on the surface of the 
mould and 5 mL of solution containing 1 mM FITC-dextran (2,000,000 MW) or 0.23 mM 
Evans Blue mixed with 0.22 mM CMC was pipetted onto the surface of the PES. Moulds 
were then centrifuged at 3000 g for 5 minutes to allow for further compaction and drying. 
This process can be repeated to achieve the desired number of layers, and thickness of 
layers, containing different payloads and/or excipients. Finally a backing layer was applied 
using 2.1 mM CMC. The moulds were then centrifuged at 3000 g for 20 minutes. The 
moulds were then placed in a sealed desiccator at 22oC containing dry-beads until solution 
had dried. The dNP array was then removed from moulds and stored in a sealed 
desiccator at 22oC. 
 
4.3.5 Standard dNP casting method for a range of payloads 
Moulds were prepared and cleaned prior to casting dNPs as stated in Chapter 4, 
Section 4.3.2. Each mould was placed in a standard biological 24-well plate followed by 
the addition of 10 L of payload solution. The payload solution consisted of delivery agent 
 53 
of interest and 1% CMC (90,000 MW). The moulds were then centrifuged at 3000 g for 
approximately 1 hour (or until payload had dried) at 25oC to facilitate compaction and 
drying. Finally, 50 L to 100 L of 2.1 mM CMC was applied to the moulds to form the 
backing layer containing no payload. The moulds were then centrifuged at 3000 g for 30 
minutes. The moulds were then placed in a sealed desiccator at 22oC containing dry-
beads, until the dNPs had dried usually within 4 – 6 hours. The dNP array was then 
removed from the moulds and stored in a sealed desiccator at 22oC under nitrogen. 
 
4.4 Results and discussion 
4.4.1 Preliminary moulding and fabrication of the dNP 
The NP silicon template was used to make a mould for fabricating dNPs. The 
general process showing the stages of fabrication was summarised in Figure 4.1 and 
described in detail in the previous Experimental Procedures section. On application of 
the payload to the surface of the mould, it was found that the payload solution formed a 
spherical shape on the surface due to the hydrophobic interactions with the PDMS (Figure 
4.1d). This resulted in the payload ‘rolling’ of the surface of the moulds during 
centrifugation (Figure 4.1e). The addition of the backing payload, which served as the 
structural support of the dNPs and also confined the payload to the shafts of the 
projections, was found to also surround the mould and dry on the edge of the plate wells 
resulting in a dNP as shown in Figure 4.1h. This meant that before each dNP could be 
used, the excess backing layer needed to be removed, which involved an intricate and 
time consuming step of cutting the excess away with scissors to produce a final dNP 
resembling the NP (Figure 4.1i). 
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Figure 4.1. Images showing the initial development stage of moulding and fabrication of 
the dissolving Nanopatch: a) Nanopatches were washed and placed in a petri dish; b) 
PDMS was poured in the dish and moulds were formed and cut to fit a standard biological 
96-well plate; c) moulds were placed in 96-well plate; d) 10 L of payload solution was 
placed on surface of mould; e) the plate was centrifuged at 3000 rpm for 10 minutes; f) 
excess solution surrounding mould was removed; g) 20-30% CMC gel was placed on 
mould and centrifuged for 10 minutes followed by drying in a desiccator; h) dissolving 
Nanopatch was removed from plate, and; i) excess backing was cut away to leave the final 
dissolving Nanopatch resembling the solid gold coated silicon Nanopatch. 
 
The key issues with the initial fabrication process mentioned are shown in Figure 
4.1d, e and h. As mentioned, PDMS is a highly hydrophobic material, however its inert, 
non-toxic and highly non-stick properties makes it ideal for moulding. To overcome the 
spherical morphology of the payload solution (Figure 4.1d), a porous membrane was cut 
to fit the surface of the moulds prior to addition of the payload, coined ‘dispersion 
membrane’. The membrane was absorbent and could evenly disperse the payload 
solution. Biological filter paper made from PES with 0.22 m pore size was used because 
it minimally bound protein to the membrane and it was a common reagent used within the 
Kendall Group. This adaptation resulted in an improved fabrication method of dNPs where 
the payload could be even delivered into the moulds (Figure 4.2). 
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Figure 4.2. Images showing the improved method of moulding and fabrication of the 
dissolving Nanopatch (highlighted in red): a) Nanopatches were washed and placed in a 
petri dish; b) PDMS was poured in the dish and moulds were formed and cut to fit a 
standard biological 96-well plate; c) moulds were placed in 96-well plate followed by the 
addition of a dispersion membrane on the surface; d) 10 L of payload solution was placed 
on surface of the dispersion membrane; e) the plate was centrifuged at 3000 rpm for 10 
minutes; f) excess solution surrounding mould and used dispersion membrane was 
removed; g) 20-30% CMC gel was placed on mould and centrifuged for 10 minutes 
followed by drying in a desiccator; h) dissolving Nanopatch was removed from plate, and; 
i) excess backing was cut away to leave the final dissolving Nanopatch resembling the 
solid gold coated silicon Nanopatch. 
 
As stated the membrane absorbs the payload prior to casting. To determine 
whether there was a significant ‘wicking affect’ of the membrane, different volumes of an 
ovalbumin protein solution were cast into dNPs. The resulting dNPs were dissolved in 
buffer and tested using a Qubit protein assay. To determine an approximate mould 
volume, the NP geometry was simplified to a cylinder, cone morphology. The volume of 
the female mould was then calculated to be 0.22 L (based on cylinder dimensions of 15 
m radius, 85 m height and cone dimensions of 15 m radius and 45 m height). Varying 
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the amount of solution cast into the mould using the above casting method resulted in 
approximately 80% of the female mould being layered at higher volumes (Figure 4.3). 
Seeing as the NP geometry was simplified to calculate a theoretical volume of the dNP 
mould the 80% yield achieved was not deemed as a significant loss. The improved 
membrane casting approach was further characterised using fluorescence microscopy in 
Section 4.4.4. 
 
 
Figure 4.3. Graph showing the volume of stock solution added to the mould compared to 
the amount which actually was loaded. Approximately 0.18 µL loading was achieved at 
higher volumes. 
 
The improved method aided in dispersing the payload evenly across the surface of 
the mould prior to centrifugation, however it did not reduce the handling steps post dNP 
fabrication. A moulding/casting apparatus was designed to improve and streamline the 
fabrication process which will be discussed in further detail in the following section 
(Chapter 4, Section 4.4.2). 
 
4.4.2 Standard moulding and fabrication of the dNP 
The previous section focussed on optimising the casting (or placement) of payload 
into the mould during fabrication. However another important issue not limited to dNPs but 
all types of dissolving/polymer microneedles was patch removal without the need of post 
fabrication handling (i.e. removal of edges) and subsequent administration into skin. To 
avoid the need for dNP modification post fabrication, I developed a moulding/casting 
apparatus as shown in Figure 4.4. The moulding plate was designed to have platforms in 
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each mould well to support the NP template (Figure 4.4a). The platforms were tapered 
towards the NP dimensions so that the resulting moulds consisted of a large reservoir for 
payload and backing gel (Figure 4.4a insert). The apparatus was designed in such a way 
so that the plate providing the wall for the moulds can be separated and used as a casting 
plate (Figure 4.4b).  
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Figure 4.4. Diagrams showing the design and use of custom moulding and casting plates: 
a) The combined moulding and casting plates with insert showing Nanopatch footing; b) 
After moulding, the casting plate was separated so that the moulds can be removed; c) 
Summary of how the release screws were used to separate the two plates post Nanopatch 
moulding. Schematics provided by Alex Ansaldo. 
 
By combining the moulding and cast plate, the number of steps in the fabrication 
process can be reduced (i.e. transfer of dNP moulds from a moulding apparatus to a 
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casting apparatus). The PDMS used for moulding forms a tight seal between the moulding 
and casting plates. To aid in separation of the two plates, release screws were designed to 
evenly push the casting plate away (Figure 4.4c). This also prevented the moulds from 
being removed at angles that may damage the NP projections. Figure 4.5 shows 
magnified photos of a representative NP template on the moulding insert, the 
corresponding mould and the resulting dNP. 
 
 
Figure 4.5. Close up photographs showing the NP moulding, footing and corresponding 
mould used for casting dNPs. 
 
The resulting enhanced moulding and fabrication method is shown in Figure 4.6. 
The detailed experimental protocol was discussed in Chapter 4, Section 4.3.5 and was 
used throughout the thesis as the ‘standard dNP fabrication method’ unless otherwise 
stated in the experimental section at the start of each chapter. Briefly, NP templates were 
adhered to the moulding plate footings using double-sided sticky tape (Figure 4.6a). The 
casting plate was then screwed to the moulding plate and PDMS was used to mould the 
NPs (Figure 4.6b). After curing the plates were separated with the resultant moulds kept 
in the casting plate (Figure 4.6c). In theory the moulds remain in the casting plate for the 
duration of the casting process, however only one casting plate was available so the 
moulds were removed and placed in a standard 24-well biological plate. The moulds were 
cleaned by sonication with 70% ethanol followed by distilled water. This was followed by 
the addition of 10 L of payload solution (Figure 4.6d). The payload solution consisted of 
delivery agent of interest and 1% CMC (90,000 MW). The moulds were then centrifuged at 
3000 g for approximately 1 hour (or until payload has dried) at 25oC to facilitate 
compaction and drying. Finally, 50 L to 100 L of 35% CMC was applied to the moulds to 
form the backing layer containing no payload (Figure 4.6e). The moulds were then 
centrifuged at 3000 g for 30 minutes. The moulds were then placed in a sealed desiccator 
at 22oC containing silica dry-beads, until the dNPs had dried usually within 4 – 6 hours. 
 60 
The dNP array was then removed from the moulds and stored in a sealed desiccator at 
22oC under nitrogen (Figure 4.6f). 
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Figure 4.6. Images showing the improved (standard) moulding and fabrication process of 
dissolving Nanopatches: a) Nanopatches were washed and adhered to the moulding plate; 
b) the casting plate was attached and PDMS was used to moulds NPs; c) after curing the 
plates were separated; d) the moulds were transferred to a standard 24-well biological 
plate and 10 L of payload solution was placed on surface; e) 35% CMC gel was placed 
on mould and centrifuged for 30 minutes followed by drying in a desiccator; f) the final dNP 
was removed and stored at 22oC under nitrogen. 
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4.4.3 Fabrication and microscopy analysis of the dNP 
The previous sections discussed the fabrication of dNPs on a macro morphological 
scale. The remaining results assess the micro-scale accuracy and reproducibility of the 
manufacturing method in regards to overall dNP morphology and projections.  
 
To assess whether PDMS was a viable polymer for moulding dNPs, an NP with 
small cone shape projections measuring 40 ± 2 m in length and 15 ± 1 m in diameter 
was used (Figure 4.7a). The dNPs were fabricated using the method described in 
Chapter 4, Section 4.3, however a 2% CMC solution was used as the payload instead of 
mixing with rhodamine dextran. Using stereo microscopy, it was shown that the PDMS 
accurately reproduced the NP template providing a reliable mould for a replicate dNP 
(Figure 4.7b). This was repeated multiple times, with the addition of rhodamine dextran 
and analysed using confocal microscopy (Figure 4.7c).  
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Figure 4.7. Preliminary fabrication of dNPs using short cone shaped projections; a) 
Scanning Electron Microscopic (SEM) image showing the Nanopatch projections; b) stereo 
microscopy image showing initial fabrication of the Nanopatch from 
carboxymethylcellulose; c) confocal fluorescence microscopy image of rhodamine dextran 
– carboxymethylcellulose dissolving Nanopatch showing reproducible projections across 
part of the array. 
 
Fabrication using the NP with small cone projections showed that accurate and 
reproducible dNPs could be produced. New moulds were made using larger projections 
approximately 130 m in length 30 m in diameter (the template and corresponding mould 
are shown in Figure 4.8). 
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Figure 4.8. Scanning electron microscopy (SEM) images showing a) gold-coated silicon 
NP array template; b) sectioned polydimethylsiloxane (PDMS) mold; c) magnified SEM of 
NP template, and; d) magnified SEM of PDMS mould. 
 
A preliminary experiment was done to assess whether PEG, sucrose and/or 
chitosan could be used in conjunction with CMC as a starting point for dNP composition 
(Figure 4.9). Sucrose and sucrose/CMC solutions were prepared and cast to produce 
dNPs. After drying the dNPs fractured easily on removal from the moulds (Figure 4.9a). 
The brittle nature of the patches was attributed to the addition of sucrose to the CMC. The 
actual projections that formed were rounded and did not represent the mould accurately, 
possibly due to crystallisation of the sucrose during drying (sucrose/CMC dNPs are 
discussed in much greater detail in Chapter 7). A pure sucrose dNP was produced; 
however this formed one large sucrose crystal that did not accurately reproduce the NP 
template (Figure 4.9b). The pure sucrose dNP was attempted again, however with just 
enough sucrose solution to coat the base of the mould. This produced a thin sucrose dNP 
that was also highly crystalline and due to its thin nature, very brittle and fragile. The thin 
sucrose dNP fractured upon handling. PEG and chitosan were cast to produce slow 
release dNPs. PEG formed a soft patch with slight indentations on its surface instead of 
projections resembling the NP template (Figure 4.9d). Chitosan formed an accurate 
replication of the NP template, however under the given conditions, the surface dried with 
several bubbles, deforming the cast (Figure 4.9f). It was hypothesised that dNP 
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fabrication using chitosan could be improved by increasing centrifugation speed and time 
during casting, however slow release dNPs were out of the scope of the project and 
therefore this was not further explored. CMC, which has been used in previous reports 
[18], produced an array of uniform microprojections, (Figure 4.9e). Unlike other reported 
studies in literature, the scale of projections was much smaller, being less than 130 m in 
length and 30 m in diameter however based on the preliminary data shown in Figure 4.9 
it was expected that CMC would produce reliable dNPs. 
 
 
Figure 4.9. Stereomicroscopy images of six different dNPs composed of different 
compounds. The insets show a magnified view of the dNPs. a) One part sucrose to 5 parts 
CMC patch with blunt projections and many fractures; b) thick sucrose patch with very 
blunt projections in the formation of single crystal; c) thin sucrose patch with little formation 
of projections and very brittle; d) polyethylene glycol polymer patch with little formation of 
projections; e) fluorescent CMC patch with accurate uniform projections and a; chitosan 
patch showing good formation of projections, however at a low efficiency. 
 
Having determined that CMC produced uniform microprojections using stereo 
microscopy, scanning electron microscopy (SEM) was then used to analyse both the 
mould and resulting projections on a micro-scale [116]. The NP template used was a slight 
variation from the previous NP shown in Figure 4.8 and consisted of projections with a 
total length of 116 ± 2 m (mean ± standard deviation) and a base diameter of 23 ± 1 m 
(Figure 4.10a). As discussed previously, PDMS – a well-established material used within 
the microfluidics field was used to construct moulds of the dNPs. SEM analysis showed a 
reduction in size of approximately 6% between the projection dimensions of the NP 
 66 
template compared to the mould (Figure 4.10b). I then used the moulds to cast dNPs 
using CMC resulting in structures mirroring the NP template (Figure 4.10c). Specifically, 
measurements of the dNP projections (n = 30 projections) resulted in a total length of 88 ± 
3 m and a base diameter of 17 ± 1 m (Figure 4.10d) corresponding to a 32 ± 5% 
reduction in size from the NP template. The decrease in dimensions was attributed to the 
loss of moisture during the casting process – leading to contraction and solidification of the 
solution/gel.  
 
 
Figure 4.10. Scanning electron microscopy (SEM) images showing a) gold-coated silicon 
Nanopatch (NP) array template; b) sectioned polydimethylsiloxane (PDMS) mould; c) 
corresponding dissolving Nanopatch (dNP) array comprised of carboxymethylcellulose 
(CMC) with insert showing magnified image of a single projection; and d) graph showing 
the lengths of the template projections (a) compared to the dissolving projections (c) 
Raphael et al. [116]. 
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4.4.4 Fabrication of multilayered dissolving Nanopatch arrays 
I then moved onto the fabrication of more complex dNPs incorporating multiple 
layers of different payload solutions, in order to reduce wastage of payload during 
administration and conceptually gain fine control over release properties within the skin 
layers. A schematic of the casting process is outlined in Figure 4.11a, showing the steps 
to form a multilayer dNP array with different payloads localised to specific length segments 
within the projections [116]. First, in Figure 4.11a: step 2 shows the placement of a 
porous membrane on the surface of the mould prior to adding the payload solution. Then 
the payload solution was absorbed into the membrane, dispersing across the surface of 
the mould before casting (Figure 4.11a: step 3 & 4). A secondary solution was cast and 
dried to form a dNP array (Figure 4.11a: step 5 – 7). During the casting of the secondary 
layer, the previous layer was hydrated facilitating fusion between the two different layers. 
This could be repeated for many layers, resulting in the formation of solid projections 
during the drying process and a single solid structure upon removal from the mould.  
 
I fabricated layered dNPs and investigated the distribution of multiple fluorescent 
payloads via fluorescence microscopy (Figure 4.11 b-d).  I started with the simplest case 
of one uniform formulation throughout the dNP projections and backing using a 
rhodamine-dextran payload (Figure 4.11b). The dimensions of these projections (n = 28 
projections) were 92 ± 5 m in length with a 23 ± 1.1 m base diameter (Figure 4.11) 
diameter, showing close agreement with the SEM measurements. I then extended the 
concept by fabricating dual-layered dNPs (Figure 4.11c) that resulted in solid structures 
with discrete layers of the two payloads. Rhodamine-dextran was localised to the 
projection tips (56 ± 2 m measured from the tip) while a secondary layer of Evans Blue 
presented a discrete layer measuring 33 ± 1 m from the Rhodamine-dextran / Evans Blue 
boundary towards the base (n = 20 projections). The third layer (dNP backing) contained 
CMC without fluorescent payload constituting the base of the array. This dNP array was 
replicated and comparison between the arrays resulted in a difference of up to 10 m in 
length of the rhodamine-dextran layer and up to 3 m in length of the Evans Blue layer. A 
four-layer dNP array was fabricated with rhodamine-dextran localised to the projection tips 
(19 ± 2 m measured from the tip) while a secondary layer of FITC-dextran presented a 
discrete layer measuring 22 ± 2 m from the Rhodamine-dextran / FITC-dextran boundary 
towards the base (n = 8 projections). A third layer containing a mixture of rhodamine-
dextran and CMC in the shafts (54 ± 1 m) was followed by a backing layer of CMC 
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without fluorescent payload constituting the base of the array. In regards to the actual 
volume deposited in the projection, a representative image is shown in Figure 4.12, with a 
calculated deposited volume of approximately 21 picolitres. 
 
 
Figure 4.11. Schematic of the fabrication process and dNPs fabricated using this process. 
a) Shows a schematic diagram of an example casting process to produce an ‘multi ’ 
layered dNP array with payload in the tips; b) dNP array consisting of rhodamine-dextran; 
c) layered dNP array consisting of rhodamine-dextran, Evans Blue and CMC backing 
(arrows indicating specified layer); and d) layered dNP array consisting of rhodamine-
dextran, FITC-dextran and CMC backing (arrows indicating specified layer) Raphael et al. 
[116]. 
 
The layering of dNPs was significantly more precise (i.e. lower variation) than 
reported existing dissolving microneedles [15, 16]. For example, it could be measured in 
previous studies that layering variations range from 8 [15] - 48 m [16] within single arrays. 
In contrast I produced – with this simple, room temperature approach – dNPs with inter-
device variation of ≤ 10 m and variation within a single device of ≤ 2 m. This 
miniaturisation of layering (Figure 4.11) compared to the work of others was important 
because it opened up the ability to target drugs (e.g. vaccines) to particular skin strata, 
each with unique immunological attributes and minimising loss of valuable payload on the 
skin surface.  
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Figure 4.12. An example of the picolitre quantity that can be layered in each micro-
projection within the array, using an image taken with fluorescent confocal microscopy. 
 
For the dNP to be suitable to a range of vaccines, it was important for the vaccine 
functionality to be maintained during the formulation process. Therefore, dNPs used in this 
thesis were fabricated under mild conditions appropriate for incorporation of sensitive 
biomolecules – fabrication took place at 22oC at relatively neutral pH (~ 6.89) using an 
FDA approved excipient (CMC) and devices were dried at either 4oC or 22oC in a 
desiccator depending on payload. The temperature and chemical attributes were within the 
range required to maintain functionality of most vaccines. This was advancement over 
existing approaches – with high temperatures (140oC – 230oC) needed to melt and solidify 
microneedle arrays.  Furthermore, the dNPs did not need particle encapsulation, while 
reported layered fabrication methods require the payloads to be in particulate form, often 
requiring the complexity of encapsulation within polymers prior to casting. 
 
4.4.5 Conclusion 
The data in this chapter encompasses objective one and as stated in the 
summary, the key question addressed was whether: 
 
Arrays of reproducible dissolving microstructures (<200 m) could be produced in a 
manner, designed to incorporate and deliver sensitive biologicals? 
 
 In this Chapter I addressed this question by introducing a fabrication method for the 
production of dNPs (~100 m in length) using carboxymethylcellulose. This technique was 
then both published and filed for patent by the Kendall Group. The new advantages of this 
fabrication process were that it did not require heating or harsh/complex chemical 
processes (eg. encapsulation) and that it was performed at a neutral pH. These attributes 
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were important in fabricating a platform for vaccine delivery – as vaccines could lose 
functionality when subjected to harsh conditions.  
Another novelty of the fabrication technique was that the formulated densely-
packed dNPs were two orders of magnitude smaller (100 m) than the standard needle 
and syringe (which currently delivers most vaccines) and that the payload within the dNPs, 
could be formulated with multiple layers and tight tolerances (e.g. ± 1.5 m) – which had 
not been achieved before. Even though the work in this chapter does not explore the 
functionality of the moulded vaccine, it set the groundwork for further analysis, which was 
done in the following chapters of this thesis. Overall the data in this chapter provided 
insights into a new technique for fabricating microstructures that could be used for a range 
of delivery techniques.  
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CHAPTER 5 
Administration of dissolving Nanopatches into skin 
 
5.1 Summary 
In the previous chapter I addressed the question of whether microstructures (< 200 
mm) in length can be fabricated using mild conditions suitable for sensitive biologicals. I 
developed a technique to produce arrays of dNPs as a platform for vaccine delivery. 
Furthermore, the technique designed provides a high degree of resolution, facilitating the 
fabrication of layered microstructures with picolitre quantities. 
 
However, the mild conditions used to fabricate dNPs for vaccine delivery, limited the 
dNP composition to sugars and cellulose derivatives (i.e. carboxymethylcellulose). I also 
did not explore in the previous chapter within objective one, the functionality of the dNP 
encapsulated payloads. Therefore the question governing objective two was: 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
The above question was the primary focus of this project and was divided into the 
following three chapters 5, 6 and 7. Within this chapter I assessed and improved the 
administration process of dNPs by applying them to murine skin and analysed the 
penetration profile with SEM and histology. Secondly, I further characterised the 
penetration and dissolution of the formulated dNPs within skin, showing consistent and 
robust penetration of the stratum corneum with diffusion within the lower viable skin layers.  
 
It was determined that the dissolution of dNP payload into the skin was rapid and 
precise: within just five minutes (due to its small scale and large surface area), which was 
a vast improvement over much larger dissolving microneedles of similar composition (1 
hour [18]). Initial administration resulted in a low delivery efficiency of approximately 1.7%; 
however this was improved with a final delivery efficiency of 12.2 +/- 4.3%. Analysis of skin 
histology images at time = 0, resulted in a depth of fluorescent payload of 34 ± 5 m, with 
an increase in signal measured to a depth of 89 ± 19 m after 2 minutes.  
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Using high resolution microscopy in conjunction with the concise delivery of the 
dNP resulted in the observation of significantly enhanced diffusion within the dermis 
compared with the epidermis. This new insight into a diffusion differential could be an 
important consideration for targeting of biomolecules to particular cells within these layers.  
 
5.2 Introduction 
In Chapter 4, I discussed the different fabrication techniques and characterisation 
of resulting dNPs. Unlike solid silicon and metal microneedles, dissolving microneedles 
typically consist of polymers, sugars and/or cellulose derivatives. Confocal fluorescence 
microscopy and SEM images of dNPs showed that CMC and labelled dextran formulations 
produced uniform and accurate projections. Previous research has shown that 
microneedles fabricated with similar formulations penetrate the stratum corneum and 
dissolve in the skin [18, 105].  
 
The penetration characteristics of dNPs entering skin were determined by key 
mechanical properties of both the skin and dNP material. These include the skin elastic 
properties (Young’s Modulus) of the stratum corneum, viable epidermis and dermis being, 
depending on hydration, 26 – 120 MPa [132], 2.9 – 11.1 MPa [56] and 2.1 – 4.3 MPa 
[133], respectively. I estimated the elastic modulus of projections were approximately 1 
GPa, because the main constituent was CMC, which had a reported value of 1 GPa [18] (I 
have confirmed a similar elastic modulus using nanoindentation, discussed in detail in 
Chapter 7). Using metal projections at a scale similar to the dNPs, Kendall et al. found 
that the skin surface would fail, facilitating penetration at ~ 13 MPa [56], which was similar 
in value (dermal elastic modulus of 7.3 to 13.5 MPa) reported by Crichton et al. 2011 [134]. 
 
To theoretically examine the robustness of the projections during insertion, I 
combined this information into an Euler buckling analysis [135]. For the ‘fixed-pinned’ case 
where the base of the projection was fixed in position and the tip can move freely, 
assuming the projection was a cylinder 100 m in length with a radius of 10 m, buckling 
load of CMC projections can be calculated using Euler’s buckling “equation (1)”:  
 
        (1) 
 73 
 
    (2) 
 
Here, Fbuckling was the force to buckle the projection; Pbuckling was the pressure at 
buckling; Aprojection_tip was area of the projection tip being loaded during penetration; E was 
the elastic modulus of CMC; I was the area moment of inertia of the projection; k was the 
length factor for the ‘fixed-pinned’ case [135]; and L was the length of the projection. Using 
this information with “equation (2)”, the calculated pressure required to buckle an individual 
cylinder projection comprised of CMC was 50 MPa. This was significantly greater than the 
pressure of failure for the skin of ~13 MPa reported [56], therefore, predicting that the 
dNPs  would successfully penetrate the skin without breakage.  
 
As described in more detail in Section 4.4, the cone length of the dNPs was 
approximately 30 m with a total length of 90 m. The combined thickness of the stratum 
corneum and viable epidermis in murine skin is approximately 20 m [56]. It was expected 
that the dNPs would initially penetrate into the viable epidermis with possible dermal 
penetration. To validate dNP penetration and dissolution in the skin, fluorescent and radio-
labelled dNPs were applied to murine skin using a spring applicator designed in the 
Kendall Group. 
 
5.3 Experimental procedures 
5.3.1 Cryo-SEM and histology analysis of dNPs 
CMC dNPs were applied to the ventral side of excised 6 week old female C57BL/6 
mouse ears. Application was with a spring applicator at a velocity of 1.9 ms-1. Following 
administration the combined dNPs and ear were frozen in liquid nitrogen slush, within 60 
seconds. The dNP array was then removed in a cryo-preparation chamber under vacuum 
(Cryo-SEM analysis). To image the dissolution of the projections the dNP array was 
separated prior to snap freezing. A Philips XL30 instrument with Oxford CT1500 Cryo-
preparation system was used to examine the ears. For histology analysis, the dNP 
remained in the skin during sectioning and sliced at 30 m slices using a cryostat. All 
mouse experiments were carried out in accordance with the Guidelines for Animal 
Experimentation of The University of Queensland at the Australian Institute for 
Bioengineering and Nanotechnology animal facility. 
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5.3.2 Fluorescent microscopy of dNPs 
Female C57BL/6 mice were anesthetised with an intraperitoneal injection of 150 L 
of 10 mg/mL ketamine and 2 mg/mL xylazil in saline. A rhodamine-dextran dNP array with 
CMC backing was applied to the ventral side of the ear. Application was with a spring 
applicator at a velocity of 1.9 ms-1 and held in place for 5 minutes. Following administration 
the dNPs were removed and the administered area was examined using multi-photon and 
fluorescence microscopy. The wavelengths used to excite the rhodamine-dextran and 
collagen was 543 nm and 840 nm respectively with all microscopy done using Zeiss 
LSM510 Meta confocal microscope. 
 
5.3.3 Cryo-histology analysis of dNP administration 
Female C57BL/6 mice were euthanised followed by excision of their ears. An 
excised ear was then placed on the vinyl backing within a cryo-sectioning cup (ventral side 
facing upwards).The cup was placed in a larger container suitable for holding liquid 
nitrogen (plastic weigh-boat). A rhodamine-dextran dNP with CMC backing was gently 
placed on the surface of the ear (no force was applied to prevent projections bending on 
the surface).The dNP was then applied using the spring applicator at 1.9 ms-1. Following 
administration, the applicator was held in place for the desired time, (time = 0 or 2 
minutes).  The cryo-sectioning cup was filled with OCT mounting media. The outer 
container was filled with liquid nitrogen, which was used to freeze the mounting media and 
fix the dNP/ear in place. The applicator was gently removed and extra mounting media 
was applied to encase the dNP and ear. After mounting samples, were stored at -20oC 
until sectioned at 50 m intervals using a cryostat. 
 
5.3.4 Load cell analysis of the force during application 
The mouse applicator used for all experiments was designed and characterised in 
the Kendall Group (Figure 4.2a). The standard calibration setup used for the spring 
applicators used a dynamic cell measurement apparatus (designed in the Kendall Group). 
The setup consisted of a load cell, stand, digital acquisition unit and a computer. The load 
cell (PCB-208C02 [PCB Piezoelectronics, Inc., USA]) has a resolution of 4 mN and 
maximum sampling rate of 36 kHz. The load cell was mounted onto a modified mouse 
patching stand (the load cell replaced the position of the mouse). The applicator was 
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applied to the load cell at 1.9 ms-1, resulting in a voltage output. Measurements were 
recorded using a LabVIEW (National Instruments, USA) program to capture data at 72 kHz 
in accordance with the Nyquest sampling criterion. The program controlled a NI USB-6221 
(National Instruments, USA) data acquisition unit, capable of sampling at up to 250 kHz. 
  
5.4 Results and discussion 
As stated previously in this thesis, there is a huge contrast in size between the dNP 
and a standard syringe (shown in Figure 5.1). The typical syringe is also constructed form 
strong metal alloys in relation to the dNP, which consists of cellulose based derivatives. 
However, based on the estimated mechanical properties of the dNP composition and 
various skin layers, I estimated that the force applied by the dNP during application would 
easily account for the force required to breach the skin. I tested the mechanical integrity 
and payload release characteristics of the solid dNPs by applying them to both excised 
and live mouse skin, and independently analysing the surface topography/penetration 
(Figure 5.10) and the penetration/dissolution process over time (Figure 5.12).  
 
 
Figure 5.1. Photographs showing the size comparison between 0.5 mL 29 gauge syringe 
and a CMC dNP. Image a) macro image showing the contrast in size; and, b) showing a 
magnified photograph of the needle tip in front of the dNP array. 
 
5.4.1 Administration of dNPs to murine skin using a patch-attach 
dNP administration was done using a well characterised internal spring applicator 
[136] designed in the Kendall Group (Figure 5.2a). A stand was designed to support both 
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the applicator and the mouse. To keep the mouse ear level and prevent excess damage to 
the ear a raised platform was situated in the application area that supported a small 
square piece of vinyl (shown by the arrow in Figure 5.2b). The vinyl was replaced after 
each patch administration. Figure 5.2c shows the complete administration rig with an 
anesthetised mouse in place. The ear was held in place with double-sided ‘sticky tape’ on 
the vinyl (shown by the arrow). 
 
It was determined in the Kendall Group that attaching the NP (or dNP) directly to 
the end of the applicator’s plunger results in bouncing of the patch upon administration. 
This was attributed to the plunger removing the patch as it bounced within milliseconds 
after application. To separate the patch from the plunger, a patch-attach was designed by 
the Kendall Group.  
 
Figure 5.2. Photographs showing the administration rig and applicator. a) shows the brass 
patch applicator, the arrow points to the internal spring within the applicator used to 
accelerate the device; b) the rig used to support both the applicator and mouse, the arrow 
is pointing to the vinyl patching platform that was used to support the mouse ear for 
administration, and; c) the combined applicator and rig with mouse in place. The arrow is 
showing the location of the ear during administration. 
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The patch-attach was composed of an adhesive carbon tab and a small piece of 
material (e.g. paper) on the backing of the tab to prevent it from sticking to the plunger 
(shown by the arrow in Figure 5.3a). The ends of the patch-attach adheres to the edges of 
the applicator with minimal force so as to prevent interference during the application 
process (Figure 5.3b). Finally the applicator was positioned above the vinyl (Figure 5.3c) 
so that the patch was not touching the mouse ear. After plunger release, it travels down 
the applicator, hitting the back of the patch-attach and upon impact on the mouse skin the 
plunger can bounce freely without pulling the patch out of the skin (bouncing effect shown 
later in Figure 5.8). 
 
 
Figure 5.3. Photographs showing the patch-attach designed in the Kendall Group. a) The 
patch (dNP) was placed on the surface of a carbon tab. Material was placed on the back of 
the carbon tab to prevent it adhering to the applicator plunger during administration 
(arrow); b) the ends of the patch-attach were adhered to the edges of the applicator, and; 
c) the applicator was positioned above the vinyl (and mouse ear when in place) so that the 
patch was not in contact with the skin. 
 
Unlike the solid silicon NPs that were on a solid flat silicon backing, the dNPs had a 
small edge due to the fabrication process. To utilise the dNPs with the Kendall Group’s 
standard application process (i.e. patch-attach), the edges of each dNP had to be removed 
prior to administration (Figure 5.3). Removal of the edges resulted in a flat patch that 
could be adhered to the carbon tab. To qualitatively assess the patching process, dNPs 
were analysed with SEM post administration (Figure 5.4). The central area of a 
representative dNP, shown in Figure 5.4 had dissolved. The inset shows a magnified 
image of the dissolved projections and it could be seen that there was no impression of 
bent projections that had dissolved on the backing of the dNP. Therefore, the dissolution 
was attributed to successful penetration with resulting dissolution within the aqueous 
region of the skin (this hypothesis is explored in detail later in this chapter). 
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Figure 5.4. SEM showing a representative image of a dNP applied to a mouse ear for 5 
minutes using a carbon tab based patch-attach (Figure 5.3). The red circle encompasses 
the dissolved area of the dNP with bent projections that did not penetrate on the outside. 
The white arrow shows a section of projections broken by tweezer handling. The inset is a 
magnified image showing the dissolved projections. 
 
It was observed (Figure 5.4), that outside the circled area, large portions of the 
projections were bent and flattened to the base of the patch. These bent projections were 
attributed to the projections not penetrating the skin and instead becoming compressed 
between the dNP backing and the skin. The post fabrication handling steps were also 
clearly visible (Figure 5.4). Cutting marks resulting from removing the edges of the dNP 
were seen as well as small regions of bent projections due to tweezer handling (arrow). 
These defects were common with all dNPs due to difficulty in their handling from their 
small size and the brittle CMC that cracked during the cutting process. To improve the 
administration process, the patch-attach was modified to remove all post dNP fabrication 
handling steps. A proof-of-principal patch-attach is shown in Figure 5.5. 
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Figure 5.5. Photographs showing a proof-of-principle patch-attach. a) Photograph showing 
the edges of the dNP post fabrication. These edges had to be removed prior to using the 
standard NP patch-attach; b) a square piece of thin high density polymer foam (PVC) was 
cut to fit within the edges of the dNP. The support was placed on the adhesive carbon tab, 
and; c) the dNP was then adhered to the square support with double-sided ‘sticky tape’ 
without the need of edge removal. 
 
Figure 5.5a shows the edges of the dNP post fabrication. As stated previously in 
this chapter, these edges had to be removed prior to using the standard NP patch-attach. 
This was so that the back of the dNP was flush with the carbon tab support for even 
distribution of force from the spring applicator plunger. A square piece of thin high density 
polymer foam (poly vinyl chloride, PVC) was cut to fit within the edges of the dNP. The 
support was placed on the adhesive carbon tab (Figure 5.5b). Finally, the dNP was 
adhered to the square support with double-sided ‘sticky tape’ (Figure 5.5c). This improved 
process resulted in a patch-attach that could evenly transmit the force from the applicator 
plunger to the dNP without the need of post fabrication edge removal. 
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SEM analysis was again used to qualitatively assess dNP administration in mouse 
skin. Unlike the previous dNP in Figure 5.4, the dNP shown in Figure 5.6 has not had the 
edges moved, which has resulted in square patch without defects in the outer projections 
due to cutting or tweezer handling. This was an obvious improvement between the two 
patch-attaches. The time between fabrication and administration was also drastically 
reduced, with edge removal of the dNPs being approximately 2 minutes per dNP. 
 
 
Figure 5.6. SEM showing a representative image of a dNP applied to a mouse ear for 5 
minutes, using the improved carbon tab based patch-attach (Figure 5.5). The red circle 
encompasses the dissolved area of the dNP with bent projections that did not penetrate on 
the outside. The inset is a magnified image showing the dissolved projections. 
 
The area of projections that didn’t penetrate the skin and dissolve was still 
significant, and like the previous dNP (Figure 5.4), only the centre projections penetrated 
and dissolved. However, unlike the non-penetrating projections seen in Figure 5.4, the 
dNP remaining projections in Figure 5.6 were not compressed flat with the backing of the 
dNP. This phenomenon was attributed to the dNP not coming in contact with the skin as 
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evenly as the original administration technique. The PVC support was cut using scissors, 
which compressed the edges of the PVC before cutting occurred. The compression of the 
PVC resulted in densification of the foam and a slightly curved surface. It was 
hypothesised that the uneven surface contributed to a reduction in penetration of the 
projections. Even though a large number of projections still did not penetrate and dissolve 
in the skin, the PVC support resulted in less damage (defects) to the overall dNP prior to 
administration and also drastically reduced the time required to prepare the dNP for 
application. Therefore an improved patch-attach was fabricated to incorporate a raised 
platform to support the dNP (Figure 5.7). 
 
 
Figure 5.7. Photographs showing the standard patch-attach used for dNP administration. 
a) Photograph showing the protruding square dNP support of the patch-attach; b) the dNP 
was then adhered to the square support with double-sided ‘sticky tape’ without the need of 
edge removal, and; c) The dNP patch-attach was adhered to the base of the spring 
applicator using an adhesive carbon tab (arrow). The dNP was positioned above the 
mouse ear as outlined previously so that the dNP does not contact the skin. 
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The standard dNP patch-attach was designed to fit within the edges of the dNP 
without the need of edge removal. The patch-attach was fabricated using the thermoplastic 
acetal (polyoxymethylene, Figure 5.7a). This is a common polymer used in the prototyping 
and manufacture of laboratory equipment because of its versatility (stiffness, shear 
strength, high tensile properties) and ease in machining precision parts [137]. The dNP 
was adhered to the square support with double-sided ‘sticky tape’ (Figure 5.7b). The dNP 
patch-attach was designed to fit within the end of the NP applicator without resulting in 
interference to the administration process. A wider circular lip can be seen in Figure 
5.7a/b. A double-sided adhesive carbon tab was adhered to the circular lip and used to 
lightly stick the dNP patch-attach to the applicator. A hole was cut in the centre of the 
carbon tab to prevent the tab from contacting and sticking to the plunger during application 
(a standard paper hole-punch was used to cut the hole).  
 
Seeing as the dNP patch-attach was a different design to the standard carbon tab 
based NP patch-attach, load cell analysis was used to calibrate the improved dNP 
application. A load cell is a transducer used to convert a force (in this case the impact of 
application) into an electrical signal. The Kendall Group uses the load cell setup (as 
described in Section 5.3.4) as a routine calibration technique within the laboratory for all 
applicators. The higher the force applied to the load cell, the higher the voltage output. 
This voltage can then be converted to an impact force (Newtons). I compared the voltage 
output after application of the standard applicator with the dNP patch-attach (n = 10 
[Figure 5.8]). As stated previously in this Chapter, after initial impact, the plunger bounces 
on the surface of the skin. This was clearly shown in the Figure 5.8a, where each peak 
corresponded to an impact on the load cell. When comparing the two application 
techniques the peaks after the initial impact peak (peak with force) could be ignored. This 
was because the NP and dNP patch-attaches were designed to be independent of the 
plunger and not bounce back with it during application. The key data obtained from the 
load cell analysis was the initial peak and its amplitude (Figure 5.8b). The amplitude 
corresponds to the moment of impact of the plunger/patch-attach on the surface of the 
load cell. The standard application resulted in 87 +/- 0.4 N peak impact force, which was 
the same peak impact force of the dNP patch-attach application (87 +/- 1 N [standard 
deviation n = 10]) peak impact. Statistical analysis (students t-test) of the data resulted in 
no significant difference between the two application techniques (p=0.784). The forces 
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achieved were suitable in applying the dNPs to skin, however this is discussed in much 
greater detail in Chapter 7. 
  
 
Figure 5.8. Load cell analysis of NP and dNP application. a) Graph showing the data of a 
representative analysis comparing the dNP patch-attach (red) and NP application (black). 
The box outlines the peak impact of application with the resulting peaks representing 
bouncing of the plunger on the load cell; b) data of peak impact from Figure 5.8a, and; c) 
analysis of the peak impact showing the tight standard deviation (n =10). 
 
Having determined that the improved dNP patch-attach does not interfere with the 
peak impact force during application, SEM analysis was again used to assess the 
dissolution profile of the dNPs post 5 minute administration in mouse skin. Like the 
previous two techniques (Figures 5.4 and 5.6), the centre of the dNP (circled area) 
consisted of a concentrated region of dissolved projections (Figure 5.9). The dNP still 
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consisted of large regions outside the circled area of bent projections from lack of 
penetration into the skin. This was qualitatively assessed to be less than that of the 
PVC/carbon tab patch-attach previously shown. The improved dNP patch-attach provided 
a quick and convenient method of applying the dNPs without the need of edge removal 
post fabrication or cutting irregular squares of PVC foam like with the previous patch-
attach. The improved dNP patch-attach was used throughout the thesis to apply the dNPs 
unless otherwise stated in the methods at the start of each chapter. 
 
 
Figure 5.9. SEM showing a representative image of a dNP applied to a mouse ear for 5 
minutes using the improved standard dNP patch-attach (Figure 5.7). The red circle 
encompasses the dissolved area of the dNP with bent projections that did not penetrate on 
the outside. The inset is a magnified image showing the dissolved projections. 
 
5.4.2 CryoSEM analysis of dNP administration into mouse skin 
CryoSEM analysis of C57BL/6 mouse skin applied with a CMC dNP show that the 
projections uniformly breach the skin surface (Figure 5.10) [116]. The combined dNP and 
ear was snap-frozen within 60 seconds resulting in the projections remaining embedded in 
the skin, anchoring and preventing them from being removed when the combined frozen 
patch and ear was separated. Figure 5.10a,b shows the typical base of a single projection 
that has penetrated and anchored with the skin. It was believed that the anchoring of the 
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projections within the skin was due to rapid dissolution and diffusion within the aqueous 
layers of the skin upon penetration and entry. The CMC component of the dNP was a 
large networked polymer that swelled within water and would provide a polymer matrix to 
anchor the projections. Figure 5.10c,d shows the projection morphology of an array that 
has been applied to the skin followed by removal after 60 seconds. It was clear that upon 
application, the projections begin to dissolve within the skin. 
 
 
Figure 5.10. Cryo-SEM images of CMC dNPs applied to mouse ear skin followed by snap-
freezing. a) CMC dNPs were applied to the ventral side of excised female C57BL/6 black 
mouse ears. Following administration the combined dNPs and ear were snap-frozen within 
60 seconds.  The dNP array was then removed in a cryo-preparation chamber under 
vacuum; b) greater magnification showing the back of a single projection embedded in the 
skin; c) CMC array applied to murine skin for 60 seconds followed by removal and snap 
freezing (arrow indicates mouse skin); d) greater magnification showing morphology of 
partially dissolved dNPs [116]. 
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5.4.3 Confocal fluorescence and MPM analysis of dNP administration into mouse 
skin 
Histology slices of a dNP array applied to the skin verifies that the surface 
breaching (Figure 5.10) translates into consistent penetration into the skin [116] (Figure 
5.12). The cryo-histology method was described in detail in the previous Section 5.3.3. 
Briefly, an excised ear was placed on the vinyl backing within a cryo-sectioning cup. The 
cup was placed in a larger container suitable for holding liquid nitrogen. A rhodamine 
dextran dNP was gently placed on the surface of the ear (Figure 5.11a). The dNP was 
applied with the spring applicator (Figure 5.11b). Following administration, the cryo-
sectioning cup was filled with OCT mounting media (Figure 5.11c). The outer container 
was filled with liquid nitrogen to freeze the mounting media and fix the dNP/ear in place 
(Figure 5.11d). The applicator was gently removed and extra mounting media was applied 
to encase the dNP and ear (Figure 5.11e). Snap-freezing immediately after the time of 
application shows that the projections have penetrated the stratum corneum barrier and 
entered the underlying viable skin (Figure 5.12a-c). Two minutes after application, greater 
than 50% of the length of the projections have begun to dissolve and diffuse within the 
layers of the skin (Figure 5.12d-f [n =12]). These results were consistent with the results 
observed by CryoSEM analysis (Figure 5.10) with the experiments validating that the 
projections penetrate the skin and in addition, subsequently dissolve. Within 5 minutes the 
entire length of the projections has dissolved.  
 
 
Figure 5.11. Flow diagram showing the experimental cryo-histology procedure used to 
analyse dNP penetration. a) dNP placed on an excised ear situated in a cryo-sectioning 
cup and liquid nitrogen container; b) the applicator was applied at 1.9 ms-1; c) OCT 
mounting media was poured into the cryo-sectioning cup; d) liquid nitrogen was poured 
around the cup snap-freezing the dNP/ear/media, and; e) the resulting mounted dNP/ear 
ready for cryo-sectioning. 
 
The rapid dissolution of the dNP was significantly faster than reported by existing, 
larger microneedles: with the 600 m CMC microneedles requiring 1 hour application for 
complete dissolution [18]; while other polymer microneedles dissolve and release their 
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payload from hours to days [138]. I expect the dNPs achieve this step-change reduction in 
dissolution time because of the significant increase in surface area achieved by the 
thousands of short projections.  This assertion was further supported when I compared 
these dNPs with the 600 m CMC microneedles [18]: both devices were constructed from 
essentially the same material, with the main difference being in device geometry. In the 
context of vaccine delivery, the dNP 5 minutes delivery time was highly relevant: 
vaccinations should be quick, preferably not much longer than current needle/syringe 
administration. Therefore the relatively fast dissolution rate was an important platform 
characteristic in vaccine delivery, where the recommended practise is to observe 
vaccinees for up to 20 minutes post administration to ensure no serious adverse reactions 
[139]. 
 
However, dNPs were not limited to vaccine delivery, with the possibility of varying 
the excipient material to change the dissolution kinetics for controlled drug release over 
time. Conceptually, further miniaturization of the microprojections into multi-layered 
payload segments provides an alternate approach for rapid dissolution using the one 
excipient. 
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Figure 5.12. Fluorescent microscopy images showing rhodamine-dextran dNPs 
penetrating and dissolving in mouse ear skin at a-c) time = 0 and d-f) time = 2 minutes. 
Images a,d) phase; b,e) fluorescence only; and c,f) merged phase and fluorescence. 
Whole ears were administered with rhodamine-dextran dNPs analysed 5 minute post 
application g) showing minimal payload on the surface of the skin (indicated by arrow); h) 
with the majority of the payload deposited in the dermal region (indicated by representative 
arrow). The lines indicate the depth and location within the skin shown in the images. i) 
Penetration of the projections was also analysed by measuring the depth of rhodamine-
dextran fluorescence within the skin [116].   
 
Penetration and dissolution was also independently confirmed by multiphoton 
microscopy, showing minimal residual material at the skin surface (Figure 5.12g) and 
payload deposition sites among collagen fibres within the dermis (Figure 5.12h). I 
confirmed dermal penetration by second harmonic generation of the dermal collagen 
surrounding the delivery sites of the dNP. The projections penetrated the skin, resulting in 
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a fluorescent signal within both the skin epidermis (Figure 5.12g) and dermis (Figure 
5.12h).  Interestingly, when I compare these sites, the fluorescent signal was greater 
within the dermis.  At first inspection, this larger volume signal of payload in the dermis – 
also observed in the histology data (at t=2 minutes; Figure 5.12d-f) – was unexpected: the 
dNPs within the upper skin strata were wider (at t=0 minutes; Figure 5.12a-c), so with all 
other parameters equal, I would expect a larger volume of signal within these upper skin 
layers.  Therefore, rather than a measure of payload mass, I assert that the higher signal 
volume within the dermis (at t= 2 minutes; seen in Figure 5.12) corresponds to a stronger 
diffusion within this layer.  My assertion was supported by reported properties of the skin 
layers that were important for diffusion. First, the skin has a hydration gradient, with a drier 
upper surface (30-40% hydration) with increasing hydration further below in the lower 
viable epidermis/dermis (65-70% hydration) [61]. This hydration gradient was linked with 
the mass of keratin in epidermal cells, which decrease from the stratum corneum to the 
dermis [140]. Keratin has a large binding affinity to water, reducing the amount of water 
available as a solvent [140]. This results in a density of diffusible ions and organic material 
within the skin increasing from the stratum corneum to the dermis due to the available free 
water [140]. 
 
To my knowledge, this was the first direct observation of enhanced dermal diffusion 
compared to the viable epidermis of precisely placed drugs within the skin – whereby the 
starting point of payload was very well defined.  Therefore, this observation of enhanced 
dermal diffusion might be important in developing ways to target drugs/vaccines to cells 
within both the viable epidermis and dermis.  These implications extend to many modes of 
delivery, including NPs – and also the larger dissolving microneedles in literature that have 
not been analysed with these methods.  
 
I extended the analysis of the dye profile in the skin following dNP application – 
finding that the depth of dye penetration was dependent on the technique used and time of 
analysis (Figure 5.12i). For example, measuring the depth of rhodamine-dextran 
fluorescence in the skin using histology images at time = 0, resulted in a depth of 34 ± 5 
m (n = 20 projection sites). At time = 2 minutes, the depth of rhodamine-dextran was 
measured to be 89 ± 19 m (n = 11 projection sites). The increase in depth was attributed 
to the diffusion of the projections within the skin (as discussed above). Independently, I 
performed a topographical analysis using MPM and fluorescent microscopy of whole skin 
– where the dNP was applied for 5 minutes following removal, resulted in depth 
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measurements of approximately 31 ± 4 m (n = 20 projection sites). I assume that the 
minor discrepancy in measured depth compared to diffusion after 2 minutes may be due to 
the scattering of the fluorescent signal within the skin as depth increases, and the limit of 
detection of the rhodamine-dextran as it disperses within the lower layers of the skin. The 
histology images in Figure 5.12 provide a more detailed representation of the depth of 
diffusion, however analysis of whole skin (Figure 5.12g,h) provides quick and simple 
observations of depth and dispersion of the bulk of the payload delivered. These findings 
could be of use to those interested in choosing the appropriate assay methods for 
drug/vaccine delivery, dissolution and diffusion within the skin. 
 
 
Figure 5.13. Fluorescent confocal microscope images of in-vivo delivery of rhodamine-
dextran dNPs – a) top view of murine skin showing four projection sites (red). Cell nuclei 
stained with Hoechst 33342 shown by the arrow (green). Auto-fluorescence of a hair 
follicle and collagen can also be seen shown by the arrow (green); b) side-view of single 
projection showing co-localisation with a cell nucleus (arrow). Cell nuclei stained with 
Hoechst 33342 shown by the arrow (green). 
  
In a further experiment, rhodamine-dextran dNPs were applied to mice ears 
followed by excision and staining with Hoechst 33342, nuclei dye. It could be seen that the 
dNPs penetrate and come into contact with nuclei, which may be significant in future DNA 
delivery and transfection studies as shown in Figure 5.13. To verify that cellular uptake 
could take place, 70 m silica particles were delivered using dNPs (Figure 5.14a). The 
tissue was excised and stained for MHC II positive cells. It can be seen in Figure 5.14b 
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and more clearly in the surface rendered image in Figure 5.14c, that cellular uptake and 
colocalisation between the particles and MHC II positive cells had occurred. Payload and 
cell colocalisation were further studied in detail in Chapter 8 using the NP as a simplified 
platform to the dNP.  
 
Figure 5.14. Fluorescent confocal microscope images of in-vivo delivery of rhodamine-
dextran dNPs; a) 3D fluorescence confocal image of a representative nanoparticle 
encapsulated dNP [scale bar 50 m]; b) representative image of a single MHC II positive 
cell (green) and delivered nanoparticles (red). The arrow points to encapsulated 
nanoparticles, and; c) surface rendered image of ‘b’ showing more clearly the nanoparticle 
encapsulation by the MHC II positive cell [scale bar 15 m].  
 
In summary, the robust penetration of the dNPs was shown using three 
independent methods (Figure 5.10 and Figure 5.12) with complete dissolution of 
projections within 5 minutes resulting in payload deposition within the layers of the skin. 
Furthermore, I observed significantly enhanced diffusion of the payload within the dermis – 
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compared to the layers above – which were consistent with higher hydration levels within 
the skin’s deeper layers. 
 
5.4.4 ‘Dotblot’ quantification of dNP delivery into mouse skin 
Preliminary analysis of payload delivery was achieved using ‘dotblot’ analysis. The 
‘dotblot’ is a standard technique for detecting and identifying specific proteins, similar to 
the Western blot but differing in that protein samples are not separated in gels by 
electrophoresis but spotted through circular templates directly onto the membrane. The 
amount of proteins in heterogeneous preparations could be calculated semi-quantitatively 
using this method by utilising the purified protein of interest, and if unlabelled (that is, no 
fluorescent markers), a specific antibody against it, in a standard curve (this was described 
in more detail in Chapter 3 Section 3.2.8). This technique is discussed in brief due to the 
technique being replaced by a much more accurate radio-tracer method discussed later in 
this Chapter. 
 
Due to limitations accessing labelled Fluvax vaccine (protein of interest throughout 
thesis) preliminary ‘dotblots’ were done using labelled ovalbumin protein. Figure 5.15 
highlights a few of the challenges encountered using this method (the samples were not 
labelled because no accurate data were obtained from these dotblots). Obtaining 
appropriate standards was crucial in extrapolating a delivered amount. If the standards 
were too high a standard curve cannot be obtained and signal from the samples could be 
masked (Figure 5.15a). It was seen that lack of membrane wetting could result in ‘edge 
effects’ with minimal fluorescence (Figure 5.15a). Excess sample solution would also 
result in ‘bleeding’ of the sample outside of the well. This was also attributed to the sealing 
of the membrane within the apparatus (Figure 5.15b). Placing the membrane on the 
surface could also result in puncture of the membrane if not careful (arrow, Figure 5.15c). 
As mentioned the amount of payload was important in not saturating the well, resulting in 
bleeding of signal outside the region of interest (Figure 5.15d). 
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Figure 5.15. Preliminary dotblot analysis using Cy5 ovalbumin protein: a) dotblot showing 
saturated standards masking the samples (the arrow points to a saturated standard); b) a 
dotblot showing sample bleeding from the sample well (arrow); c) practice standard 
samples with the arrow showing a puncture in the membrane, and; d) dotblot showing a 
saturated well with resulting bleeding outside of the well. 
 
The dotblot technique was further improved until a reproducible standard curve and 
accurate samples were achieved. Following this, the dotblot was used to quantify the 
delivery of labelled Fluvax with the dNP (Figure 5.16). A detailed method of the procedure 
and amount of standards used was discussed in Chapter 3, Section 3.2.8. Dual layered 
dNPs were fabricated with a fixed concentration of labelled Fluvax vaccine mixed with 
different excipients followed by a CMC gel backing. The samples analysed in Figure 5.16 
were S1: Fluvax only; S2: Fluvax with 1% CMC; S3: Fluvax with 1% trehalose, and; S4: 
Fluvax with 0.08% Quil-A. There were 3 samples (dNP/ear applications) per variable. The 
dNPs were applied to the ear at a velocity of 1.9ms-1 for 5 minutes followed by excision 
and homogenisation of the ears. The solution was centrifuged and the supernatant 
removed. It was seen in the dotblot in Figure 5.16, that the standards and a few of the 
samples contain precipitates. This was attributed to aggregation of the Fluvax with the 
CMC, however it did not have a significant effect on the standard curve (Figure 5.17). 
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Figure 5.16. Dotblot analysis of Cy5 labelled Fluvax2008®. 
 
As mentioned, the dotblot when combined with a standard curve could be used to 
calculate the amount of a specific protein delivered in a heterogeneous protein mixture. 
The standard curve was used when it resulted in a linear line when compared to the 
relative fluorescence intensity (rfu) of the specific protein in the sample well and the actual 
amount delivered in the well. A trendline was then done to produce an equation relating 
the rfu to an actual amount of specific protein (Figure 5.17). 
 
Figure 5.17. Standard curve of Cy5 labelled Fluvax2008® from the standards in Figure 
5.16.  
 
The rfu of the samples were used in the equation in Figure 5.17, which was then 
rearranged to solve for ‘x’. The delivery of labelled Fluvax was calculated to be 
approximately 360 to 420 ng under the given application conditions (Figure 5.18). Using 
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ANOVA analysis, it was determined that there was a significant difference between Fluvax 
delivered with 1% CMC compared to Fluvax delivered with 1% trehalose (422 +/- 56 ng 
and 320 +/- 25 ng). This variation in delivery was attributed to trehalose reducing the 
strength of the projections, possibly due to crystal defects from the sugar (this is explored 
in detail in Chapter 7). 
 
 
 
Figure 5.18. Amount of Cy5 labelled Fluvax2008® delivered using dual layered dNPs. The 
dNPs consist of Fluvax mixed with different excipients in the projections with a CMC gel 
backing. 
 
It was shown that dotblot analysis could be used to determine the amount of 
labelled Fluvax delivered by the dNPs (Figure 5.18). It was also outlined that this 
technique was quite complex and the results could only be derived if an accurate standard 
curve was achieved. The technique was also limited to non-specific fluorescence 
background from the mouse skin (melanin) and mouse hair. The blots also required a fine 
solution of protein with no aggregation; however this was variable and led to higher relative 
fluorescent readings. In parallel to the dotblot technique the Kendall Group setup a radio-
tracing method that was much more accurate and directly quantified the amount of protein 
delivered. This method replaced the dotblot technique within the Kendall Group. 
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5.4.5 14C-radiolabelled ovalbumin protein quantification of dNP delivery into mouse 
skin 
The Kendall Group designed a radio-tracing method to determine the delivery 
efficiency of the NP. The same method was modified for use with the dNP (discussed in 
detail in Chapter 3, Section 3.2.6). Briefly, 14C-radiolabelled ovalbumin protein 
(approximately 8 nCi per patch) was cast into a dual layer dNP with CMC gel backing. The 
dNP was applied to an anaesthetised mouse ear using standard conditions (1.9 ms-1, 5 
minutes). The dNP was removed and dissolved in 1 mL PBS. The ear was gently swabbed 
with a moist cotton bud and the bud was then soaked in 1 mL PBS. The ear was excised 
and liquefied by heating overnight at 60oC in 1 ml of Solvable®. The following day, 
scintillation fluid was added to the samples and the samples were analysed using a beta 
counter with a read out of disintegrations per minute (DPM). To determine the delivery 
efficiency, the DPM counts of the dNP, swab and ear were summed and percentage of 
each was calculated from the total DPM count.  
 
The initial dNP delivery efficiency experiment was done using the initial carbon tab 
patch-attach shown in Figure 5.3, with the addition of 10 L of payload solution to each 
dNP. This resulted in 1.27 +/- 0.57% of delivered ovalbumin protein (n = 8). This low 
amount was unexpected given that qualitative analysis of the dNP post administration 
showed at least 20% of the projections dissolved (Figure 5.4). The experiment was 
repeated and similar results obtained (Figure 5.19).  
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Figure 5.19. Delivery efficiency of dual layered 14C-radiolabelled ovalbumin protein dNPs 
into mouse skin.   
 
As stated, the fabrication of the dNP required the filling of a mould. In Chapter 4, it 
was calculated that the mould volume was approximately 0.22 L. Therefore excess 
solution in the mould backing can greatly decrease the delivery efficiency due to trapped 
radio-labelled protein in the CMC backing layer. Therefore based solely on volume 
analysis, without any compaction of dried payload during casting, one would expect that if 
10 L was added to the mould, that 2.2% would be delivered. This delivery efficiency was 
similar to the calculated 1.27% delivered.  
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 Figure 5.20. Delivery efficiency of dual layered 14C-radiolabelled ovalbumin protein dNPs 
into mouse skin using improved casting conditions. 
 
During the casting process it was noted that the payload solution was not dry prior 
to the addition of the backing layer. It was hypothesised that the backing gel could displace 
the payload solution if it was not dry. The patching process was also improved as stated 
previously in this chapter using a dNP patch-attach. The combined patch-attach and 
enhanced casting method resulted in a delivery efficiency of 12.2 +/- 4.3% (Figure 5.20). 
This delivery efficiency was achieved using 10 L of solution in the mould during casting. 
The delivery efficiency described in the previous paragraph based on theoretical volume 
analysis was 2.2%. This was 10% lower than the improved experimentally derived delivery 
efficiency. The increase in delivery was attributed to compaction of the payload during the 
casting process as the water in the payload solution evaporated. The delivery efficiency 
could potentially be improved by reducing the amount of payload solution added prior to 
casting. This was explored in detail in Chapter 9. 
 
5.4.6 Conclusion 
As stated, this chapter sets the groundwork for objective two and the primary focus 
of this project, which was: 
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Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
The dNPs I developed penetrated through the stratum corneum into the viable 
layers of the skin. Indeed, when I applied the formulated dNPs to the skin, consistent and 
robust penetration was achieved, targeting the strata of interest. It was found that the 
dNPs not only penetrated the skin, delivery of payload occurred within 5 minutes post 
administration. These findings were very interesting because larger dissolving 
microneedles of similar composition required at least 1 hour for complete dissolution. It 
was assumed that the difference in dissolution time was associated to the small scale and 
large surface area of the dNPs (discussed in more detail in Chapter 7).  
 
Furthermore, due to the minimally invasive nature of the dNP and high resolution 
microscopy used to analyse administration, I observed significantly enhanced diffusion 
within the dermis compared with the epidermis. This new insight into a diffusion differential 
could be an important consideration for targeting of biomolecules to particular cells within 
these layers and was further analysed in Chapter 8. 
 
However, the mild conditions used to fabricate dNPs for vaccine delivery, limited the 
dNP composition to sugars and cellulose derivatives (i.e. carboxymethylcellulose). I also 
did not explore in the previous chapter within objective one, the integrity of the dNP 
encapsulated payloads. Therefore the question governing objective two was: 
 
The above question was the primary focus of this project and was divided into the 
following three chapters 6, 7 and 8. Within this chapter I assessed and improved the 
administration process of dNPs by applying them to murine skin and analysed the 
penetration profile with SEM and histology. Secondly, I further characterised the 
penetration and dissolution of the formulated dNPs within skin, showing consistent and 
robust penetration of the stratum corneum with diffusion within the lower viable skin layers.   
 
 
 100 
 101 
CHAPTER 6 
Vaccine delivery using dissolving Nanopatches 
 
6.1 Summary 
In the previous chapter, I showed that dNPs composed of CMC can penetrate the 
skin followed by diffusion and dissolution. It was determined that the high surface area to 
volume ratio of the  dNPs compared to much larger dissolving microneedles results in 
rapid dissolution within 5 minutes compared to an hour. I also showed that once the 
payload had dissolved within the skin, a large diffusion gradient resulted with increase 
depth and moisture within the skin.  
 
In this chapter, I assessed the integrity of the fabrication method developed in 
Chapter 4 (objective one) and validated the dNPs as a vaccine delivery device, delivering, 
in separate experiments, multiple antigens – ovalbumin protein, Fluvax2008® and 
Fluvax2010® – brands of trivalent inactivated influenza vaccine. The data in this chapter 
compliments the administration data in the previous chapter and also addressed the 
question in objective two: 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
It was determined using ovalbumin protein and Fluvax2008® that dNP vaccination 
resulted in strong systemic immune responses in mice; with lower payloads required than 
the standard needle and syringe vaccination. At the time of publication of these data 
showing potent immune responses from skin targeted vaccinations had not been reported 
before using any form of dissolving microneedle or dNP.  
 
However, the antibody responses achieved with the dNP were not initially as potent 
as NP immunisation, which had shown 100 fold dose reduction compared to the needle 
and syringe [11]. It was later determined in the Kendall Group that concentrating the 
influenza vaccine resulted in lower immune responses than fresh unconcentrated vaccine. 
The dNP vaccination with unconcentrated Fluvax2010® resulted in 6 ng of Fluvax2010® 
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delivered by dNPs, comparable to 600 ng IM. This correlated to 100-fold dose reduction 
(which was now similar to NP immunisation) using the dNP as a delivery platform and 
emphasised the potential of this system as a delivery device for vaccine delivery.  
 
6.2 Introduction 
In Chapter 5, I showed that dNPs dissolve and diffuse within murine aqueous skin 
layers within two minutes. It was shown indirectly that the payloads delivered by the dNPs 
could interact with the cells within the skin resulting in cellular uptake. However, the key 
objective of dNPs was to deliver a biological payload resulting in a systemic response (i.e. 
dNP immunisation followed by systemic immune responses [antibody response]). To show 
proof of principal, I used ovalbumin protein, a commonly used model antigen. The Kendall 
Group has also reported successful immunisation with ovalbumin protein post NP 
vaccination [9]. Fluvax2008® and Fluvax2010®, commercial influenza vaccines were used 
to determine whether an immune response could be generated by the dNP delivery of 
vaccines. 
 
Influenza is a seasonal disease that impacts globally, killing many people and 
incurring large economic costs [36]. Production of influenza vaccines are time consuming 
and resource intensive [141]. An administration method, which uses far less vaccine to 
provide an immune response than standard needle and syringe injections, is one possible 
way to increase the relative availability of influenza vaccines without increasing production. 
Previous reports from the Kendall Group using solid silicon NPs with similar dimensions to 
dNPs were successful in delivering vaccine to mice resulting in strong antibody responses 
[4, 9, 11, 94, 95]. In this Chapter I reported on the successful immunisation of mice using 
dNPs as the delivery platform, which was published in the journal SMALL in 2011 [116]. 
 
As outlined in the literature review other larger microneedle technologies used for 
immunisation have also achieved strong immune responses comparable to the needle and 
syringe [124, 142-145], however at the start of this PhD project, to my knowledge, there 
were no reports of successful vaccination with any form of dissolving microneedle. It 
wasn’t until recently (August 2010), that the first two publications using dissolving 
microneedles for immunisation were published (my paper and another paper from a group 
in the USA were simultaneously published). One paper used large (650 m) tall 
microneedles in a 10 x 10 square grid array, consisting of a laboratory made inactivated 
whole influenza virus vaccine encapsulated in polyvinylpyrrolidone (PVP) [115]. 
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Microneedles were applied for 15 minutes resulting in delivery of 6 g of influenza vaccine. 
The immune responses achieved resulted in more efficient lung virus clearance and 
enhanced cellular recall responses after challenge compared to intramuscular injection, 
however no dose-sparing was investigated [115]. I published the other dissolving 
microneedle paper, using the data described in this, and the previous two chapters of this 
thesis [116]. 
 
6.3 Experimental procedures 
6.3.1 Preparation of ovalbumin dNPs 
PES membrane was cut to fit the surface of the moulds in the 96 well multiwell 
plate. Vaccine formulation containing 30 mg/mL ovalbumin protein and 0.8 mg/mL Quil-A 
as the adjuvant in MilliQ water was prepared and 10 L was pipetted onto the surface of 
PES. Moulds with loaded PES were then centrifuged at 3000 g for 10 minutes. The PES 
membrane was then removed with any excess formulation. Moulds were then centrifuged 
at 3000 g for 10 minutes to allow further compaction and drying. A viscous solution 
containing 1.4 mM CMC was then added to the moulds to provide the array backing layer. 
The moulds were then centrifuged at 3000 g for 20 minutes. The moulds were then placed 
in a sealed desiccator at 22oC containing dry-beads until the formulation had dried 
followed by storage at 4oC. Low dose dNPs were also prepared using the above 
procedure, however with 1.5 mg/mL ovalbumin. 
 
6.3.2 Preparation of influenza dNPs 
Influenza vaccine formulation was concentrated to 0.5 mg/mL using an Amicon 
Ultra Centrifugal Filter (10,000 MWCO) with respect to hemagglutinin protein concentration 
in the vaccine (Fluvax2008®) and 10 L was pipetted onto the surface of the moulds. 
Moulds were then centrifuged at 3000 g for 10 minutes.  A viscous solution containing 1.4 
mM CMC was then added to the moulds to provide the array backing layer. The moulds 
were then centrifuged at 3000 g for 20 minutes. The moulds were then placed in a sealed 
desiccator at 22oC, until the formulation had dried (4 -6 hours). The dNP array was then 
removed from the moulds and stored in a sealed desiccator at 4oC until vaccination. 
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6.3.3 Preparation of influenza suspensions with different excipients 
To determine whether the two different excipients had an influence on immune 
responses post vaccination, 24 g of Fluvax2008® was either formulated with 2% MC, 2% 
CMC or neat (no excipient), and air-dried overnight. The dried formulations were 
resuspended in 120 L of injection water. Four mice per group were IM immunised with 
6.0 g of Fluvax2008® under each condition. The positive control was 6.0 g of fresh 
Fluvax2008® and the negative control consisted of unimmunised mice. The mice were 
bled 21 days post immunisation, and sera analysed by direct ELISA. 
 
6.3.4 Delivery of antigen 
Six week old female C57BL/6 mice were anesthetized with an intraperitoneal 
injection of 150 L of 10 mg/mL ketamine and 2 mg/mL xylazil in saline. Each group 
contained four mice. An ovalbumin dNP array was applied to the ventral side of each ear. 
Application was with a spring applicator at a velocity of 1.9 ms-1 and held in place for 10 
minutes. The positive control consisted of a 5 L injection into the caudal thigh muscle 
(intramuscular [IM]) of vaccine formulation containing 0.8 mg/mL Quil-A, 67.7 M 
ovalbumin and CMC. The negative control was a patch with no projections coated with 10 
L of vaccine formulation containing 0.8 mg/mL Quil-A, 67.7 M ovalbumin and CMC. The 
negative control was applied using the same protocol as the ovalbumin dNP arrays. Low 
dose ovalbumin dNP arrays were applied using the same protocol as for the high dose. 
The same protocol was used to vaccinate with the influenza, however for only one dNP 
array was applied to the low dose group. The positive control consisted of a 5 L 
intramuscular injection of vaccine formulation containing 5 g influenza vaccine. The 
negative control was a patch with no projections coated with 10 L of vaccine formulation 
containing approximately 5 g of influenza. The payload delivered by the dNPs was 
calculated using 14C radio-labelled ovalbumin protein as a tracer cast within dNPs and 
applied to mouse skin as described in Chapter 3, Section 3.2.6. Mice were bled 28 and 
102 days after the single vaccination. Approximately 50 L of blood was taken from each 
mouse. The blood samples were allowed to clot at room temperature and then centrifuged 
at 5000 g for 10 minutes to separate sera. The sera were removed and stored at -80oC for 
analysis by direct ELISA. 
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6.3.5 ELISA protocol 
ELISA was performed as previously described [118]. Briefly, the ELISA plates 
(Nunc, Maxisorp) were coated with the commercial trivalent split virion Fluvax2008® at a 
concentration of 3 g/ml total haemagglutinin or 50ug/ml ovalbumin in 0.1M sodium 
bicarbonate buffer overnight at 4oC and were used to determine the titres of antigen 
specific IgG induced. The colour development was performed using ABTS (2,29-azino-
bisc) as the substrate. The absorbance readings at 405 nm were measured against control 
wells containing no antiserum in the reaction. 
 
6.4 Results and discussion 
6.4.1 In-vivo delivery of model antigen 
Having established that the dNPs robustly penetrate and deliver payload to the 
targeted skin layers (Chapter 5), I progressed to load the devices with functional vaccines 
and test the proof-of-principle of the dNPs in generating systemic immune responses for 
effective vaccination.  
 
First, I used ovalbumin protein as a model antigen to elicit an immune response in 
mice. The dNP array consisted of dual layers with the ovalbumin protein mixed with Quil-A 
adjuvant localized without payload in the backing layer. This morphology was used to 
minimise loss of antigen on the surface of skin. I vaccinated the mice with these dNPs, and 
by day 28 after vaccination, the 7.6 ± 1.7 g dose group showed antibody levels 
comparable to the 15 g ovalbumin / Quil-A IM needle injection group (Figure 6.1a) [116]. 
By day 102, the 7.6 ± 1.7 g dose group showed greater antibody levels than the IM group 
(Figure 6.1b) and the 0.4 ± 0.1 g dose group showed comparable results to the IM group 
(Figure 6.1b). These results showed that a viable immunogen was cast into the dNP array 
and successfully delivered to immune cells in the skin, resulting in efficient antibody 
responses which were stronger than IM vaccinated mice at later time points (memory 
response). 
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Figure 6.1. Total IgG levels of mice measured by ELISA. Total ovalbumin IgG levels a) 28 
and b) 102 days post vaccination. The positive control consisted of an intramuscular 
injection with needle and syringe and the negative control consisted of a dNP array with no 
projections [116]. 
 
6.4.2 Initial study of in-vivo delivery of influenza vaccine to mice 
To further verify and validate the dNP array as a potential platform for vaccine 
delivery, a commercial influenza vaccine (Fluvax2008®) was used to vaccinate mice. The 
dNP array consisted of dual layers with the active compound localized within the 
projections using the dispersion membrane technique. The backing layer consisted of the 
excipient without payload. Three dose groups of 0.05 g, 0.05 g and 0.05 g were 
delivered using the dNP and compared to IM and ID delivery using the same dosage 
amounts. The mice were bled 14 days post immunisation followed by analysis of their sera 
for total anti-Fluvax2008® IgG. Interestingly, dNP vaccination resulted in no immune 
responses regardless of dose (Figure 6.2). Based on strong immune responses from 
Fluvax2008® immunisation with the standard NP [11], it was expected that even a low 
dose with the dNPs should elicit a response greater than the negative control. 
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Figure 6.2. Total Fluvax2008® IgG levels of C57Bl/6 mice measured by ELISA 14 days 
post immunisation. Positive controls consisted of IM and ID immunisations and the 
negative control was Fluvax2008® dNP without projections. 
 
IM and ID immunisation resulted in positive immune responses relative to the dose 
given. This suggested that the ELISA assay worked correctly. As stated previously in the 
methods section of this Chapter (Section 6.3.2), the influenza vaccine was concentrated 
prior to casting in the moulds. Unlike ovalbumin protein (model antigen), which is a 
relatively small highly soluble protein, Fluvax2008® is a large complex mixture of proteins 
from an inactivated split influenza virion. The major immunogenic protein in influenza 
vaccines (e.g. Fluvax) is a large membrane bound haemagglutinin protein [146, 147]. It 
has also been noted in the Kendall Group that concentrations about 1 mg/mL results in 
visible aggregates in the Fluvax2008® solution. Therefore, it was hypothesised that the 
dispersion membrane used in the casting of the vaccine was trapping and not distributing 
the vaccine into the moulds. 
 
 
Figure 6.3. Fluorescence confocal microscopic images of Cy5-labelled Fluvax2008® 
dNPs: a) dNPs cast using the 0.2 m polythersulfone (PES) dispersion membrane, and; b) 
dNPs cast without the dispersion membrane. The scale bars are both 50 m. 
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 The Fluvax2008® casting method was validated using Cy5-labelled Fluvax2008® 
and analysed using fluorescence confocal microscopy. The dNPs were fabricated using 
the standard casting procedure with the labelled Fluvax. A CMC backing without excipient 
was applied as the backing layer. It was seen that minimal fluorescence was detected in 
the projections of the dNP (Figure 6.3a). This was done for n=3, with all dNPs containing 
minimal to no fluorescence in the projections. Lack of fluorescence corresponded to an 
absence of the Cy5-labelled Fluvax2008®. An alternate casting method was used for the 
Fluvax dNPs, where the influenza vaccine was cast into the projections without using the 
dispersion membrane. 10 L of vaccine solution was applied to the mould so that the 
entire surface was saturated with vaccine solution. Figure 6.3b showed a high intensity of 
fluorescence in the projections of the dNPs. A CMC gel backing was applied with no 
payload and this resulted in minimal to no fluorescence within the backing layer. Therefore 
using this casting method for the influenza vaccine resulted in a dual layer dNP with a high 
concentration of Fluvax2008® in the projections with minimal payload in the backing layer. 
The following Fluvax dNPs were fabricated using this method unless stated otherwise. 
 
6.4.3 In-vivo delivery of influenza vaccine to mice using improved dNPs 
Having validated the casting process, influenza vaccination was repeated using 
dNPs. Two different doses of 0.06 ± 0.02 g and 0.12 ± 0.04 g were delivered using the 
dNPs and this was compared to an IM positive control of 5 g. The mice were bled at days 
14, 28 and 102 days post immunisation. 
 
By day 28, both patched groups (0.06 ± 0.02 g and 0.12 ± 0.04 g) resulted in 
strong antibody generation (Figure 6.4a) [116]. Similar to the ovalbumin vaccination, 
antibody responses to Fluvax2008® remained strong, even after 102 days past 
vaccination (Figure 6.4b). These results extend on the generic ovalbumin vaccination, by 
confirming a particular test-case of dNPs delivering a commercial vaccine (here, 
Fluvax2008®, a split virus trivalent influenza vaccine) to the skin setting the foundation 
that dNPs can be used as a suitable platform for a range of vaccines. However, 
appropriate assays would need to be conducted for each different vaccine delivered with 
this system. 
 
Importantly, a significantly lower antigen dose was sufficient with the dNP arrays to 
elicit strong long lasting immune responses compared to the intramuscular needle 
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injections (15 g ovalbumin protein IM compared to 0.4 g ovalbumin patched, 102 days 
post vaccination [Figure 6.4b]).  As discussed in the literature review the design of the NP 
and hence dNP was based on maximal direct targeting of projection with skin immune 
cells [11] and I hypothesised this important enhancement in vaccination efficiency and 
effectiveness was a direct immunological benefit achieved by controlled device design and 
miniaturisation. Currently, most vaccines are delivered by the needle and syringe (several 
mm in length; > 0.5 mm in diameter) into muscle with fewer immunologically sensitive 
cells, therefore requiring relatively large amounts of vaccine. In contrast, the skin contains 
an abundance of potent immunological cells, with sub-classes located within the thin outer 
layers of the epidermis and dermis (approximately 17 µm and 60 µm, in thickness, 
respectively for the mouse ear used in this study) [128]. On the other hand, dNP delivery 
of vaccine, place the antigen directly to these tightly defined skin strata. At the time of 
publication of this data, to my knowledge, these results showing potent immune responses 
from skin targeted vaccinations had not been shown before using any form of dissolving 
microneedle.  
 
 
Figure 6.4. Total IgG levels of mice measured by ELISA. Total anti-Fluvax2008® IgG 
levels a) 28 and b) 102 days post vaccination. The positive control consisted of an 
intramuscular injection with needle and syringe and the negative control consisted of a 
dNP array with no projections [116]. 
 
6.4.4 Improved dose-sparing using dNPs for influenza immunisation 
 As stated in 6.1 Introduction, the coated NP has achieved much greater immune 
responses (100-fold) compared to IM needle and syringe post Fluvax2008® immunisation. 
Successful dNP immunisation using the same vaccine (Figure 6.4) resulted in strong 
immune responses but far less than the NP. To investigate the discrepancies between the 
two platforms, the excipient formulations were analysed. The key excipient in the NP 
 110 
coating formulation was methylcellulose in contrast to the dNP key excipient of 
carboxymethylcellulose. Both were cellulose derivates and commonly used as viscosity 
modifiers or thickeners. Both have also been reported as useful excipients in the 
microneedle field [9, 148]. 
 
Figure 6.5. Total Fluvax2008® IgG levels of C57BL/6 mice measured by ELISA 21 days 
post immunisation. All formulations except the ‘Fresh Fluvax’ group were air-dried followed 
by resuspension in water and IM immunisation. (Each group consisted of a 6.0 g dose). 
 
To determine whether the two different excipients had an influence on immune 
responses post vaccination, Fluvax2008® was either formulated with MC, CMC or neat 
(no excipient), and air-dried overnight. The dried formulation was resuspended and used 
to IM immunise mice under each condition. The mice were bled 21 days post 
immunisation, resulting in comparable immune responses from the dried Fluvax2008® 
groups (Figure 6.5). No difference in immune response was determined between the dried 
Fluvax, MC-Fluvax and CMC-Fluvax suggesting that either could be used as an excipient 
for the dNP. Based on this data I did not change CMC with MC for dNP fabrication. It was 
obvious that drying the vaccines resulted in a negative impact on immunogenicity when 
intramuscularly injected. The fact that when the dried formulation was delivered to the skin 
with the NP/dNP a large immune response was achieved further supports the argument 
that targeted delivery of vaccines is important in obtaining potent immune responses with 
less vaccine.  
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It was determined in the Kendall Group that concentration of Fluvax2008® resulted 
in lower immune responses than unconcentrated (neat) vaccine at the same dose (data 
not shown) indicating loss of immunogenicity of the vaccine during the concentration step. 
The previous dNP immunisation with Fluvax2008® (Figure 6.4) consisted of concentrating 
the vaccine prior to casting. Therefore an experiment was designed to assess whether 
unconcentrated Fluvax2008® immunisation with dNPs results in strong immune responses 
comparable to high dose IM immunisation. To determine if further stabilisation of the 
vaccine could be achieved, a group was designed with the addition of trehalose (sugar 
used to stabilise proteins in dry formulations [149, 150]). The experiment consisted of a 
total of four groups with four mice per group. The delivered Fluvax2008® amount in the 
dNP groups was 270 ng and the IM consisted of a delivered dose of 5000 ng. The 
negative control group were unimmunised mice. The mice were bled 21 days post 
immunisation resulting in strong immune responses from the dNP groups (Figure 6.6). 
Both dNP groups with and without trehalose showed comparable results with no significant 
difference suggesting that trehalose did not further stabilise the Fluvax2008® proteins 
during fabrication. Secondly, both dNP groups showed comparable results to the 5000 ng 
IM group. Under the given conditions, the results showed that immunisation with dNPs 
using Fluvax2008® resulted in approximately 20-fold dose reduction compared to IM 
immunisation. 
 
Figure 6.6. Total anti-Fluvax2008® IgG levels of C57BL/6 mice measured by ELISA 21 
days post immunisation. The positive control was 5000ng IM and the negative was 
unimmunised sera. 
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I then examined the functional relevance of the antibody produced in protection 
against the influenza virus. To do this, I tested the same sera against each of the three 
vaccine component strains of virus for haemagglutination-inhibitory (HI) activity (Figure 
6.7). The HI activity assay is the most widely accepted ‘gold standard’ used as the 
surrogate for influenza protective effectiveness [151, 152]. 
 
 
 
Figure 6.7. Haemagglutination-inhibitory (HI) activity of Fluvax2008® antibodies 21 post 
dNP and IM immunisation.  
 
First, considering the H1N1 (A/Solomon Islands) component of the Fluvax2008®. 
By 21 days after vaccination, that both the dNP vaccinated groups generated equivalent or 
higher HI titres than the 5000 ng IM vaccinated group (however no groups were 
statistically different). Second, turning to the H3N2 (A/Brisbane) component of 
Fluvax2008®, it was observed that both dNP groups induced higher HI titres compared to 
the 5000 ng IM injection. However, like the previous strain, there was no statistically 
significant difference. Third, considering the type B virus (B/Florida) component of the 
Fluvax2008®, it was shown that dNP resulted in significantly lower HI titres. This result 
was similar to what has been reported with NP vaccination compared to IM using 
Fluvax2008® [11]. It was also noted that there was higher variability with for the dNP 
groups than IM. This was attributed to the slight variability in delivered dNP dose and more 
importantly the low dose (270 ng) delivered. The IM group was designed to be a positive 
control and saturate the immune response, unlike the dNP group. Collectively for each of 
the three strains, an approximate 20-fold reduction of delivered antigen dose was 
observed for HI responses when the vaccine was administered using the dNPs – and as 
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stated previously, a similar magnitude of improvement was observed from the IgG 
antibody responses in the ELISA (Figure 6.6). 
 
 
Figure 6.8. Total anti-Fluvax2010® IgG levels of C57BL/6 mice measured by ELISA 21 
days post immunisation.  
 
Preliminary investigation into dose-reduction using dNPs showed that up to 20-fold 
dose sparing could be achieved by casting without a dispersion membrane and using neat 
influenza vaccine without concentration. To further assess the dose-sparing nature of the 
dNP, the amount of influenza vaccine was titrated and compared with various doses of IM 
immunised mice. However, due to absence of supplies of Fluvax2008® (the vaccine was 
no longer being produced), the influenza vaccine was changed to the current Fluvax2010® 
vaccine.  
 
Four groups of 8 mice were IM immunised with Fluvax2010® (0 ng, 60 ng, 600 ng 
and 6000 ng) and another four groups using Fluvax2010® dNPs (0 ng, 3 +/- 0.2 ng, 6 +/- 
0.5 ng and 13 +/- 1 ng). The mice were bled 21 days post immunisation and sera analysed 
with ELISA (Figure 6.8). It was shown that the both the negative controls (0 ng IM and 
dNP) produced background levels of absorbance. The lowest responding groups were the 
60 ng IM and 3 ng dNP mice, however both showed comparable antibody levels. The 6000 
ng IM dose resulted in the highest immune response that at higher sera dilutions (> 200) 
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were significantly different to the 600 ng IM and remaining dNP groups. The 6 ng and 13 
ng dNP groups both showed comparable immune responses that were not significantly 
different to the 600 ng IM group. This result showed that dNP immunisation of 
Fluvax2010® could achieve a dose reduction of up to 100-fold (6 ng compared to 600 ng) 
compared to IM administration based on antibody responses. As stated previously, I 
believe this important enhancement in vaccination efficiency and effectiveness was a 
direct immunological benefit achieved by accurate targeting of vaccine within the skin 
compared to IM. 
 
 
Figure 6.9. Repeat of total anti-Fluvax2010® IgG levels of C57BL/6 mice measured by 
ELISA 21 days post immunisation. 
 
The previous Fluvax2010® (Figure 6.8) was repeated using higher doses for the 
dNP groups (38 and 76 ng) (Figure 6.9). There were a total of 7 groups with 8 mice per 
group. Mice were bled 21 days post immunisation and the sera analysed by ELISA 
(Figure 6.9). The negative controls mirrored what was previously seen with both the dNP 
and IM groups showing low background absorbance. The 6000 ng IM dose resulted in the 
highest immune responses and like the previous experiment was significantly different at 
dilutions greater than a factor of 200. Interestingly, both the 38 and 76 ng dNP groups 
showed comparable results to the 600 ng IM group. 
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Figure 6.10. Haemagglutination-inhibitory (HI) activity of Fluvax2010® antibodies 21 post 
dNP and IM immunisation: a) A/Perth/16/2009; b) A/California/7/2009, and; c) 
B/Brisbane/60/2008. 
 
The functional relevance of the antibody produced in protection against the 
influenza virus was examined using HI (as discussed previously [Figure 6.7]). Once again, 
the sera were tested against each of the three vaccine component strains of virus for HI 
activity (Figure 6.10). First, considering the A/Perth component of the Fluvax2010® – by 
21 days after vaccination, both the dNP vaccinated groups generated higher HI titres than 
the 600 ng IM vaccinated group (with the 38 ng being statistically different, however there 
was no significant different between the dNP groups). Second, turning to the A/California 
component of Fluvax2010®, it was observed that the higher 76 ng dNP group induced 
higher HI titres compared to the 600 ng IM injection, however like the previous strain, there 
was no statistically significant difference. In fact, there was no significant difference 
between the 38 ng dNP vaccinated group and the 600 ng IM vaccinated group. Third, 
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considering the type B virus (B/Brisbane) there was no significant result observed with all 
groups showing no significant increase over the negative controls. It has been reported 
using Fluvax2008®, that the type B virus (B/Florida) also produced H.I. titres lower than 
the other three strains [11], which suggested that the H.I. titre was strain sensitive. 
However when comparing the trends collectively for each of the three strains, the 38 ng 
dNP vaccinated group was equivalent to the 600 ng group correlating with the results from 
the ELISA (Figure 6.9). 
 
In summary, when combining all the data from the Fluvax2010® experiments 
(Figures 6.8, 6.9, 6.10), immune responses from dNP delivery doses between 6 and 76 
ng all resulted in similar antibody responses. This suggested that within this dNP delivery 
range there was a threshold or plateau effect. A similar effect was shown with the coated 
NP for Fluvax2008® delivery where delivery from and above 34 ng was equivalent to 6000 
ng IM delivery of Fluvax2008®.  To compare whether the coated NP had a similar 
response, sera from NP coated Fluvax2010® mice were analysed with the dNP mice sera 
(Figure 6.11).  
 
 
Figure 6.11 Total anti-Fluvax2010® IgG levels of mice measured by ELISA 21 days post 
immunisation. 
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It was shown that both dNP and NP immunisation of mice with Fluvax2010® results 
in comparable immune responses (Figure 6.11). The results were also comparable to 600 
ng IM immunisation. Similar to the previous two experiments (Figure 6.8 and 6.9), the 
6000 ng IM immunisation resulted in significantly higher antibody responses than the 
patched groups. NP immunisation with Fluvax2008® showed higher immune responses 
than similar doses with Fluvax2010® when compared to IM immunisation [11]. Even 
though the results were similar, the discrepancies could be related to the different strains 
within the influenza vaccine. Therefore, each vaccine should be analysed for dose sparing 
with each particular vaccine being administered with both the NP and dNP platforms 
compared to IM. 
 
6.4.5 Conclusions 
The previous two chapters established and verified that dNPs could not only be 
fabricated using mild conditions but the microprojections were also capable of skin 
penetration. In this chapter, I validated the integrity/functionality of vaccines encapsulated 
within dNPs, by immunising mice in separate independent experiments using three 
antigens – ovalbumin protein, Fluvax2008® and Fluvax2010®. The data within this 
chapter addressed the question in objective two: 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
It was found that dNP vaccination resulted in strong systemic immune responses in 
mice; with lower payloads required than the standard needle and syringe vaccination. 
More specifically, dNP immunisation resulted in antibody responses correlating to a 100-
fold increase over IM (6 ng compared to 600 ng). The functional relevance of the antibody 
response produced in protection against influenza was also analysed using a 
haemagglutination-inhibitory assay. The 6 ng Fluvax2010® dNP immunised groups once 
again showed comparable results to the 600 ng IM groups. The significance of these 
results was that the HI data confirms the integrity of the dNP encapsulated protein, 
verifying the fabrication method designed in Chapter 4. Overall the data in this chapter 
showed that the dNP could be a potent and potential platform for vaccine delivery to the 
skin.  
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CHAPTER 7 
Analysis of micro-crystallinity, penetration and diffusion of 
dissolving Nanopatches for enhanced delivery and dissolution 
 
7.1 Summary 
The previous chapters characterised and analysed the fabrication, administration, 
and vaccine application of dNPs using carboxymethylcellulose (CMC) as the excipient. It 
was shown that CMC not only produced reliable dNP structures, it also provided a 
structural support – facilitating penetration (Chapters 4 and 5). In addition, vaccines 
administered with CMC dNPs produced strong immune responses, greater than their 
equivalent IM delivered doses (Chapter 6). 
 
Similar to the previous two chapters, this chapter addresses the question of 
objective two, which was: 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
As stated above, Chapter 5 showed that dNPs were capable of penetrating skin; 
however in-depth analysis was not done on the physical/mechanical properties of the dNP 
microprojections. Within this chapter, I analysed the macro and micro physical properties 
of dNPs composed of CMC. In addition, I discussed the potential of sucrose, trehalose, 
mannitol and sorbitol, four common pharmaceutical sugar/sugar alcohols (polyol) as 
excipients for dNP fabrication. Different w/w ratios of sugars/polyols to CMC dNPs were 
fabricated and analysed using stereomicroscopy, far infrared spectroscopy (IR), 
nanoindentation and fluorescence microscopy. Stereomicroscopy provided information on 
the macro properties of the formulations. Nanoindentation and IR gave insight into the 
micro-scale features of dNPs, which was then followed by administration and analysis 
using fluorescence microscopy. Overall, the results showed that the microcrystalline 
properties of dNPs could be controlled, influencing the mechanical properties and hence 
failure modes of the microprojections.  
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7.2 Introduction 
As stated and shown in this thesis, administration of dissolving microneedles/dNPs 
were similar to dry-coated microneedles/NPs, wherein both technologies, the payload 
dissolves in the aqueous environment of the skin followed by subsequent diffusion to the 
surrounding immunologically–sensitive cells [95]. Administration time of microneedles vary 
– from fast release vaccine coated microprojections (10 seconds) [153] to sustained 
release drug encapsulated dissolving microneedles (72 hours) [18]. There are two main 
factors that affect microneedle dissolution, being size and composition of the projections. 
For the technology to be effective as a vaccine delivery platform, administration time 
should be similar to the time taken for a traditional intramuscular needle and syringe 
injection as discussed in Chapter 2. I have shown in this thesis (Chapter 5) that CMC 
dNPs completely dissolve much faster than larger microneedles (600 m in length) of 
similar composition (i.e. 5 minutes compared to 1 hour, respectively) [18, 116]. 
 
The use of highly water soluble sugars in the composition of dissolving 
microneedles have the potential to dramatically reduce the administration time, and 
enhance diffusion, however this has yet to be adequately explored. More recently, Lee et 
al., 2011 [154], published a paper consisting of CMC microneedles (600 m in length, and 
300 m in diameter) with the addition of 1:1 trehalose. The addition of trehalose was 
designed to increase the dissolution rate compared to the standard CMC microneedles for 
the delivery of human growth hormone.  The microneedles were applied to the skin for 24 
hours followed by SEM to visually assess the amount dissolved. Even after the long 
administration time the bulk of the CMC microneedles could still be seen, however there 
was a noticeable decrease in volume of the trehalose/CMC microneedles. In-vitro analysis 
of the remaining payload of the applied patches resulted in approximately 69% and 17% of 
the payload remaining in the CMC and trehalose/CMC microneedles respectively. 
 
This chapter assesses the potential of sucrose, trehalose, mannitol and sorbitol, 
four common pharmaceutical sugar/sugar alcohols (polyols) as excipients for microneedle 
fabrication. The micro-crystalline properties of the formulations were analysed by Fourier 
transform far infrared (FT-FIR) spectroscopy using synchrotron radiation. The high 
intensity light source and liquid helium cooled detectors at the Australian Synchrotron 
enables high resolution and sensitivity down to extremely low wavenumbers (~40cm-1), 
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which provides information on the intercrystalline vibrational modes within diverse samples 
[155, 156]. The formulations were further characterized using nanoindentation. This 
method of mechanical testing uses an extremely small probe (<40 m) or atomic force 
microscopy (AFM) tip to apply a force to individual dNP projections and characterize their 
failure modes. To my knowledge this type of force analysis on such small individual micro-
structures has not been shown before and provides important insight into the interactions 
of micro-projections with skin. Lastly the dNPs were applied to skin and fluorescence 
confocal and multiphoton microscopy was used to assess the penetration and diffusion of 
a fluorescent dye within the skin to assess their performance for intracutaneous vaccine 
delivery.  
 
7.3 Experimental procedure 
7.3.1 Macroscopic morphology analysis of dNPs fabricated using various CMC 
sugar/polyols ratios 
dNPs were fabricated using various formulations to investigate their macroscopic 
morphological features. Moulds were prepared and cleaned prior to casting dNPs as 
described in Chapter 4, Section 4.3.2. Each mould was placed in a standard biological 
24-well plate followed by the addition of 50 L of payload solution. The following Table 7.1 
outlines the weight to weight ratio of CMC to sugar/polyol formulations used in this study. 
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Table 7.1: weight for weight ratio (CMC:sucrose, trehalose, sorbitol or mannitol) 
 w/w ratio (CMC:sucrose, trehalose, sorbitol or mannitol) 
1:1 1 : 7.5 
1 : 1.25 1 : 8.3 
1 : 1.7 1 : 10 
1 : 2.5 1 : 12.5 
1 : 3.3 1 : 15 
1 : 3.75 1 : 20 
1 : 5 1 : 25 
1 : 6.25 1 : 30 
1 : 6.7  
 
The moulds were then centrifuged at 3000 g for approximately 1 hour at 25oC, followed by 
placement in a sealed desiccator containing silica dry-beads overnight at 30oC, until the 
dNPs had dried. The dNP arrays were then removed and analyzed using stereo 
microscopy. 
 
7.3.2 Fluorescence microscopy, nanoindentation and payload quantification of 
dNPs fabricated using various CMC and sugar/polyol ratios 
dNPs were fabricated using a variation of the standard dNP fabrication method 
discussed in Chapter 4, Section 4.3.5. Briefly, each mould was placed in a standard 
biological 24-well plate followed by the addition of payload. For the purpose of 
nanoindentation, 10 L of sugar/polyol formulation were added to the moulds. 3000 MW 
rhodamine dextran (final concentration 0.1 mg/mL) was added to the payload solutions for 
fluorescence microscopy and diffusion studies. To compare the delivery of the dNPs, 14C 
radiolabelled ovalbumin protein was used as a tracer in dNP formulations. 14C Ovalbumin 
solution was prepared so that each mould received 10 l of solution spiked with a 
minimum of 25 nCi 14C Ovalbumin.  The moulds were then centrifuged at 3000 g for 
approximately 1 hour (or until payload had dried) at 25oC to facilitate compaction and 
drying. Finally, 50 L of 2.1 mM CMC was applied to the moulds to form the backing layer 
containing no payload. The moulds were then centrifuged at 3000 g for 30 minutes. The 
moulds were then placed in a sealed desiccator at 22oC containing dry-beads, until the 
dNPs had dried usually within 4 – 6 hours. The dNP array was then removed from the 
moulds and stored in a sealed desiccator at 22oC under nitrogen. 
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7.3.3 FT-FIR analysis of dNP formulations using synchrotron radiation 
Fourier transform far infrared was used to investigate the microcrystalline nature of 
the dNP samples. By using synchrotron radiation it was hypothesized that we could 
analyze the sugar/CMC formulations at a much higher resolution and sensitivity than 
standard benchtop IR spectrometers. Samples were prepared by pipetting 100 L of each 
sample in triplicates onto the surface of a parafilm wrapped glass slide. The formulations 
were dried in a desiccator overnight followed by storage in a sealed desiccated container. 
The Australian Synchrotron operates at 3 GeV with a maximum current of 200 mA 
and the beam dimension was 480 micron (horizontal) by 13 micron (vertical), the opening 
angle collected was 50 mrad (horizontal) by 16 mrad (vertical). The FT-FIR instrument 
consisted of a Fourier transform IFS 125/HR Brüker spectrometer (Brüker Optics, 
Ettlingen, Germany) fitted with a 6 μm Mylar multilayer beam splitter, scanner velocity of 
40 kHz, and a liquid helium-cooled Si bolometer detector with aperture setting of 4 mm. 
The spectrometer was connected to a Michelson interferometer with an optical path length 
of 942 cm for single-sided data acquisition; optics f/6.5 (Figure 7.1). The instrument was 
operated under high vacuum and controlled by OPUSTM software v.6.5.  
 124 
 
 
Figure 7.1. The far infrared section of the Australian Synchrotron. a) Brüker IFS125/HR 
FTIR Spectrometer; b) Liquid helium cooled Si bolometer detector, and; c) sample 
chamber with liquid nitrogen cooled sample holder in position. 
 
 The synchrotron sample holder required round discs approximately 5-8 mm in 
diameter (sample holder shown in Figure 7.2).  
 
Figure 7.2. Sample holder for the Brüker IFS125/HR FTIR Spectrometer at the Australian 
Synchrotron. The circled region shows the holder plate that up to three 5-8 mm discs can 
be attached to. 
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The sample process produced samples with slight discrepancies in height and 
morphology. Curved/thick samples were compressed to form flat discs using a tablet press 
with pressures ranging from 2 to 6 tonne. Hard crystalline samples could not be 
compressed (due to shattering) and instead were crushed and mixed with 100 mg 
polyethylene, followed by pressing into a pellet using the tablet press. Each sample 
spectrum was an average of 26 scans recorded with the maximum frequency limit of 21.0 
THz (700 cm-1) and at a resolution of 7.5 GHz (0.25 cm-1). 
 
7.3.4 Preparation of bulk formulations for mechanical testing 
Mechanical analysis of the bulk properties of the dNP formulations was carried out 
using a variation of the standard dNP fabrication method discussed in Chapter 4, Section 
4.3.5, however the moulds contained no projections. Each mould was placed in a standard 
biological 24-well plate followed by the addition of 10 L of sugar/polyol formulation. The 
moulds were then centrifuged at 3000 g for approximately 1 hour (or until payload had 
dried) at 25oC to facilitate compaction and drying. The bulk disc was then removed from 
the moulds and stored in a sealed desiccator at 22oC under nitrogen. 
 
7.3.5 Nanoindentation analysis of dNP formulations 
Nanoindentation was used to characterize the micro mechanical properties of the 
different dNP formulations using a Triboindenter (Hysitron TI900 ™, Minneapolis, USA).  
The system consisted of a Hysitron MultiRange Nanoprobe™ with a maximum travel of 80 
m and a maximum force of 2N.  Manufacturer minimum noise floor was 0.0007 % at the 
maximum load. The experimentation that was conducted on these formulations was split 
into two experimental approaches.  These were: 
1. Identification of the elastic properties of the bulk materials that were used in dNP 
fabrication, and; 
2. Measurement of the structural rigidity of individual projections.  
As stated, the first part of these experiments was to identify the bulk properties of the 
materials by using Nanoindentation.  This required an understanding of the contact 
mechanics used during small scale material interrogation.   
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The most widely used nanoindentation methods are depth-sensing indentation 
coupled with the analysis method of Oliver and Pharr, 1992 [157].  Their theory utilizes the 
elastic recovery of a material after it has been indented to determine its elastic modulus.  
Within these experiments the first part of the nanoindentation consisted of a three sided 
Berkovich tip which was translated 3 m into the material surface at a rate of 1 m/s.  
Although this method has been widely utilized in literature, a brief overview is included in 
the supplementary material. 
 
Figure 7.3 shows two figures from Oliver and Pharr detailing the geometry of the 
Berkovich indenter and the geometry of the surface indentation.  Essentially during 
nanoindentation, the surface of the material was compressed to a depth h and the force P 
was measured.  In the loading phase of the indent, the material was stressed and will 
deform in both an elastic and plastic manner.  This means that there will be some 
permanent deformation which will absorb energy and change the shape of the loading 
curve.  During unloading however the curve will be dominated by the elastic recovery of 
the material.  Of interest in this work were the elastic properties of the material, as that 
would serve to highlight the rigidity of the material for mechanical stability – material failure 
was examined directly with individual projection indentation.  
 
 
 
Figure 7.3. Figures from Oliver and Pharr 1992, detailing the geometrical parameters used 
in depth-sensing nanoindentation of materials [157]. 
 
 
The theory of nanoindentation of Oliver and Pharr fits the following relationship: 
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Adh
dP
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
 2
11

         (3)
 
 
Where Er was the reduced elastic modulus, which was measured when the compliance of 
the probe tip had not been accounted for (machine frame compliance was accounted for in 
calibration).  β was a correction factor to account for any non-linearities in the material that 
stopped it from acting as a perfectly theoretical material.  This value was usually taken as 
1.034 by King [158].  
dh
dP
 was the initial slope ‘S’ of the unloading that indicated the elastic 
stiffness of the material.  A was the area function of the probe which defined the amount of 
contact (and hence the stress) that the Berkovich applied to the material.  
 
To calculate the area function of the material, indentations were conducted on fused 
quartz (elastic modulus of 69 GPa) at 50, 100, 150 and 200 mN.  The area function was 
then determined as a function of the contact depth (hc).  This was of the form shown in 
Equation (4). 
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In turn, the contact depth was calculated from the elastic unloading curve (equation 5), 
with the displacements used as shown graphically in Figure 7.3. 
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         (5)
 
 
Where Pmax was the maximum load and the other values have been defined previously. 
This way, the values of the reduced moduli would give quantified values for the material 
rigidity and allow a direct mechanical comparison of formulations.  
 
In the second part of the nanoindentation experiments, a custom fabricated probe 
that was developed within our group was used [159].  The probe consisted of a single 
tungsten probe of 40 m diameter, attached to the high load transducer.  It was fabricated 
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from 200 m diameter Tungsten wire stock (Advent Research Materials, Oxford, England) 
by use of electropolishing in a solution of sodium hydroxide (2.5 M) and then micro-
machined to give a flat tip by using Focused Ion Beam (FIB) milling.  The resulting flat tip 
was of a scale that could access projections individually (Figure 7.4a). 
 
 
Figure 7.4. Image of probe used for projection indentation and schematic of indentation: a) 
40 m diameter tungsten probe, and; b) schematic emphasizing that only individual 
projections were indented with the probe. 
 
Once mounted on the Nanoindenter, the probe was calibrated optically with the 
attached microscope to ensure that the location of indentation could be precisely dictated.  
This was done by performing indentations on a soft material (in this case chocolate).  It 
was then possible to press directly onto individual projections and measure their 
behaviour.  This is shown graphically in Figure 7.4b.   This technique was particularly 
useful as it allowed the projections to be tested in the same manner as they would be 
during insertion into skin. 
 
7.3.6 Rhodamine-dextran dNP administration   
Lysine-fixable rhodamine-dextran dNPs were applied to the inner earlobe of the 
ears of female C57BL/6 mice aged 6 to 8 weeks using a variation of the method described 
in Chapter 3, Section 3.2.1. Two mice were used for each formulation with a single dNP 
applied onto each ear (4 patches per formulation of CMC only, sucrose:CMC 10:1, 
trehalose:CMC 10:1 and sorbitol:CMC 30:1). Both mouse ears were patched 
simultaneously. Immediately after applying the dNPs for the specified formulation, the 
patches were removed, the mouse was euthanized and ears excised. Using a 6 mm 
diameter circular hole-punch, the patched ear area was excised and tissue sample fixed in 
4% paraformaldehyde for 30 minutes at 25oC. The ears were washed 3 times in 1 x PBS 
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and stored at 4oC in 1 x PBS until imaged. For all samples the total number of projections 
analyzed was n = 324. The wavelengths used to excite the rhodamine-dextran and 
collagen was 543 nm and 840 nm respectively with all microscopy done using Zeiss 
LSM510 Meta confocal microscope. 
 
7.3.7 Delivery analysis using 14C Ovalbumin dNPs 
14C radiolabelled ovalbumin dNPs were applied to 6 week old female C57BL/6 mice 
using a similar protocol as discussed in Chapter 3, Section 3.2.6, (total of 6 ears per 
group). The key variable that was changed was the administration time. To gain an 
understanding of the dissolution profile of the dNPs, administration time varied with the 
fastest time being 5 seconds and the longest time being 5 minutes.  
 
7.4 Results and discussion 
7.4.1 Morphology of dNPs comprising CMC and ranging amounts of sucrose, 
trehalose, sorbitol or mannitol 
As discussed throughout this thesis, the core excipient used within the dNP was 
carboxymethylcellulose (CMC). CMC is an FDA approved excipient used in multiple 
industries including the food industry and more importantly the cosmeceutical industry as 
dermal filler, which made it an ideal excipient in transdermal delivery devices. In Chapter 
4, Section 4.4.3, I preliminary explored the addition of sucrose as a potential excipient. 
Briefly, dNPs produced with 100% sucrose did not form a dNP representing the 
morphology of the NP template – instead a large solid sucrose crystal resulted. The 
combination of CMC and sucrose resulted in dNPs more closely representing the NP 
template, however they were extremely brittle and the projection tips weren’t formed. As 
stated, in this chapter I explore in-depth the effect of varying amounts of sugars (sucrose 
and trehalose) and polyols (sorbitol and mannitol) in combination with CMC as potential 
excipients. 
 
Four different sugar/polyols were used as possible additives (bulking agents) to the 
CMC excipient. These were chosen based on their rapid dissolution properties and current 
use as excipients in the pharmaceutical industry. Sucrose, trehalose, sorbitol and mannitol 
rapidly dissolve in aqueous environments and have the added benefit of having been 
shown to protect proteins in the dry-state [160]. In particular sucrose and trehalose are two 
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very effective protein stabilisers constituting up to 50% and 20% respectively of dry-weight 
in anhydrobiotic organisms [161] (organisms undergoing extreme dessication). In fact 
trehalose had been used as a protein stabiliser within influenza vaccine formulations used 
to dry-coat microneedles [149, 150]. Sorbitol and mannitol on the other hand are common 
bulking agents used within the pharmaceutical industry [160, 162]. The two key functions 
of bulking agents are: 
 mechanical support for the solid formulation matrix [160], and; 
 the ability to increase the dissolution rate of the solid matrix [160]. 
Therefore, bulking agents should have: 
 high solubility; 
 protein compatibility, and;  
 no or minimal toxicity. 
The four sugars/polyols investigated fit into the above criteria. 
 
Figure 7.5. Images showing the macroscopic morphological features of representative 
dNP formulations: a) all sucrose/CMC formulations produced brittle dNPs, higher CMC’s 
did lead to a reduction in the brittle nature; b) trehalose/CMC dNPs were also very brittle. 
The dNPs with a w/w ratio of trehalose:CMC greater than 2.5:1 also resulted in random 
formation of large crystalline dNPs (inset); c) sorbitol/CMC dNPs resulted in a more ductile 
dNP than the other formulations, and; d) all w/w ratios of mannitol/CMC dNPs produced 
large irregular crystal dNPs with no patch morphology. 
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As stated in the previous paragraph sucrose, trehalose, sorbitol and mannitol have 
been well characterised within the pharmaceutical industry – with trehalose also being 
extended to the microneedle field. These agents however, have not been explored as 
bulking agents for use in dissolving microneedles, potentially due to their physical 
properties within a heterogeneous matrix (i.e. crystal morphology, mechanical properties). 
To determine the potential of using these sugars/polyols, a range of dNPs with varying w/w 
ratios of sugar/polyol to CMC were produced (Figure 7.5). Similar to what was observed in 
Chapter 4, Section 4.4.3, sucrose:CMC dNPs resulted in a brittle clear glassy material 
(Figure 7.5a). An increase in the amount of sucrose resulted in dNPs that qualitatively 
appeared to be more brittle. The higher w/w ratios (>10:1 sucrose:CMC) resulted in 
projections that did not mimic the NP template (rounded tips). The trehalose:CMC dNPs 
resulted in a similar trend to the sucrose:CMC dNPs, with the formation of a hard brittle 
material that fractured upon handling (Figure 7.5b). The dNPs were also clear and glassy. 
However the trehalose based dNPs also resulted in the random formation of large opaque 
crystalline structures from w/w ratios as low as 2.5:1 trehalose:CMC (Figure 7.5b inset). 
This suggests that unlike sucrose based dNPs, trehalose was able to crystallise with a 
large number of nucleation events and crystal growth resulting in a change of the macro 
morphology of the dNP. The addition of sorbitol to the CMC formulation resulted in dNPs 
with very different macroscopic properties to the sucrose and trehalose based dNPs. 
Instead of a brittle dNP being produced, sorbitol:CMC dNPs were highly malleable (Figure 
7.5c). As the content of sorbitol increased the malleability of the dNPs decreased, however 
they were still pliable. Even though the sorbitol based dNPs were ductile they were still 
relatively hard and maintained the projection morphology for w/w ratios. One similarity to 
the sucrose and trehalose dNPs was that the sorbitol dNPs also formed clear structures. 
None of the w/w ratios produced large crystals like the several trehalose dNPs. The 
addition of mannitol to the CMC formulation resulted in large crystal structures for all w/w 
ratios (even the 1:1 ratio) with no suitable formation of dNP projections. From this point 
further in the chapter, mannitol was excluded from the experiments due to lack of dNP 
formation. 
 
 132 
 
Figure 7.6. Representative fluorescence confocal images of dNPs fabricated with 
rhodamine dextran and different CMC/sugar formulations. a) CMC only as the excipient; b) 
10:1 w/w ratio of sucrose to CMC as the excipient; c) 10:1 w/w ratio of trehalose to CMC 
as the excipient; d) 30:1 w/w ratio of sorbitol to CMC as the excipient, and; e) cross section 
of a CMC excipient with rhodamine dextran payload dNP administered to skin for 5 
minutes. The arrow indicates the remaining stump of a dissolved dNP projection. 
 
As shown in Figure 7.5, sucrose and trehalose based dNPs had a very brittle 
nature, fracturing on handling. However, the sorbitol based dNPs were very pliable, 
potentially due to sorbitol crystals disrupting the CMC matrix, as discussed later. To 
strengthen the backing of the dNP so that they could be handled the fabrication was varied 
to incorporate a CMC only backing layer (as discussed in Chapter 4). Briefly, 3000 MW 
fixable rhodamine-dextran was added to the sugar/polyol CMC formulation (w/w ratios of 
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1:1 and 10:1 for sucrose/trehalose:CMC and 1:1 and 30:1 for sorbitol:CMC).  The 
formulations were cast as described in Section 7.3.1. The viscous (approx. 30%) CMC gel 
was then cast into the moulds. The resultant dNPs were then analysed using fluorescence 
confocal microscopy to further characterise the morphology of the dNPs and verify the 
rhodamine-dextran/excipient formulation remained within the projections (Figure 7.6). For 
each formulation case (Figure 7.6a-d), the rhodamine-dextran mixture remained in the 
projections down to the tips. This was expected and correlated with previous data within 
this thesis, which I published showing layered payloads concentrated towards the tips of 
dNPs [116]. Importantly, the projection morphology was maintained for each formulation 
case with uniform sharp projections produced. These dNPs were applied to skin (Figure 
7.14, as discussed later in the chapter; however a representative CMC dNP which was 
applied for 5 minutes resulted in only small stumps remaining where the projections once 
were (shown by the arrow) and this was seen for all formulation cases (Figure 7.6e). 
Previous work published using CMC as the only excipient, also showed cross sectional 
images of a microneedle array applied to skin at varying time points (10 seconds, 1 
minute, 15 minutes and 1 hour) [18]. For these large microneedles (600 m height and 
300 m diameter) it took an hour for the whole projection to dissolve [18]. As discussed in 
Chapter 5, the small nature of dNP projections has a large advantage over larger 
microneedle projections in relation to rapid dissolution (discussed in greater detail later in 
this chapter). 
 
Overall, the addition of sugars/polyols into the CMC dNP matrix resulted in obvious 
physical and morphological changes from pure CMC dNPs. However by combining the 
dual layer casting approach to incorporate sugar/polyols into the projections, 
morphological successful dNPs could be produced 
 
7.4.2 FT-FIR analysis of CMC sugar/polyol dNP formulations 
The previous data in Figure 7.5 and Figure 7.6 assessed the macro and micro 
morphology of dNPs fabricated with CMC and either sucrose, trehalose and sorbitol. It was 
noted that the dNPs produced resulted in a clear glassy solid material (except in several 
trehalose:CMC cases where large crystalline dNPs formed). Due to the complexity of the 
formulation and the varying amounts of sugars/polyols mixed with the CMC, macro 
visualisation of the solid dNPs could not rule out the possibility of micro-crystalline 
structures forming. In the solid state, sugars can be divided into two main solid types – 
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crystalline or amorphous. Crystalline sugars are connected by hydrogen bonds resulting in 
a highly ordered lattice arrangement (i.e. long-range translational-orientational symmetry 
[163, 164], compared to amorphous sugars that possess crystal-like short-range molecular 
arrangement but lack the highly ordered long range molecular arrangement [163, 164]. 
Multiple analytical techniques have been developed characterising the molecular structure 
of solids utilising the variation in molecular arrangement between crystalline and 
amorphous solids. These include but are not limited to powder X-ray diffractometry 
(PXRD), differential scanning calorimetry (DSC), isothermal microcalorimetry (IMC), 
solution calorimetry (SC), dynamic vapour sorption (DVS), infrared spectroscopy (IR) and 
solid state nuclear magnetic resonance (ss-NMR) as reviewed in Shah et al. 2006 [165].  
 
IR analysis of carbohydrates have been well established with initial emphasis of the 
studies being analytical i.e. determination and differentiation between carbohydrate 
samples [155]. Advances in IR spectrometers and light sources have allowed for accurate 
analysis in the near (~13,000 cm-1 – 4,000 cm-1), mid (~4,000 cm-1 – 700 cm-1) and far 
infrared (~700 cm-1 – 10 cm-1) [166]  ranges providing information on various molecular 
vibrations within sugars [155]. My region of interest was below 200 cm-1 because it 
provided information on the molecular interactions involving hydrogen bonding and 
intercrystalline forces (i.e. information on the amorphous or crystalline properties of the 
CMC sugar/polyol formulation.  
 
It had been reported in literature that detailed high resolution infrared spectra 
require systems that can be cooled using liquid nitrogen/helium [164, 167, 168]. As stated 
the Australian synchrotron provided a liquid nitrogen cooled sample holder and liquid 
helium cooled detector resulting in much higher resolution and sensitivity than standard 
benchtop IRs, especially useful in the low wavenumber range of the far infrared terahertz 
region. I utilised these advantages and analysed the microcrystalline properties of the 
dNPs using FT-FIR spectroscopy ([Figure 7.7] Australian Synchrotron, Melbourne). 
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Figure 7.7. Fourier transform far-infrared (FT-FIR) analysis of the amorphous or crystalline 
properties of carboxymethylcellulose (CMC) sugar/polyol dNP formulations. a) 
Representative CMC spectrum (all were amorphous i.e. no definite peaks), and; different 
w/w ratios of b) sorbitol:CMC; c) trehalose:CMC, and; d) sucrose:CMC. 
 
 The FT-FIR assay was designed to provide a positive or negative read out on the 
crystallinity of the dNP formulations.  As discussed, crystalline structures result in 
reproducible defined peaks (in the far infrared region) corresponding to the intermolecular 
interactions of the crystal lattice. None of the pure CMC samples tested (n=6) resulted in 
define peaks corresponding to an amorphous material (Figure 7.7a). However, the 
addition of sorbitol to the CMC formulation resulted in the presence of strong crystalline 
peaks relating to crystalline sorbitol (Figure 7.7b). This was interesting, seeing that in 
Figure 7.5, no crystal structure was seen using stereomicroscopy. The discrepancy 
between the two techniques could be attributed to the scale and resolution of the two 
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instruments. The stereomicroscope was able to detect traits on millimetre scale; however 
the synchrotron provided information on a micron scale detecting a combination of 
molecular vibrations (angstrom level). This suggested that the crystal structures formed 
were at a micron scale much smaller than the resolution capable of the laboratory’s 
stereomicroscope.  As the w/w ratio of sorbitol:CMC decreased, the peaks of the different 
spectra overlapped indicating the same type of crystal structure. At w/w ratios below 3.3:1, 
no crystalline peaks were detected. The addition of trehalose resulted in two types of 
spectra (Figure 7.7c). As discussed in Figure 7.5, trehalose:CMC dNPs resulted in either 
a clear glassy material or an opaque crystalline material. These qualitative visual results 
were validated by the FT-FIR spectra obtained for the various trehalose:CMC samples. 
The samples tested from the clear glassy trehalose:CMC formulations resulted in no 
defined peaks in the FIR region, however the large crystalline samples were analysed 
resulting in strong defined peaks (Figure 7.7c). These peaks correlated with the trehalose 
crystalline control and spectra reported in literature[167]. The sucrose:CMC samples 
resulted in no defined peaks for any of the w/w ratios (Figure 7.7d). To confirm this wasn’t 
a reagent issue, pure sucrose was analysed, resulting in strongly defined crystal peaks 
within the FIR region correlating with spectra reported in literature [164] (Figure 7.7d). The 
combined results for the two sugars and polyol indicated that CMC did not crystallise 
under the given conditions (or if it did, was negligible).  
 
Overall FT-FIR analysis of the different dNP formulations within the FIR region 
provided accurate and reproducible information on the intermolecular interactions 
(crystalline/amorphous properties) of complex heterogeneous solid formulations. This data 
verified other work published showing spectra of both crystalline and amorphous glucose, 
where crystalline glucose formed defined peaks and amorphous glucose resulted in a 
featureless absorption profile [164]. However, this was the first time FT-FIR had been done 
using heterogeneous solid formulations.  
 
When combining the FT-FIR data (Figure 7.7) with the visual microscopy data 
(Figure 7.5 and Figure 7.6), a crystalline/amorphous trend could be seen within the 
different samples. Sorbitol:CMC dNPs resulted in malleable solids with microcrystalline 
regions of sorbitol within an amorphous CMC matrix. Trehalose:CMC dNPs resulted in a 
brittle solid with a combined amorphous trehalose and CMC matrix. However, trehalose 
was able to crystallise in the presence of CMC resulting in a large brittle opaque crystalline 
matrix. Sucrose:CMC dNPs also resulted in a brittle solid, however under the given 
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fabrication methods sucrose was not able to form crystals resulting in a combined 
amorphous matrix of sucrose and CMC. 
 
7.4.3 Nanoindentation analysis of the bulk dNP formulations 
 I previously showed that dNPs fabricated with CMC as the sole excipient penetrated 
mouse skin (Chapter 5) [116]. However accurate analysis of the failure modes and forces 
involved had not been characterised. It was qualitatively observed in this chapter in Figure 
7.5 that the addition of sucrose, trehalose and sorbitol to the CMC dNP formulation results 
in different macro morphological attributes and also macro mechanical properties. Further 
micro analysis using fluorescence confocal microscopy (Figure 7.6) and FT-FIR (Figure 
7.7) showed that accurate projections could still be produced however the dNPs varied in 
their crystalline or amorphous properties. The various formulated dNPs were compared to 
the standard CMC dNP using nanoindentation analysis, providing information on the 
micro-mechanic properties of the bulk dNP formulations and their corresponding 
projections (Figures 7.8 to 7.13). 
 
 Initially the reduced elastic modulus was determined for the different formulations 
using flat samples approximately 3 mm2 in size fabricated using a similar casting method 
to dNP fabrication (Figure 7.8). CMC resulted in a reduced elastic modulus of 8033 +/- 
1614 MPa. The addition of sucrose 1:1 w/w ratio resulted in slightly higher modulus of 
9366 +/- 1694 MPa; however it was not significantly different from CMC only. 
Sucrose:CMC 10:1 resulted in a low modulus significantly different from all the samples 
tested of 48 +/- 11 MPa. All the samples (including sucrose/CMC formulations) were 
tested in an enclosed environment at 25oC and 25-30 % relative humidity (RH). It had 
been reported that increasing the relative humidity from 10% to 35% only led to a small 
increase of water content in amorphous sucrose (~ 1%) [169]. Therefore, the slight change 
in relative humidity was not believed to have been a contribution to the low modulus of the 
sucrose:CMC 10:1 formulation.  Even though the samples were all fabricated at the same 
time and treated under the same conditions (i.e. temperature and humidity), the decreased 
modulus could potentially be attributed to excess residual moisture within the 
CMC/sucrose matrix. The trehalose samples resulted in a reduced elastic modulus of 
10,560 +/- 589 MPa and 12,750 +/- 1428 MPa for w/w ratios 1:1 and 10:1 respectively. 
Sorbitol:CMC 1:1 w/w ratio resulted in a lower modulus of 1966 +/- 1072 MPa differing 
significantly from all the other formulations (for clarity significant symbols were only shown 
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for CMC and sorbitol samples [Figure 7.8]). The modulus increased with the additional 
w/w ratio of sorbitol:CMC (5:1 and 30:1) to 8085 +/- 12,665 MPa and 12,818 +/- 9825 
MPa. It was noted that for all the sorbitol samples there was a large standard deviation, 
especially when compared to the error associated with the sucrose/CMC and 
trehalose/CMC samples.  Based on the FT-FIR data in Figure 7.7, it was determined that 
the sucrose and majority of the trehalose samples were amorphous compared to the 
sorbitol formulations which were crystalline. It was assumed that the increase in error 
associated with the sorbitol samples was due to the pockets of crystalline regions within 
the amorphous CMC matrix, disrupting the material. This trend had been reported in 
literature [170], where Ward et al. compared the mechanical properties of pure crystalline 
and amorphous sorbitol using nanoindentation and observed a greater error for the 
crystalline samples compared to amorphous. Ward et al. also observed that the crystalline 
samples had a higher modulus than the amorphous samples [170], which agreed well with 
the data in Figure 7.8, where the highest moduli achieved was with the crystalline sorbitol 
samples.  
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Figure 7.8. Reduced elastic modulus of bulk dNP formulations. Significance set at p < 
0.05. 
 
Overall the elastic modulus obtained from the nanoindentation tests correlated with 
the macro fracture characteristics that were observed in Figure 7.5, where the sucrose, 
trehalose samples were brittle but uniform structures compared to the sorbitol/CMC dNPs, 
which were highly malleable. The malleability of those dNPs were attributed to pockets of 
crystalline regions interfering with the CMC matrix leading to greater flexibility, which on a 
micron level resulted in a greater variation of reduced elastic modulus. In fact sorbitol is 
commonly used as a plasticizer in thin films to improve their mechanical properties (i.e. 
flexibility, impact resistance, toughness, etc) [171, 172]. 
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7.4.4 Nanoindentation of the formulated dNP projections 
Nanoindentation provided the information on the bulk properties of the various CMC 
sugar/polyol dNP formulations. An even more significant use of this method was its ability 
to apply forces to individual projections in the dNP array with accuracy. To my best 
knowledge this has never been shown before in literature. By applying a load right on the 
top of an individual projection, information on the force required to fail (buckle) the 
projection could be determined. A flat cylindrical probe of 40 m in diameter was axially 
applied to a depth of 20 m onto the dNP projections (n = 5 projections per 3 dNPs per 
formulation – total of 15 projections per formulation). After indentation the dNPs were 
analysed using SEM to visually assess the failure of the projections (Figure 7.9).  
 
When the projections that had been compressed were examined under SEM, there 
were three distinct failure modes overall, which can be seen in the representative images 
of the failed projections (Figure 7.9). These are: 
1. Failure in bending of the tip.  This was shown in Figure 7.9b, e where the top 
half of the projection has deflected. This was where a small initial bending or 
buckling of the very tip of the projection had initiated a deflection which had 
been continued in plastic failure.  This was characteristic of a more ductile 
material with quite low rigidity. 
2. Failure due to buckling.  The projections in Figure 7.9c, h show where material 
had bent, plastically, just below the tip (approximately 5 – 10 m) and at a lower 
point between 10 – 20 m from the tip. This was ductile failure model for a 
material with substantial rigidity. 
3. Failure due to abrupt (brittle) failure. Observed in Figure 7.9d, f, g the tips of the 
projections could be seen to have bent over on themselves.  There was 
evidence of the tip having broken substantially in these cases (as opposed to 
simply just bending).  These appeared to be a catastrophic failure, as the 
ultimate stress of the material had been reached.  This behaviour was where 
there was some brittle nature of the projection material. 
 
Whilst previous studies performed some simple experiments on microneedles to 
examine their strength, they had been on needle arrays [18].  This work was unique 
because it allowed identification of individual failure properties and identification of what 
materials would most appropriately breach the skin’s surface.  Additionally, this work 
highlighted both the bulk properties and the micro-scale projection material behaviour. 
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Figure 7.9. Representative SEM images showing the failed projections of the different 
formulated dNPs after nanoindentation (arrows indicate indented projections). 
 
In conjunction with the individual projection SEM data in Figure 7.9, indentation 
force-displacement  curves were produced for each of the formulated dNPs – CMC only 
(Figure 7.10), sucrose:CMC (Figure 7.11), trehalose:CMC (Figure 7.12) and 
sorbitol:CMC (Figure 7.13).  
For all formulations that were examined, the force increased during indentation, due 
to the resistance from the projection.  Within these the force displacement curves for the 
CMC projections resulted in two predominant types of behaviour (Figure 7.10a). The first 
population could be described as a steady increase in force followed by a sudden drop, 
which was associated with buckling/failure of the projection tip under the given load. For 6 
out of 15 projections the force increased after the abrupt drop – indicating that the probe 
remained in contact with the projection following the buckling or failure. The other main 
population of the curves showed an initial increase in force, followed by a change in 
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gradient indicating a greater resistance to the probe. The initial gradient was associated 
with the probe coming into contact with the projection tip causing it to bend followed by an 
inflection point where the probe started to come in contact with the more substantial shaft, 
resulting in greater resistance and hence increase in force. For some cases, after the 
increase in force related to probe-shaft contact, the force decreased and plateaued. This 
decrease in force or inflection point was potentially due to the projection failing and rolling 
over on itself (for example – Figure 7.9g). These definite signs of failure were quantified 
for the maximum force at the inflection point before buckling. The maximum failure force 
for the buckled projections was 7021 +/- 2078 N. 
 
One common trend between all the curves was that there was a change in gradient 
at approximately 500 nm (shown in detail in Figure 7.10b). This change in gradient was 
associated with the very tip of the projections failing under load. This was also observed 
with the other formulated dNPs in the same 500 nm region. 
 
Figure 7.10. Force displacement curves of indented CMC dNP projections  
 
No other studies had reported the indentation of individual projections on this scale 
and formulation, except for the work done by Lee et al. [18], where they indented an array 
of CMC microneedles (3 x 3 array of microneedles 600 m length and 300 m diameter) 
and averaged the force over the microneedles to produce a force displacement curve per 
microneedle. These much larger microneedles produced similar force displacement curves 
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however there was no observation of brittle failure (Figure 7.10a). The limitation of their 
experimental design was that there was only a single curve produced/shown with the key 
assumption that all the microneedles behaved the same under the applied force. The SEM 
examination of the compressed projections (Figure 7.9) clearly showed that Lee’s 
assumption was not accurate. More importantly during in-vivo application of 
microneedles/dNPs the surface roughness of the skin and the small scale of projections 
meant it was highly unlikely skin contact would be completely uniform across the array, 
hence resulting in different failure modes. 
 
Figure 7.11. Force displacement curves of indented sucrose:CMC 1:1 (a) and 10:1 (b) 
dNP projections 
 
 The force displacement curves for the sucrose:CMC 1:1 projections (Figure 7.11a) 
were noticeably different from the CMC results. Besides Sample 1,2 in Figure 7.11a, the 
other projections showed no significant drop in force with the increased load. The 
maximum force reached during the 20 m indentation, which varied from 4114 to 25847 
N with the average being 10582 +/- 6483 N. The large error was associated to intra-
patch variations with two populations of curves corresponding to Sample 2 and Sample 3. 
The distinct populations were attributed to the possibility of projection/dNP angle during 
loading potentially making it easier for the projections to bend.  However, when combining 
the curves with the SEM results (Figure 7.9), all the sucrose:CMC 1:1 projections were 
bent/buckled, indicating that the addition of sucrose to CMC 1:1 resulted in ductile 
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projections. This was interesting considering that in Figure 7.5, the large macro properties 
of the sucrose/CMC dNPs resulted in a brittle structure. 
 
 Increasing the w/w ratio of sucrose:CMC to 10:1 resulted in a different set of force 
displacement curves (Figure 7.11b). These curves were similar to the CMC only 
indentation curves (Figure 7.10a) with curves indicating brittle failure or buckling of some 
of the projections. For 7out of 15 projections the force increased after the drop 
corresponding to the probe contacting the remaining projection shaft at the base of the 
initial buckle. The associated maximum fracture force for the buckled projections was 6164 
+/- 2020 N. Overall the nanoindentation results suggested that increase in sucrose 
resulted in a more rigid material with more pronounced catastrophic buckling of the 
projections compared to lower sucrose amounts. This was potentially due to the formation 
of large amorphous regions of both CMC and sucrose within the projections resulting in 
voids or boundaries where failure could occur. 
 
 
Figure 7.12. Force displacement curves of indented trehalose:CMC 1:1 (a) and 10:1 (b) 
dNP projections 
 
The force displacement curves for the trehalose:CMC 1:1 projections (Figure 
7.12a) were similar to the sucrose:CMC 1:1 results, however the total forces were a lot 
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lower (i.e. highest force achieved for trehalose was 8710 N compared to 25847 N for 
sucrose 1:1). Besides Sample 1,4 in Figure 7.12a, the other projections showed no 
significant drop in force with applied load. However there were regions where the curve 
began to plateau with a slight decrease in force. This form of significant failure was related 
to the projections bending (or falling over with increase load), which was seen in (Figure 
7.9).  These regions of failure where the curve has begun to plateau (5 out of 15 
projections) could be quantified in relation to a maximum fracture force resulting in a force 
of 5003 +/- 2584 N, which was lower but still comparable to CMC alone and 
sucrose:CMC 10:1 fracture forces. However, overall trehalose:CMC 1:1 produced force 
displacement curves similar to sucrose:CMC 1:1 indicating the material was more ductile 
than CMC alone. 
 
 Increasing the w/w ratio of trehalose:CMC to 10:1 resulted in a similar trend to w/w 
ratio 1:1 (Figure 7.12b). For all the projections there was no sudden drop in force 
indicating a significant buckling failure and instead the force displacement curves either 
began to plateau with a gradual decrease in force. Like trehalose:CMC 1:1 (Figure 7.12a) 
this trend indicated a softer ductile material that bent under an applied load. The 
associated maximum fracture force for the buckled/bent projections (5 out of 15) was 6420 
+/- 2314 N. Overall the nanoindentation results suggested that the addition and increase 
of trehalose to CMC resulted in much more ductile material than CMC alone. This was 
potentially due to trehalose disrupting the CMC matrix. 
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Figure 7.13. Force displacement curves of indented sorbitol:CMC 1:1 (a) and 30:1 (b) dNP 
projections 
 
The force displacement curves for the sorbitol:CMC 1:1 projections (Figure 7.13a) 
were similar to the CMC alone results, however fewer projections showed brittle failure (4 
out of 15 for sorbitol compared to 6 out of 15 for CMC [Figure 7.10a]). Overall 
sorbitol:CMC 1:1 showed three distinct populations of curves, the other two being a steady 
increase in force with increased displacement and the third being what was seen for 
sucrose and trehalose where the force began to plateau followed by a slight decrease in 
force. Quantification of the failed projections resulted in a maximum fracture force of 5404 
+/- 1687 N (n= 5 out of 15 projections). Overall the results indicated that this material had 
higher ductility than CMC alone, but was more brittle than both the sucrose and trehalose 
samples. 
 
 Increasing the w/w ratio of sorbitol:CMC to 30:1 resulted in a trend unique to the 
other formulations and w/w ratios (Figure 7.13b). There were still curves indicating a 
ductile material like what was observed for the sucrose and trehalose samples, however 
there were also curves which had a large increase in force followed by a decrease 
indicating buckling. The initial increase in force (Sample 1,1 Figure 7.13b) was much 
greater than what was seen for the other formulated dNPs (19579 N). The average 
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fracture force for the buckled projections (9 out of 15) was 9495 +/- 4712 N. These 
results correlated with the reduced elastic modulus data showing sorbitol:CMC 30:1 w/w 
ratios having the stiffest material, however large error potentially due to the pockets of 
crystalline regions within the sample. Overall, the nanoindentation results suggested that 
the addition and increase of sorbitol:CMC ratio resulted in stronger dNPs that were more 
brittle than the other formulations. Controlling sorbitol’s crystal growth within the CMC 
matrix could potentially lead to hard semi-crystalline dNPs with more consistent 
mechanical properties. 
 
 In summary, the introduction of sucrose, trehalose and sorbitol to the CMC matrix 
resulted in slight changes in the mechanical properties of the reduced elastic modulus and 
buckling properties of the dNPs when tested by nanoindentation. More importantly these 
results for the first time provided insight into the different failure modes of dNP projections, 
which in principle could also be applied to the larger microneedles. The addition of sucrose 
and trehalose to CMC resulted in a more ductile material than CMC alone compared to an 
increase in sorbitol which resulted in a stiffer material. 
 
A rigid structure is important for penetration, due to resistance to bending on 
administration. The forces achieved (all greater than 1000 N) should be capable of 
penetrating skin for all formulations at this scale as discussed in Crichton et al. [134, 159].  
The materials here were soft compared to the original silicon NP template.  A crystalline 
material would fail in a far more brittle mode compared to the soft materials here, which 
could cause a failure to penetrate.  Here, even where buckling had occurred, the 
projections maintain the ability to resist substantial forces (several millinewtons) indicating 
that even with slight buckling, the projections would still enter the skin. 
 
7.4.5 Characterisation of the dissolution and diffusion profiles of dNPs formulated 
with CMC and sugar/polyol excipients 
It was observed in the data in Figure 7.5 that the addition of sucrose, trehalose and 
sorbitol to the CMC formulation resulted in dNPs with different morphological features (i.e. 
brittle compared to malleable). However further analysis of the dNPs using 
nanoindentation showed that on average for all the formulations, a force greater than 5000 
N was required to significantly buckle the projections. As discussed in Crichton et al., 
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2011 [159], a force of approximately 1000 N is required to puncture the skin, when using 
projections with tip profiles less than 1000 nm in diameter – i.e. NP and dNP projections. 
 
To visually validate successful penetration of the various dNP formulations, 
rhodamine-dextran encapsulated dNPs were fabricated and applied to mouse skin 
followed by fluorescence confocal and multiphoton microscopy (Figure 7.14, [n=3 dNPs 
per formulation, 3 areas imaged per dNP resulting in a total of 108 projection sites per 
formulation]). Qualitative analysis showed that all the dNP formulations successfully 
penetrated the mouse skin. Furthermore, second harmonic generation of the dermal 
collagen using multiphoton microscopy (MPM) showed clear channels where the 
projections had penetrated into the dermis (Figure 7.14). The penetration achieved by the 
various formulated dNPs verified with the data in Chapter 5 showing penetration and 
diffusion within the dermis for CMC dNPs [116]. 
 
Figure 7.14. Fluorescence confocal and multiphoton microscopy analysis of dNP delivery 
of rhodamine-dextran. Rhodamine-dextran fluorescence is shown in red and second 
harmonic generation of the dermal collagen is shown in blue for a) CMC; b) sorbitol:CMC 
30:1; c) sucrose:CMC 10:1, and; d) trehalose:CMC 10:1 w/w ratios. 
 
The microscopy images in Figure 7.14 validated the nanoindentation results, 
showing successful penetration in skin. By analysing the distribution of rhodamine-dextran 
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within each projection site, diffusion profiles were determined for the different formulations 
(Figure 7.15). Overall for all dNP formulations within the 5 minute administration time, the 
payload diffusion saturated the deposition site within the stratum corneum, viable 
epidermis and upper dermis spreading to neighbouring projection sites (Figure 7.15a-d). 
Figure 7.15e showed the combined diffusion profiles of the dNPs and it was seen that 
there was no significant difference between the formulations with a resulting depth of 
approximately 90 m under the defined conditions and fluorescence threshold. 
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Figure 7.15. Analysis of the diffusion profiles of dNP delivery of rhodamine-dextran for a) 
CMC; b) sucrose:CMC 10:1; c) trehalose:CMC 10:1; d) sorbitol:CMC 30:1 w/w ratios; with 
the combined fronts (error bars are shown on individual plots [a-d]) shown in e).  
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 Having confirmed that the formulated dNPs were capable of penetrating skin, the 
delivery and dissolution rate was quantified using 14C-radiolabelled ovalbumin protein as a 
tracer (Figure 7.16). To determine the total amount delivered between the different 
formulations, the dNPs (n=6 per formulation) were applied to mouse ears for 5 minutes. 
The ears were then excised, homogenised and analysed for total disintegrations per 
minute (DPM [Figure 7.16a]). Overall, there were no significant differences in the total 
payload delivered between the different formulations. These results complement the 
microscopy images (Figure 7.14), which showed a uniform penetration profile for all the 
formulations tested. Given that the force required to penetrate the skin with these 
projections was approximately 1000 N [159] and that the projections failed at 
approximately 5000 N, it was not surprising that the total amount delivered was 
comparable for all the projections. The data indicated that as long as the force was over 
the 1000 N threshold successful penetration could be achieved for any formulation.  
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Figure 7.16. Analysis of the delivery and dissolution properties of dNPs. a) Comparison of 
the delivery amount for dNPs consisting of CMC, sucrose:CMC 10:1, trehalose:CMC 10:1 
and sorbitol:CMC 30:1. b) Dissolution rate of CMC dNPs and; c) dissolution rate of 
sorbitol:CMC 30:1 dNPs. 
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 It was shown in Chapter 5 that dNP projections penetrated the skin and started 
dissolving immediately with the majority of each projection dissolved within 2 minutes of 
application [116]. However to be confident that the maximum amount of payload was being 
released, the standard application time of 5 minutes was selected. An assumption in this 
chapter was the addition of sugars/polyols to the CMC matrix could potentially increase the 
dissolution rate and therefore reduce the total administration time required for delivery. 
CMC dNPs were used to deliver 14C ovalbumin protein using administration times of 5, 10, 
30, 120 and 300 seconds (Figure 7.16b). The results showed that there was no statistical 
difference between the total amounts delivered for each time point suggesting that the 
dissolution rate of dNP projections occur within 5 seconds. Sorbitol:CMC dNPs with a w/w 
ratio of 30:1 were also used to deliver 14C ovalbumin protein using administration times of 
5, 10, 30, 120 and 300 seconds (Figure 7.16c). Similar to the CMC dNPs, there was no 
significant difference in delivery for any of the time points indicating that the dNPs 
dissolved within 5 seconds post application.  
 
 Even though there was no significant difference between the time points for both 
CMC and sorbitol:CMC dNPs was noted that there was a slight decrease in the amount 
delivered before the delivery plateaus. It was hypothesised that this slight decrease was 
due to the extremely small tips of the projections dissolving immediately on administration 
followed by the absorption of fluid by the shafts and base of the projections. The 
projections act like a sponge, absorbing a negligible amount of delivered payload. This 
assumption was supported by the cryo-SEM data shown in Chapter 5, where it was seen 
that the base of dissolved projections had become swollen. Lee et al., 2008 [18], also 
observed significant swelling of the backing of an applied dissolving microneedle 
(composed of CMC) applied to skin for 15 hours [18]. The small size of the dNP 
projections resulted in a negligible amount of payload absorption; however this should be 
an important consideration for the much larger microneedles – that could absorb much 
more fluid in the shafts and base of their projections, possibly being a limiting factor in their 
rate of dissolution.  
 
7.4.6 Conclusions 
The work in this chapter examined the micro-crystalline formulation properties and 
the physical/mechanical behaviour of dNP microprojections, providing fundamental 
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knowledge on the formulation and failure modes of complex microstructures. By varying 
the type of sugar/polyol and the amount within the dNP CMC matrix, dNPs could be 
produced with either crystalline or amorphous properties. More importantly, the data 
showed that incorporation of sugers/polyols resulted in either a reproducible array 
(sucrose, low amounts of trehalose and sorbitol) or large disrupted crystals (mannitol). 
This study has sets the foundation for choosing the type and concentration of sugar/polyol 
used in future stabilisation studies not only for dNPs but also for the larger dissolving 
microneedles.  
 
After the microcrystalline properties were analysed the formulations were further 
characterized using nanoindentation. This method of mechanical testing used an 
extremely small probe (<40 m) or berkovich tip to apply a force to individual dNP 
projections characterizing their failure modes. This type of force analysis on such small 
micro-structures had never been shown before and provided important insight into the 
interactions of micro-projections with surfaces (i.e. skin). It was determined that the 
majority of the formulations consisted of both partial brittle and ductile failure. However, the 
bulk of the failure for the examined projections was ductile. This was not surprising given 
that in general the dissolving polymers used were soft compared to the original silicon NP 
template.  A rigid crystalline material would fail in a far more brittle mode compared to the 
soft materials explored, which could cause a failure to penetrate.  However, even where 
buckling had occurred, the projections maintained the ability to resist substantial forces 
(several millinewtons) indicating that even with slight buckling, the projections would still 
enter the skin. These results provided insight into the mechanisms of dNP penetration and 
relate back to the question in objective two: 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
 Finally the formulated dNPs were compared to each other in relation to their 
dissolution and diffusion properties. It was determined under the given conditions that the 
driving factor for rapid dissolution (seconds) at this scale was the large surface area to 
volume of the dNPs. These findings were significant because they provided insight into the 
reason why much larger dissolving microneedles of similar composition require at least 1 
hour for complete dissolution. 
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CHAPTER 8 
Diffusion properties of skin and payload kinetics post 
Nanopatch administration 
 
8.1 Summary 
The previous chapters and objectives of this thesis focused on the development, 
administration and application of dNPs for vaccine delivery, answering the applied 
question of whether or not dissolving microstructures could be produced to deliver 
sensitive biologicals to skin. It was noted in Chapter 5 that administration of the dNP 
within mouse skin resulted in a large diffusion gradient of the payload within the different 
layers of the skin. This chapter further analysed and quantified the diffusion of the 
delivered payload locally within the skin as well as extending the approach to assess long 
term diffusion kinetics of the payload over weeks, addressing the question at the core of 
objective three: 
 
What governed the diffusion behaviour within the upper layers of the skin and how does 
this impact the distribution of skin delivered payloads?  
 
I studied the interaction of NP delivered vaccine (the NP was used to simplify the 
analysis and relate the work to current Kendall Group experiments) directly after 
application followed by analysis of local payload diffusion up to 10 minutes post 
application. I determined that approximately 52% of the vaccine was co-localised with 
APCs in the skin, which supported the theoretical probability analysis of 50% [95]. 
Following administration the payload diffused rapidly within the skin resulting in almost 
complete saturation of the patched area. This in theory extended the probability of payload 
contacting the APCs in the skin (epidermis and dermis) to 75-100%. I further analysed the 
long-term diffusion of the vaccine in the skin using fluorescently labelled Fluvax2008® and 
14C-labelled ovalbumin protein. It was determined that after 48 hours approximately 75% 
of the vaccine had left the ear and after 1 week approximately 90% of the vaccine had 
gone. Combined, these results suggested that NP delivery of vaccine resulted in rapid 
diffusion and cellular uptake by skin APCs resulting in the potent immune responses found 
by the Kendall Group [11]. Overall, the data obtained in this chapter provided important 
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insights into the mechanisms of NP/dNP and microneedle/dissolving microneedle 
intracutaneous delivery. 
 
8.2 Introduction 
The NP design was based on maximising the probability of directly targeting the 
abundant immune cells in the skin with individual projections within the NP array. I showed 
qualitatively in Chapter 5, Section 5.4.3, that the degree of payload diffusion varied 
greatly from the stratum corneum down to the dermis. It was hypothesised that the 
diffusion of payload within the skin would result in an increase in the number of cells 
targeted by NP/dNP delivery. This was briefly explored in the Kendall Group but not 
quantified 3-dimesionally using high resolution. The purpose of this chapter was to analyse 
the diffusivity and distribution of large molecules within the individual layers of skin; an 
approach which to my knowledge had not been previously reported in the literature. To 
simplify the approach and to correlate with the research being undertaken in the Kendall 
Group, all experiments in this chapter used the solid NP and not the dNP. 
 
Multiple approaches have been attempted to characterize and quantify the diffusion 
properties of tissues, but have been hindered by the need for harsh mechanical and 
chemical processing of the tissue prior to and during experimentation. One common 
technique designed to analyse diffusion within ex vivo tissue (more specifically – skin) use 
modifications of the Franz diffusion cell method which provide properties of the rate limiting 
layer only [173-177]. Disruption of these barriers to measure the diffusivity of deeper strata 
affects the structural integrity of the tissue providing experiment-dependant results. For 
example, Xing et al. removed subcutaneous fat from excised human skin, immersed in 
60oC water and then tape-stripped the stratum corneum (SC) and blade-stripped the VE 
for dermis absorption of an applied radioactive tracer [175]. Similarly, Cornelissen et al. 
used fluorescence recovery after photobleaching (FRAP) to analyse dermal diffusion by 
using tweezers to peel off the epidermis followed by exposure to a 25mW laser beam at 
100% power [178]. 
 
The previously discussed techniques have provided insight into biomolecular 
diffusion within tissue. However, their limitations have led to incomplete experimentally-
obtained information, which in turn has held back our ability to use recent and powerful 
modelling methods.  Both approaches in parallel would help provide a more complete 
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understanding of the transport of biomolecules within tissue. Here, using the skin, which is 
a highly complex multilayered material comprising both epithelial (epidermis) and 
connective tissue (dermis) as a test-case, I:  
a) minimally-invasively and precisely deposited biomolecules directly into strata of  in 
vivo tissue; 
b) imaged the diffusion of  these biomolecules throughout the skin strata – using 
excised full thickness skin, and; 
c)  applied this high-resolution experimental diffusion data to establish the diffusion 
characteristics continuously throughout the skin strata. 
In doing so, I observed the relative diffusion throughout the skin strata for the first time, 
and linked these characteristics to the morphology of the skin. This not only served as a 
key template for meeting the challenge of targeted biomolecule delivery into skin (e.g. 
vaccines to antigen presenting cells), but also provided a new methodology that could be 
applied to the study and optimization of the transport of biomolecules within other tissues, 
in particular other epithelium and connect tissues. 
 
8.3 Experimental procedures 
8.3.1 Coating of payload onto microprojections  
NPs were dry-coated as described previously [9]. Briefly, The NPs were first 
cleaned in a mixture of glycerol and distilled water in a 1:1 ratio for 10 min and washed 
with an excess of water. The patches were then dried under ambient conditions. Next, 
coating solution containing 10 mg/mL of methyl cellulose (MC) and either 0.1 g/mL of 2 
MDa rhodamine or 0.1 g/mL 70 kDa rhodamine dextran was prepared for the localised 
diffusion experiments. The radio-tracer experiments consisted of 10 mg/mL MC with 8 nCi 
14C ovalbumin per patch. The fluorescence confocal experiments consisted of labelled 
ovalbumin protein or Fluvax2008® with 10 mg/mL MC. The coating solution (8 L) was 
applied onto each individual patch. A nitrogen gas-jet (25.1 ± 0.3 L/min) was used to 
evenly distribute the solution on the whole NP while simultaneously localising the 
respective payload on the projections where it would be delivered to skin. 
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8.3.2 Radioactivity (14C) labelled ovalbumin protein (OVA) and Cy5-labelled influenza 
vaccine delivery in the skin and the subsequent migration away from the ear skin 
To study the long term kinetics of payload diffusion, C57BL/6 mice had their ears 
treated by applying either Cy5-Fluvax 2008® or 14C-OVA coated patches at 1.9 m/s. NPs 
were applied using a similar protocol as discussed in Chapter 3, Section 3.2.6. After each 
time point of 0 hour, 5 hours, 48 hours and 1 week post ear treatment, two of the 14C-OVA 
coated NP treated mice were sacrificed and ears were excised for measuring the 
remaining radioactivity. The Kendall Group animal ethics regulation only allowed 
radioactivity measurement on living mice for up to a week. Therefore, for longer time 
points, Cy5-Fluvax was used in the study. After each time point of 0, 1, 2, 3 and 4 weeks 
post ear treatment, four of the Cy5-Fluvax treated mice were sacrificed and eight ears 
were excised. Four ears were for subsequent immediate investigation under fluorescence 
confocal microscopy. The other four ears were stored at -20 ºC for later quantitative 
analysis of the remaining Cy5-Fluvax. Untreated ears were used as the negative control. 
Four ears were treated with the Cy5-Fluvax coated patches and then excised immediately, 
storing at 35 ºC for 2 weeks as a positive control. The amount of Fluvax remaining in the 
skin was measured with a dot-blot assay described previously [9]. 
 
8.3.3 Payload – MHC-II positive cell co-localisation image analysis 
3The number of MHC II+ cells, antigen deposit sites, and co-localisation of immunogen 
and MCH II+ cells were determined by image analysis in the epidermis through optical 
sectioning.  NPs containing fluorescently-labelled ovalbumin were applied to the ventral 
side of mouse ears as described previously [95].  Ears (n=3) were harvested at 0, 1, and 3 
days post NP application.  The area where the NP was applied clearly stood out under 
fluorescence microscopy.  The NP application area was divided into 9 equally sized areas 
and one z-stack the depth of the epidermis (top10-20 µm) and an area of 420.8 µm x 
420.8 µm was taken per area.  Each image contained 36 potential deposition sites.  
Therefore, nine image stacks were analysed for each of three NP ears per time point for a 
total of 36 analysed image stacks per group over three time points.  Three aspects were 
visually tallied for each image stack: number of MHC II+ cells, deposition sites, and co-
localisation/deposition site. 
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8.3.4 Nanopatch administration of rhodamine dextran for local diffusion study 
Coated patches were applied to the inner earlobe of the ears of female BALB/c 
mice aged 6 to 8 weeks using a variation of the method described in Chapter 3, Section 
3.2.1. Two mice were used for each time point with a single NP applied onto each ear (4 
patches per time point). During application, each NP was kept in place on the skin for 2, 4, 
7 and 10 minutes. Both mouse ears were patched simultaneously. Immediately after 
applying the NPs for the specified time, the patches were removed, the mouse was 
euthanized and ears excised and snap-frozen in methanol at approximately          -80oC 
and stored at -20oC for imaging.  
 
8.3.5 Imaging of local payload diffusion within skin 
The patched mice ears were imaged using a Zeiss LSM510 Meta confocal 
microscope. Rhodamine-dextran was excited using a beam of light at 543 nm and the 
fluorescent light collected between 560 and 615 nm. To determine the surface of the skin, 
surface reflectance was used. The reflectance was excited at 780 nm and all reflected light 
was collected. The laser power, gain and pinhole threshold was kept constant between all 
samples of respective payload. Excised ears were kept in place with a cover-slip sample 
holder that also served to flatten the ears for imaging. No buffer solution was placed on the 
ear prior to imaging to prevent the possibility of further diffusion. A 3-dimensional image 
was produced by taking z-stack slices every 1 m within the region of interest. To prevent 
the possibility of further diffusion in the lower layers (VE and dermis) during microscopy 
(approximately 10 minutes per sample), z-slices were imaged from the base of the dermis 
up towards the stratum corneum. A total of 36 deposition sites per ear were imaged, 
resulting in up to 144 deposition sites per time point. The images were co-analysed by 
Stefano Meliga (PhD student in the Kendall Group as per Appendix Three). 
 
8.4 Results and discussion 
8.4.1 Co-localisation of payload with antigen presenting cells 
As discussed in Chapter 2, the NP was designed to penetrate the stratum corneum 
of the skin and come in contact with the high number of APCs in the viable epidermis. 
More specifically, Fernando et al. stated that “if all the projections penetrate the skin to the 
Langerhans cell layer, 6728 projections (i.e. using two Nanopatches; 3364 projections per 
Nanopatch covering 0.16 cm2 of skin) will accordingly target the bodies of 2000 
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Langerhans cells” [11]. In summary the NP was “theoretically configured to deliver antigen 
directly to more than 50% of both the epidermal and dermal APCs available under the 
patch area within the skin” [11]. Optical biopsy of the epidermis (top 10-20 µm) using 
confocal microscopy was used to visualise the spatial and temporal relationship between 
the fluorescently labelled OVA and APC after NP application of OVA/Quil A.  As stated, 
skin is rich in Langerhans cells, which are the main MHC II+ APCs in the epidermis.  These 
cells upon exposure to antigens and adjuvants increase in size, display a reduced number 
of dendrites, and migrate to the lymph nodes where they are capable of inducing 
protective immunity [179].   
 
Immediately after NP application, fluorescently labelled OVA was found co-
localising with MHC II+ cells in the epidermis, with 52% of the antigen delivery sites co-
localising with epidermal MHC II+ cells (Figure 8.1a) [95].  OVA co-localised with 91.4±4.1 
epidermal APC per mm2 (about 2925 APC in total); which agreed well with the Kendall 
Group’s probability-based theoretical design of the NP predicting that approximately 2000 
MHC II+ cells would be directly targeted in this experiment, prior to antigen diffusion.  
 
The total number of epidermal MHC II+ cells within the patched area decreased 
between day 0 and 1 after application of the NP from 772 ± 41 to 635 ± 37 per mm2; a 
18% decrease (Figure 8.1b).  However, the number of epidermal MHC II+ cells co-
localising with OVA sites decreased more rapidly, from 77 ± 6 to 26 ± 3 per mm2, a 66% 
reduction seen from day 0 to day 1 (Figures 8.1c).  These observations suggested that 
NP application resulted in migration of the APCs from the skin, and that this process was 
accelerated with the addition of antigen/adjuvant.  Changes in morphology were also 
evident in epidermal MHC II+ cells after NP OVA/Quil A application suggestive of activation 
(compare Figure 8.1a insets, Day 0 and Day 1).  Although APC had left the patch area, 
epidermal MHC II+ cells remained outside the NP area (Figure 8.1d). These results 
provided an important insight into the relationship between NP delivered payload with 
APCs prior to diffusion within the skin.   
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Figure 8.1.  Release and MHC II+ cell response following NP application.  In Panels a and 
d, MHC II+ cells can be seen green, whereas the delivery sites and antigen can be seen in 
red and highlighted with a white arrowhead.  The insets in Panel a show morphological 
changes in MHC II+ cells from 0 to 3 days post NP application.  The number of MHC II+ 
cells within the NP zone were counted and shown at the day of immunisation (Day 0), 24 
hours after immunisation (Day 1), and three days after immunisation (Day 3) in Panel b.  
The MHC II+ and antigen co-localised cells decreased dramatically faster than that non-co-
localised MHC II+ cells (Panel c), supporting the hypothesis that MHC II+ cells closest to 
the projections were the first to become activated and migrate away.  Over a period of 3 
days the MHC II+ cells disappear from the area where the NP was applied (Patch area and 
Margin), but not outside the patched area (Outside patch area, Panel d) [95]. 
 
8.4.2 Minimally invasive Nanopatch delivery of 70 kDa and 2 MDa dextran into skin 
In the previous section I showed that approximately 52% of NP delivered payload 
came into contact with APCs in the skin prior to payload diffusion. I also showed 
qualitatively in Chapter 5 and published in the journal SMALL, that there was a significant 
increase in diffusion of the payload from the stratum corneum down to the dermis over 
time [116].  
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By the use of the NP, I further explored and quantified the diffusion of payload 
within the skin and mapped the diffusion coefficient as a function of depth within each layer 
of the skin (SC, VE and dermis). The NP was a 4 x 4 x 1 mm silicon chip containing, on 
one side, 58 x 58 projections with spacing of 70 m between adjacent projection centres 
(Figure 8.2a). The projections were cone-shaped, 100 m in length and tapered to less 
than 1 m at the tips. The base diameter of the projections were 35 m (Figure 8.2b). The 
NPs were coated with 70 kDa or 2 MDa rhodamine-dextran using a well characterised 
nitrogen gas-jet coating technique [9]. The NP was chosen because it was both minimally-
invasive (i.e. thousands of very small projections entering the uppermost layers of the skin) 
and also precise (targeting biomolecules to both the epidermis and dermis, with >90% of 
the projections [136]). 
 
Figure 8.2c schematically showed the key attributes of the experimental design at 
the location of the projection sites within the skin. First, the NP penetrated into the SC, 
followed by the VE and upper dermis (as characterized by Crichton et al., 2010 [136]). 
Second, following application to the skin, the biomolecules rapidly dissolved from the 
projections within two minutes, which the Kendall Group have previously observed [9, 11] 
– within the wet VE and dermis.  Third, as shown schematically, the dissolved 
biomolecules then diffused within the skin strata. Throughout the experiments, the NP 
remained in the skin, in situ, so that the biomolecules would not ‘back-diffuse’ into a vacant 
hole left behind by removed projections. Any excess payload deposited on the skin surface 
could not significantly cross the SC (Figure 8.2c) because of the high molecular weight 
(>>500 Da [75]) of the biomolecules that were selected. 
 
It was then asserted that overtime, the fluorescent molecules would diffuse within 
the interstitial fluid and their concentration profile would flatten towards a uniform 
distribution. The array periodicity of the NP (i.e. 70 m xy distance between projection tips) 
was utilised to perform a statistical analysis of the mass transport within one deposition 
site – defined as the cuboid of skin around the needle axis having xy dimensions equal to 
70 m (Figure 8.2c). 
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Figure 8.2. Schematic showing the morphology of the Nanopatch projections used to 
administer the payload into the skin. a) Photograph showing the size of the Nanopatch 
compared to an index finger; b) SEM image of the Nanopatch showing the repetition of the 
projection array, and; c) the mid-way line between projections was 35 m as shown by the 
dotted line. Diffusion fronts were measured at different time points horizontally from the 
projection as shown by the diffusion front measurements for t = 1, 2, 3 (arbitrary units). 
The skin layers were designated as SC = stratum corneum, VE = viable epidermis and D = 
dermis. Panel C contributed from Stefano Meliga, Kendall Group. 
 
8.4.3 Three-dimensional high resolution confocal fluorescence imaging of temporal 
biomolecule diffusion 
Following application of biomolecule coated NPs to the ears of mice; confocal 
microscopy was used to measure the subsequent diffusion within the skin strata. 
Representative compressed z-stacks were shown in Figure 8.3 for each time point and 
molecular weight. It was seen qualitatively that as time increased, the overall rhodamine-
dextran fluorescence intensity in each deposition site also increased (Figure 8.3a-d, e-h). 
At the centre of the deposition sites in the top views of Figure 8.3, minimal fluorescence 
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was observed (as shown by the microprojection schematic in the inserts).  This was 
consistent with where the silicon projections were held in situ within the skin.  Indeed, the 
lack of fluorescent signal within the centre of the deposition sites correlated with the 
previous assertions in Figure 8.2, where it was assumed that keeping the NP in situ during 
application would prevent any significant back-diffusion. 
 
Figure 8.3. Representative 3D confocal imaging of payload delivery into skin. The depth of 
the compressed z-stacks was between 70 – 80 m. Images a – d show 70 kDa 
rhodamine-dextran and images e – h show 2MDa rhodamine-dextran. The insets show a 
representative cross-sectional view of a deposition site, emphasizing the projection track 
within the skin. The reflectance channel used to determine the surface of the skin was also 
shown in the inset. The scale bars are 100 m (main images) and 20 m (insets). 
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Furthermore, surface reflectance of the SC was detected to provide a fixed point for 
extrapolating the location of the VE and dermis (Figure 8.3 insets [approx. thickness of 
SC and VE, 5 m and 15 m respectively or more specifically as stated in Mulholland et al. 
2006, 4.4 +/- 1.2 m and 17.5 +/- 2.1 m respectively [180]]). It was seen in the Figure 8.3 
insets that the NP had punctured the SC resulting in a channel within the skin. The 
subsequent payload delivered has dissolved with resultant diffusion below the SC as 
observed in previous reports [11, 95, 116]. 
 
8.4.4 Calculation of mean molecular transport within individual deposition sites 
The deposition sites were analysed by averaging the payload fluorescence intensity 
for all samples for a given time point (i.e. t = 2, 4, 7 and 10 minutes). The slight variations 
between deposition sites within the individual samples as shown in Figure 8.3 were 
attributed to the local biological variation of the skin and to a lesser extent the variability in 
the delivered payload across the NP array. Briefly, each individual site was averaged by 
calculating the mean 3D intensity over 16 sites per ear and 4 ears per time-point (n = 64 
deposition sites per time point). The average fluorescence intensity distribution in the 
individual deposition site for each time point was shown in Figure 8.4.  The volume of the 
70 kDa rhodamine-dextran increased from approximately 7.3 x 104 m3 to 4.7 x 105 m3 
between 2 and 10 minutes and the volume of the 2 MDa rhodamine-dextran increased 
from approximately 2.2 x 104 m3 to 1.5 x 105 m3 between 2 and 10 minutes.  
Interestingly, both cases had a similar relative increase of volume between 2 and 10 
minutes (6.4 and 6.8 fold; respectively).  It was seen that the 70 kDa rhodamine-dextran 
saturated the entire deposition site within the 10 minute time frame analysed (where 
saturation was defined as the point where signal at the specified intensity was seen in all 
areas of the deposition site [Figure 8.4a-d ]). In contrast, the 2 MDa rhodamine-dextran 
did not saturate the deposition site in the 10 minutes examined. However there was still a 
relatively large amount of diffusion, with signal saturating the VE and at least 35 m lateral 
diffusion in the upper dermis (Figure 8.4h). 
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Figure 8.4. Mean 3D payload diffusion within deposition sites for 2, 4, 7, 10 minutes 
application time. Magenta and green show respectively the fluorescence of rhodamine-
dextran and skin reflectance.  The isosurface delimits the diffusion front at 32% of the 
maximum intensity. 70 kDa molecule (a-d) has faster lateral and vertical diffusion 
compared to the larger 2MDa molecule (e-h). Figure produced in conjunction with Stefano 
Meliga. 
 
The visualization of diffusion fronts and calculation of diffusivity was simplified by 
analysing the fluorescence distribution within orthogonal 2D skin cross-sections. Based on 
the relatively uniform morphology of the deposition sites (Figure 8.3) it was assumed that 
the properties governing diffusion within the skin along the x and y directions were similar. 
Therefore, the fluorescence intensity profile of the 4 sections along the horizontal 
projections lines was averaged. Figure 8.5b shows a contour plot of the mean 2D intensity 
calculated from 4 dashed sections in Figure 8.5a. The diffusion of the rhodamine-dextran 
was then quantified by measuring the distance of selected fronts (2 m intervals from skin 
surface) from the hole axis along the horizontal direction as a function of depth (diffusion 
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measurements were represented by red bars in Figure 8.5c). However, the actual 
distance of the diffusion front was between the edge of the projection and the diffusion 
front. Therefore the hole radius (n=17) that was attributed to the NP penetration was 
measured as a function of depth using the skin reflectance signal of the SC (holes 
measurements were represented by black bars in Figure 8.5c).  The method shown in 
Figure 8.5 was used to quantify and graph the diffusion fronts from the data represented 
in Figure 8.4. 
 
 
Figure 8.5. Schematics of image processing steps used to measure the mean sectional 
diffusion fronts within a deposition site. (a) From the mean 3D intensity of rhodamine-
dextran fluorescence at one time-point the 4 orthogonal sections (dashed yellow lines) 
were averaged. (b) The resulting 2D distribution was represented with a contour plot and 
used to compute the xz diffusivity map; the red curves mark fronts at different intensity 
thresholds; SC=stratum corneum, VE=viable epidermis, D=dermis. (c) One threshold was 
consistently chosen to represent one diffusing front, with the distance from the hole axis 
depicted by the dark red bars; the black bars show the distance from the hole axis to the 
skin interface. Figure contributed from Stefano Meliga. 
 
Figure 8.6 showed the diffusion fronts (defined as 32% of the peak intensity) for 
time-points for both molecular weights. The threshold was chosen at 32% because it 
provided a high signal that did not saturate the deposition sites and hence come into 
contact with the plane of symmetry at the early time points. Yet low enough to show 
diffusion away from the projection sites and still be confident that the signal was attributed 
to the rhodamine-dextran and not background noise. Both 70 kDa (Figure 8.6a – d) and 2 
MDa rhodamine-dextran (Figure 8.6e-h) diffusion increased laterally and vertically as time 
increased. On average, the diffusion front of the smaller molecule reached the plane of 
symmetry (e.g. joined with the front from the neighbouring projection) after 7 minutes, 
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whereas the larger molecule did not make contact until 10 minutes post application. 
Although the hole and front distances were measured with 1 m-depth resolution, the 
graph represents one bar every 2 m for clarity. 
 
Figure 8.6. Measurements of the diffusion fronts for the different time points in the stratum 
corneum (SC), viable epidermis (VE) and dermis (D). The fronts (shown in red) were 
measured horizontally from the projection hole (shown in black) at a threshold of 30% of 
the maximum intensity (n = 64 per time point). Projection hole measurements in the skin 
were analysed using surface reflectance showing skin morphology (n = 20 per slice and 
time point). Graphs a – d show the fronts for 70 kDa rhodamine-dextran [a) 2 min, b) 4 
min, c) 7 min and d) 10 min post administration] and graphs e – h show the fronts for 2 
MDa rhodamine-dextran [e) 2 min, f) 4 min, g) 7 min and h) 10 min post administration]. 
 
8.4.5 Calculation of diffusivity of dextran in the skin layers 
The diffusivity as a function of depth for 70 kDa and 2 MDa rhodamine-dextran were 
calculated (Figure 8.7) from the xz maps as described in the Appendix Three. Overall the 
diffusivity increased by one order of magnitude from the top of the epidermis to the bottom 
of the dermis due to the multilayered biological nature of the skin. The diffusivity of both 
molecular weight rhodamine-dextrans correlated with the behaviour of smaller molecules 
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from previous works [173-176, 181]. The poorly hydrated ‘brick and mortar’ structure of the 
SC inhibited diffusion [61] and also, as was discussed in Chapter 2, the aqueous VE (≈ 
70% hydration) [61], consists of a tightly packed epithelial cellular arrangement, which also 
limited the rate of diffusion. The fibrous dermal region however is loosely packed with few 
cells and was observed in the results by an increase in diffusivity compared to the previous 
layers (Figure 8.7). It was also seen that separately within the dermis, there was a further 
increase in the diffusivity as dermal depth increases (Figure 8.7). This was potentially due 
to an increase in hydration within the dermis and a decrease in the collagen packing from 
the upper papillary dermis to the deeper reticular dermis [65, 182]. 
 
When comparing the diffusivity for two different molecular weight rhodamine-
dextrans, the diffusion coefficient for the 70 kDa was on average 50% ± 40% larger than 
for the 2 MDa rhodamine-dextran, which correlated with the 57% increase measured in 
biofilms [183]. In the shallow to mid dermal region the diffusivities between the two 
molecular weight dextrans were similar (approximately 50 m deep in the dermis). 
However, even though the diffusivity was similar, the behaviour and magnitudes of 
diffusivity were in agreement with previous work [175] – although skin diffusion of such 
large molecular weights had never been studied before. 
 170 
 
  
Figure 8.7. Resultant calculated diffusivities within the skin; compared with previously 
reported lumped model works. Diffusivity of skin layers (SC, VE, Dermis) as a function of 
depth (distance from the surface). Calculations for 70 kDa and 2 MDa rhodamine-dextran 
are represented in bold. Vertical error bars extending to negative values were omitted. 
Horizontal error-bars (±3 m) were omitted for clarity. The other data represents previous 
works on other molecules [173-176, 178, 181, 184]. The full lines represent diffusion 
results on molecular weights >1kDa. The dashed lines represent data from small 
molecules. Acetone and O/W cream were used as permeabilizing vehicles where 
indicated. The skin used was from mouse unless otherwise specified: H = human, R = rat, 
P = pig. Figure contributed from Stefano Meliga. 
 
As stated, the skin is a highly complex, multilayered material that was yet to be 
accurately characterised in terms of molecular diffusion for large molecules (>> 500 Da). A 
reliable approach to diffusion analysis under in vivo conditions (or conditions 
approximating in vivo behaviour) is vital in providing accurate information for the 
construction of bio-scaffolds and more recently, providing possible explanations for the 
potent immune responses gained from skin-targeted vaccinations. I have demonstrated a 
unique method of analysing the distribution and diffusion of large molecular payloads 
within skin in a minimally invasive manner. The experimental procedure was designed to 
avoid major skin disruption during payload delivery (i.e. avoid ex vivo delivery) and hence 
maintain the skin in a naïve state. Current techniques analysing diffusion of drugs within 
skin consist of highly manipulated ex vivo systems that could not provide accurate details 
on drug diffusion within the multiple skin layers [173-177]. The small, tightly confined 
deposition sites coupled with the array symmetry of the NP allowed for the first time, the 
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quantification of the mass transport of high molecular weight molecules within the skin on 
a micrometer scale. 
 
8.4.6 Long-term diffusion of payload from ear 
Having analysed the immediate and local diffusion of payload delivery using the NP, I 
then studied the long-term kinetics of NP delivered vaccine in the skin. To assist the 
coating of vaccine onto the microprojections, a viscosity enhancer was generally added 
and the Kendall Group had used methylcellulose (MC) for this purpose (as stated 
previously, MC was similar to CMC therefore these results could be related to dNPs). 
Once the coated microprojections were in the skin, the viscosity enhancer and the vaccine 
were released together as a mixture. Usually viscosity has an important influence on drug 
release [185, 186] and it may therefore affect the antibody kinetics by ‘trapping’ the 
vaccine in the skin. With kinetics of vaccination being a focus within the Kendall Group, a 
key part of this study was gaining insight into the residence time of the vaccine once it had 
been delivered into the skin, before it was transported via the immune system to the 
draining lymph nodes to initiate immune responses.  
 
I qualitatively explored this, by analysing NP delivered fluorescently labelled influenza 
vaccine (Cy5-labeled Fluvax2008®) to the skin using fluorescence confocal microscopy at 
different time points (Figure 8.8). Coated NPs were applied for 2 minutes, with subsequent 
hydration and dissolution of the vaccine into the skin. The deposited vaccine was 
qualitatively observed by high levels of fluorescent intensity signal at the projection sites 
(week 0). After one week, the majority of the fluorescence signal had decreased inferring 
that the delivered antigen had migrated away from the delivery sites. Furthermore, by the 
second week there was minimal to no fluorescence signal detected within the examined 
regions under the NP. Overall these results qualitatively showed that the delivered vaccine 
completely migrated away from the delivery sites within 2 weeks, correlating with my 
previous experiment (Figure 8.1) [95] where I determined that the bulk of the antigen had 
migrated from the delivery sites three days after NP application.  
 172 
 
Figure 8.8. Image showing the remaining influenza vaccine in skin at after delivery. Mouse 
ears were patched with Cy5-labelled Fluvax2008® coated patches for 2 minutes. Ears 
were then excised from live mice at 0, 1 and 2 weeks post patching and imaged using a 
Zeiss LSM multi-photon microscope. The samples were excited with 633 nm wavelength 
and the emission signal was collected within the wavelength range of 650-710 nm. Prior to 
imaging the patched area of the excised ears were cut out to make sure that this was the 
area being imaged. Fluorescent confocal slices were taken from the surface of the ear at 
3.0 µm intervals to produce a total z-stack of 72 µm in depth. Using Zeiss LSM image 
software, the slices of the z-stack were compressed into a single 2D image as shown in 
the figures. These figure panels qualitatively show that the majority of vaccine migrated 
away from the delivery sites, within one week. 
 
Having qualitatively confirmed rapid vaccine transport kinetics from the ear, the 
migration of antigen was then quantified by two independent methods (Figure 8.9). Firstly, 
I examined vaccine kinetics up to a week, using radioactivity labelled ovalbumin vaccine. 
From Figure 8.9a, it was seen that after only 5 hours, the vaccine amount in the ear skin 
started to show the trend of dropping even though the amount was not statistically different 
from that in the ear immediately after patch application (potentially due to the small 
number of samples analysed and hence lacking sufficient statistical power to detect small 
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differences). Then approximately 75 % and 90 % of the vaccine had migrated away from 
the ear skin at 2 days and 1 week, respectively, after NP application.  
 
Secondly, I independently quantified the migration of NP delivered fluorescent 
labelled influenza vaccine (Cy5-labeled Fluvax2008®) (Figure 8.9b). I determined that 
approximately 10% of influenza vaccine was still remaining in the ear skin at one week 
after vaccination correlating with my previous 14C technique (Figure 8.9a). Two weeks 
after vaccination, the amount of influenza vaccine remaining in the skin did not produce 
any signal above that of untreated ears (negative control). This indicated that the delivered 
influenza vaccine had migrated away from the ear skin within two weeks of application 
supporting my qualitative analysis (Figure 8.8). The positive control samples consisted of 
ears treated by the coated NPs in the same way as all of the other samples but the ears 
were excised immediately after NP application and stored covered in DMEM complete 
media at 35 C. As the fluorescence values in these samples remain high, this excludes 
the possibility that the vaccine was completely bleached in the skin environment after 2 
weeks. Indeed, the detected amount of influenza vaccine remaining in the positive control 
ears did not show statistical difference with that measured at week 0 (immediately after 
patch application). 
 
 
Figure 8.9. The amount of vaccine remaining in skin at different time points after 
application. (a) Radiolabelled ovalbumin vaccine; (b) fluorescence labelled influenza 
vaccine. The negative control was the skin without being patched. The positive control in 
(b) was the skin being patched, excised immediately and stored covered in a DMEM 
complete media for 2 weeks at 35 ºC. This confirms that the disappearance of the Fluvax 
from the skin at two week post-delivery was not due to photobleaching of Fluvax in the 
skin environment. 
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My collective qualitative and quantitative studies showed that 90 ± 5% of the 
delivered vaccine migrated away from the delivery sites within one week of delivery into 
the ear skin by NP, indicating that the delivered vaccine was not held in the delivery sites 
by the added viscosity enhancer. Having a delivery device that did not trap the vaccine in 
an excipient matrix after application was important for allowing rapid and efficient uptake of 
the vaccine by the abundant APCs within the skin. In this study I hypothesized that the 
mechanism of transport of at least a major component of antigen from the skin was via 
migration of these APCs - this assumption is yet to be tested directly. However as stated, 
the Kendall Group previously found that, with the densely packed microprojections, the 
influenza vaccine was first delivered to directly contact over 50% of the epidermal and 
dermal APCs under the NP application area [11]. After NP application, skin APCs started 
to migrate away from the ear skin (18% reduction in the number of the epidermal MHC II+ 
cells after 24 hours) and the number of the epidermal MHC II+ APCs contacting with the 
delivered vaccine decreased more rapidly (66% reduction at the same period of time 
[Figure 8.1]) [95]. These previous studies correlated with the antigen kinetic results 
reported in this chapter and supported my hypothesis. 
 
8.4.7 Conclusion  
Utilising the minimally invasive nature of the NP design to deposit payloads in the 
skin in conjunction with high resolution imaging and analysis using multiphoton and 
fluorescence confocal microscopy, this chapter addressed the question in objective three: 
 
What governed the diffusion behaviour within the upper layers of the skin and how does 
this impact the distribution of skin delivered payloads?  
 
Initially I examined the interaction of NP delivered vaccine directly after application 
and its resultant diffusion locally within the skin. I determined that approximately 52% of 
the vaccine was co-localised with APCs in the skin, which supported the theoretical 
probability analysis of 50%. Following administration the payload diffused rapidly within the 
skin resulting in almost complete saturation of the patched area. This in theory extended 
the probability of payload contacting the APCs in the skin to 75-100%.  
 
The distribution of payload and diffusion was quantified showing that there was a 
correlation between the layers of the skin and the diffusion of payload within. The tightly 
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packed ‘brick and mortar’ structure of the SC resulted in very little diffusion. As depth 
increased, hydration also increased and the rate of diffusion increased in the VE. 
However, it wasn’t until the payload reached the dermis that the rate of diffusion increased 
significantly. This increase in diffusion rate within the dermis compared to the VE had not 
been reported elsewhere due to limitations in skin delivery and high resolution microscopic 
analysis. It was assumed that the change in diffusion rate was associated with the cellular 
make-up of the VE compared to the dermis. The VE contains an abundance of densely 
packed cells whereas the dermis contains much fewer cells and instead a network of 
relatively porous collagen fibres. These results provided insight into payload distribution 
and amounts required for targeted therapeutic delivery that relate to all skin delivery 
technologies. 
 
 I further analysed the long-term diffusion of the vaccine in the skin using 
fluorescently labelled Fluvax2008® and 14C-labelled ovalbumin protein. It was determined 
that after 48 hours approximately 75% of the vaccine and after 1 week approximately 90% 
of the vaccine had left the ear skin. The data obtained would benefit both direct (physically 
targeted) and indirect (topically applied) drug delivery to the skin providing insight into the 
distribution of payloads within the skin and also the impact of direct approaches on 
immune cell migration. 
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CHAPTER 9 
Looking forward – overcoming the limitations of current 
dissolving Nanopatches design and fabrication 
 
9.1 Summary 
As stated, the scope of this PhD project contained both applied and fundamental 
research. The applied focus was to develop an alternate vaccine/drug delivery platform 
(dNPs) for the targeted delivery of vaccines into the skin. This was achieved by first 
developing and optimising a fabrication method utilising the gold-coated silicon NP 
developed in the Kendall Group (Objective 1). Once a reproducible technique was 
developed, the dNP administration including penetration, dissolution and diffusion was 
examined and the dNP was used to deliver a variety of different payloads including 
commercial vaccines as test cases for the platform (Objectives 2 & 3). 
 
This chapter indirectly addressed the objectives of the thesis, providing information 
on two of the key challenges/limitations observed during this project. This chapter provided 
a line of sight for addressing the issues of reduced fabrication handling and improved 
delivery efficiency in relation to the question: 
 
Could dNPs be translated from the research bench-top to the clinical setting? 
 
It was shown in Chapter 5 that by improving the administration process and 
simplifying the handling steps that the delivery efficiency could be improved more than 10-
fold. In this chapter I further investigated potential methods of improving the delivery 
efficiency by accurately depositing the payload on the surface of the mould. It was 
determined that simply by reducing the amount of payload cast, delivery efficiencies up to 
approximately 90% could be achieved. Overall, there was a clear line of sight for further 
optimisations of the dNP fabrication and administration process to move it from the 
research setting to the clinic. 
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9.2 Introduction 
The scope of this thesis was to develop and fabricate dNPs for vaccine delivery to 
the skin – which was successfully achieved. In Chapter 4, I discussed the development 
and optimisation of a method for fabricating dNPs, which I published and filed a patent 
throughout the course of this project [116, 129]. Furthermore the results in this thesis 
further supported the information discussed in the literature review in Chapter 2, that the 
skin was an ideal site for vaccination if targeted with optimal delivery devices (in this case 
being the dNP). In particular, I showed this by the robust penetration and rapid dissolution 
of dNPs discussed in Chapter 5, which resulted in potent immune responses compared to 
the standard intramuscular injection (Chapter 6). 
 
A key challenge highlighted in Chapters 4 and 5 with dNP fabrication and 
administration was the issue with excess payload and its corresponding relatively low 
delivery efficiencies. This challenge was not unique to the dNP and instead was applicable 
to all forms of dissolving/ non-dissolving polymer microneedles. The process of using a 
dispersion membrane to evenly disperse the payload across the mould prior to casting had 
to some degree helped to address the issue of excess payload – with the ability to cast 
picolitre quantities of payload into tips of projections [116]. However it still did not directly 
address the issue of excess payload, which I explored in more detail in this chapter. 
 
The other major challenge faced with dNP administration was the incorporation of a 
patch-attach. The addition of the patch-attach was to reduce the handling steps involved 
post fabrication, thereby minimising damage to the projections and increasing the overall 
penetration into skin (Chapter 5). The patch-attach also provided a separation between 
the applicator plunger and the dNP, which was believed to have helped prevent bouncing 
of the dNP with the plunger on application. However, the patch-attach design was limited 
by the need to carefully place the dNPs onto the surface of the patch-attach resulting in 
minor damage to the dNP due to handling and also discrepancy in how horizontal the dNP 
was. Therefore, this chapter looked at possible improvements to the patch-attach design 
and utility.  
 
As discussed the dispersion membrane facilitated accurate layering and payload 
deposition, however it still did not directly address the issue of excess payload. For dNPs 
(and other polymer microneedles) this is an important issue that should be addressed 
before the platforms could be used within a clinical setting (seeing as their competitor, the 
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needle and syringe is cheap to produce). This chapter discussed preliminary data 
addressing the above issues and looked at potential improvements to the design and 
fabrication of dNPs. The overall aim was to show a line of sight and the future work 
required to help translate dNPs from a pure research setting to a clinical tool.  
 
9.3 Experimental procedures 
9.3.1 dNP fabrication in conjunction with inserted patch-attach 
The dNPs were fabricated using CMC. Moulds were prepared and cleaned prior to 
casting dNPs as described in Chapter 4, Section 4.3.2. Each mould was placed in a 
standard biological 24-well plate followed by the addition of 10 L of 10 mg/mL CMC 
solution. The initial payload was cast using the standard fabrication technique. After 
drying, 100 L of a viscous 20% CMC gel was added to the mould and cast. Instead of 
centrifuging the dNPs until dry, they were removed after 30 minutes. A patch-attach was 
then inserted into the mould followed by slight pressure to indent the gel. The dNPs were 
then placed in a sealed desiccator for 24 hours until dried. 
 
9.3.2 Slow motion capture of dNP application 
 The dNPs were applied to vinyl using the standard spring applicator designed in the 
Kendall Group (discussed in Chapter 3 and 5). The applicator of interest was clamped in 
place using a custom steel stand manufactured in the Kendall Group. A ruler was held 
perpendicular to the device to serve as a scale bar present in all videos. A FastCam SA5 
Model 775K-C3 high speed camera (Photron Ltd, Australia) with CMOS image sensor was 
used to image the application. The frame was 8000 frames per second and a shutter 
speed of 1/20,000 seconds. The system was lit with a 500 W incandescent bulb without a 
diffuser. A post trigger was employed to maintain simplicity of the setup i.e. the camera 
was activated (put in record mode where it filled its memory buffer with frames and 
dumped them as the buffer became full) followed by dNP application. Immediately after 
application which was defined as the point where the applicator came to rest, the camera 
was stopped whereby the last buffer-full of frames was saved and dumped to the attached 
computer for analysis. 
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9.3.3 Optimisation of dNP delivery using 14C-radiolabelled ovalbumin 
To determine the delivery efficiency of the dNPs, 14C radiolabelled ovalbumin 
protein was used as a tracer in dNP formulations. A stock solution of 1% CMC and Fluvax 
was prepared so that each mould received 10 l of Fluvax solution spiked with a minimum 
of 25 nCi 14C Ovalbumin. The dNPs were then fabricated using the standard fabrication 
method, however the volume of payload was reduced from 5 L down to approximately 
0.3 L. The dNPs were then administered to mice and analysed using the standard 14C 
protocol described in Chapter 3. 
 
9.4 Results and discussion 
9.4.1 Incorporation of patch-attach into the fabrication design 
As discussed in Chapter 5, a patch-attach was incorporated into the design of the 
Kendall Group’s applicator to prevent bouncing of the NP/dNP on the surface of the skin 
during administration. To reduce the handling steps involved with dNPs, a modified patch-
attach was designed to support the base of the dNP without interference from the dNP 
edges. However it was observed that the dNPs did not always sit flush with the surface of 
the patch-attach (Figure 9.1). It was assumed that during the fabrication process, as the 
dNPs dried, stresses were formed in the solidified material due to concentration of dried 
material in the corners and edges.  
 
By combining the patch-attach with the mould during casting it was hypothesised 
that as the dNP dried, the CMC backing could mould around and become flush with the 
patch-attach. Therefore the fabrication process was varied to include the patch-attach into 
the casting process. After the backing CMC gel was cast into the mould the patch-attach 
was impressed into the gel so that the backing formed an approximate 2 mm lip around 
the end of the patch-attach. The combined mould was then placed in a desiccator and 
dried at 25oC. After drying the patch-attach was removed and it was observed that the 
dNP remained fixed to the end of the patch-attach (Figure 9.1b). Unlike the dNPs formed 
using the standard condition, the dNP-combined-patch-attach was relatively flat and 
uniform.  
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Figure 9.1. Images showing the dNP morphology and attachment to the patch-attach. a) 
Fabricated dNP using standard conditions placed on patch-attach (arrow indicates curved 
dNP face at corners), and; b) dNP fabricated by casting with patch-attach in place. 
 
However, the dried CMC, formed a very thin layer around and at the base of the 
patch-attach (Figure 9.1b) compared to the standard dNP fabrication (Figure 9.1a). Also 
not all the dNPs fabricated using this approach remained fixed to the patch-attach after 
removal due to the CMC not bonding with the smooth inert plastic patch-attach. Therefore, 
concept ideas for an improved patch-attach were constructed that could be combined with 
the casting process so that dNPs could be removed from the casting plate and applied 
without further handling (Figure 9.2). 
 
As stated, the two main issues with the incorporated patch-attach design (Figure 
9.1) were lack of gel backing and poor adherence of the dNP to the patch-attach. A 
possible solution was to use a hollow patch-attach with a mesh bottom designed to 
interfere with the dNP backing layer (Figure 9.2a). The mesh would need to be strong 
enough to support the dNP but brittle so that on application it would separate from the 
edges without impeding penetration. After casting of the payload solution, the patch-attach 
would be placed within the mould so that the mesh grid sits on the mould. The backing gel 
layer can then be applied and cast into the mould. It was assumed that as the backing 
layer dried it would form around the grid incorporating it into the backing.  
An alternate approach (Figure 9.2b), with a finer mesh that would not continue to 
the edges of the patch-attach designed. The aim of this design was to have a mesh that 
was weaker around the edges so that on impact with the applicator, the dNP would 
separate more readily than the design in Figure 9.2a. The walls of the dNP would have a 
slight taper so that it could fit via an interference fit with the applicator. The following two 
designs would consist of the same mesh design shown in Figure 9.2b, however instead of 
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using an interference fit, the patch-attach would consist of either a screw fit (Figure 9.2c) 
or a bayonet fit (Figure 9.2d). 
 
Figure 9.2. Schematics of potential patch-attaches designed for in-situ fabrication. 
Schematics provided by Alex Ansaldo. 
 
Even though I have only shown a few basic patch-attach concepts, it was clear that 
careful thought should be done on all aspects of dNP design and fabrication, especially if 
the end goal would be to translate the research into the clinic. A simple approach that 
could be reproducible with minimal handling steps during the fabrication process to 
administration would be ideal. 
 
9.4.2 Improving the delivery efficiency by optimising payload casting  
As discussed in Chapter 5, the initial administration resulted in a low delivery 
efficiency of approximately 1.7%; however with optimisation a final delivery efficiency of 
12.2 +/- 4.3% was achieved. Even though the delivery efficiency was relatively low, it was 
suitable for the research setting, where the key focus was on the actual amount of vaccine 
delivered and its resulting immune responses. However, in translating a delivery platform 
(in this case the dNP) to the clinic, minimal wastage of expensive vaccine should be an 
important aspect (i.e. high delivery efficiency). 
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As discussed in Chapter 4, the dNP casting process consisted of filling a mould 
with a payload volume. The payload solution was cast using centrifugation to apply a force 
which concentrated the solid payload into the tips and shafts of the projections. However, it 
was hypothesised that if excess volume of payload solution was added to the mould, the 
overall delivery efficiency would decrease because there would physically not be enough 
volume within the mould projections (Figure 9.3). 
 
Figure 9.3. Schematic showing the effect of excess payload solution on payload wastage 
into the backing layer of dNPs. 
 
To test the above hypothesis, the delivery efficiency was compared using dNPs 
cast with varying volumes of 14C ovalbumin solution (Figure 9.4). Theoretically, if the 
volume of payload added was halved (keeping payload concentration constant), the 
delivery efficiency should double (as shown in the dashed black line in Figure 9.4a). When 
the volume was decreased experimentally, the results showed a similar trend to the 
theoretical calculations. However, at very low volumes (0.3 L), the delivery efficiency 
resulted in a large spread of results ranging from 45.9% to 91.1% (Figure 9.4b).The 
hydrophobic nature of the PDMS moulds resulted in difficulty in depositing such small 
volumes of solution, where the payload solution remained in the tip of the pipette tip due to 
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surface tension. Therefore, the large error was associated with the technical difficulty in 
pipetting such small amounts onto a hydrophobic surface.  
 
 
Figure 9.4. Improved delivery efficiency using an enhanced casting method. a) Graph 
showing the change in delivery efficiency related to the reduction in volume of payload 
cast (optimisation), and; b) graph showing the spread of delivery efficiency related to the 
addition of small amounts of payload. 
 
 Overall it was shown that controlling the amount of volume loaded within the dNP 
mould can greatly enhance the resulting delivery efficiency. It was reported that 
microneedles (926 m in length and 465 m in diameter) could successfully be coated 
using high precision ink jet printing of a payload solution [187]. This technique could 
potentially be modified so that microneedle/dNP moulds could be filled with a specific 
payload solution as shown schematically in Figure 9.5a. Based on the previous results 
shown in Figure 9.4, it was hypothesised that depositing small amounts of payload in such 
a controlled and concise manner would drastically improve the resulting delivery efficiency. 
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Figure 9.5. Schematics of two conceptual fabrication modifications for the improved 
delivery efficiency of dNPs. 
 
An alternate method of concentrating the payload within the dNP projections without 
using inkjet printing would be the use of a mould consisting of a semi-permeable 
membrane at the base (Figure 9.5b, inset indicates semi-permeable membrane). The 
benefit of having such a membrane would be that the payload fluid could flow out of the 
mould, while the remaining solid payload concentrated and compacted forming the 
projections. An additional benefit to this mould design would be that the payload solution 
could be vacuumed through the mould instead of using centrifugation, which would lead to 
improved scale-up and quicker fabrication times. 
 
9.4.3 Conclusion 
This chapter addressed two important technical challenges/limitations (reduced 
fabrication handling and improved delivery efficiency) observed during this project. As 
mentioned these challenges need to be addressed so as to provide a line of sight for 
addressing the question:  
 
Could dNPs be translated from the research bench-top to the clinical setting? 
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It was determined that by reducing the amount of payload cast, delivery efficiencies 
up to approximately 90% can be achieved. These results have important implications on 
fabrication methods for dissolving/polymer micro-structures. Due to the extremely small 
scale of fabrication it is essential that the method of payload deposition into moulds be 
tightly controlled so as to maintain high encapsulation efficiencies and resulting 
downstream delivery efficiencies. Overall the data in this chapter provided a clear line of 
sight for further optimisations of dNP (and by extension polymer microneedle) fabrication 
and administration to move it from the research setting to the clinic.  
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CHAPTER 10 
Conclusions 
 
10.1 Project summary 
As discussed in Chapter 2, the majority of vaccines are administered 
intramuscularly with the needle and syringe. This method has several limitations, including 
needle phobia, accidental needle-stick injuries, plus improper and unsafe use contributing 
to the spread of infectious diseases. More importantly, the needle does not place vaccine 
doses to the body sites known to elicit optimal immune responses. Instead, the needle and 
syringe deposits antigen in muscle where immunologically-sensitive cells are present at a 
much lower density. This is in contrast to the thin viable skin layers, which contain a high 
density of APCs – required for potent immune responses. 
 
The objectives in this PhD project contained both applied and fundamental 
research. The applied focus was to develop an alternate vaccine/drug delivery platform 
(dNPs) for the targeted delivery of vaccines into the skin by addressing the core questions 
of objectives 1 and 2: 
 
Could arrays of reproducible dissolving microstructures (<200 m) be produced in a 
manner, designed to incorporate and deliver sensitive biologicals? 
 
Could fabricated dNPs comprising sugars and cellulose derivatives penetrate skin 
resulting in successful dissolution and delivery of bioactive payloads? 
 
The data obtained would provide valuable insight into the development, delivery and 
dissolution of biological payloads using dNPs as an alternate platform for vaccine delivery.  
 
The fundamental focus of this PhD project was to provide information on the 
structure dependant diffusion characteristics of the skin and more specifically the diffusion 
of dNP/NP delivered payloads by addressing the key question of objective 3: 
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What governed the diffusion behaviour within the upper layers of the skin and how does 
this impact the distribution of skin delivered payloads?  
 
The data obtained would benefit both direct (physically targeted) and indirect 
(topically applied) drug delivery to the skin providing insight into the distribution of 
payloads within the skin and also the impact of direct approaches on immune cell 
migration. Overall, the data in this project would benefit the microfabrication, micro-
mechanics, pharmaceutical and dermatology fields, and more specifically cutaneous 
drug/vaccine delivery. 
 
10.2 Project limitations and future work 
As discussed throughout this thesis, the project was divided into two main areas – 
applied and fundamental. The applied aspects of the project consisted of the design, 
fabrication and administration of the dNP. The fundamental aspects gained utilised the 
unique morphology and delivery approach of the dNP resulting in a greater understanding 
of the layered diffusion pattern within the skin and the impact of formulation on the 
physical/mechanical properties of micro-structures. However, the core focus was to 
determine the feasibility of dNPs as a platform for vaccine delivery – which was achieved. 
In the previous chapter I discussed two important limitations in the dNP fabrication and 
administration process with potential methods to overcome them. The following section 
briefly summarises additional limitations of the project and future work that could be 
undertaken.  
 
10.2.1 Limitations of project 
Even though the core aspects of the objectives were achieved, there were still 
limitations to certain aspects of the project design and the corresponding results obtained. 
The fabrication technique described consisted of a moulding and casting technique using 
PDMS as the moulding polymer and centrifugation as the casting technique. It was 
hypothesised that this technique could be useful for other microneedles with different 
shape design, length, width and spacing. However, the project was limited to the NP 
design, preventing critical comparison with other microneedle designs and the validation of 
the hypothesis that the designed fabrication technique was suitable for various 
microneedle morphologies.  
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Having one microneedle design (dNP) also prevented direct comparison of the 
vaccine administration results with those reported in literature. This was a limitation within 
the project because even though it was observed that dNPs result in potent immune 
responses compared to others, the vaccines and animals used are different, which would 
lead to discrepancies in immune responses achieved. Additionally, the immune responses 
observed only give partial insight into the integrity (functionality) of the encapsulated 
vaccines. The two assays used post vaccine administration (ELISA and HI) do not provide 
any mechanistic understanding of the vaccine integrity (i.e. protein degradation / 
deformation). There was also no investigation on the vaccine functionality over time, which 
would provide important information on storage and shelf-life of dNP encapsulated 
vaccines. Lastly, all the studies were done in one animal model (mouse), which served its 
purpose for this project but for translating the dNP to the clinic it would be important to 
administer dNPs to larger animal models (for example, pigs) and eventually human. 
Although addressing these limitations was out of the scope of this thesis project, they are 
important considerations that must be taken into account when drawing conclusions from 
the data obtained. 
 
10.2.2 Future work 
In considering the future work from a fundamental standpoint, the solid formulations 
of NPs and dNPs lend itself to the possibility of enhanced vaccine stability – with the end 
goal being long term stability without the need for cold storage/transport. Therefore, 
besides the points discussed in the previous chapter, future work should be on assessing 
the stability of dNP encapsulated biomolecules. As discussed in Chapter 7, sugars 
trehalose and sucrose are commonly used within nature and the pharmaceutical industry 
to stabilise sensitive dehydrated biomolecules. That was one of the reasons why in 
Chapter 7, I investigated the feasibility of incorporating sucrose and trehalose into the 
dNP formulation in a manner that maintained the dNP mechanical integrity and dissolution 
properties. Other studies have touched on the benefit of dry formulated microneedles, 
including the Kendall Group, which have seen enhanced stability of influenza vaccines 
using dry methylcellulose formulations. The next step should be to repeat these results 
using dNP encapsulated vaccines. 
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10.3 Project conclusions 
At the start of this thesis, I introduced a fabrication method for the production of 
dNPs (~100 m in length) using carboxymethylcellulose. This technique was then both 
published and filed for patent by the Kendall Group. At the time of commencing this project 
no reports had been published using dissolving microstructures for the delivery of large 
biological (vaccines). This was due to the harsh and complex fabrication methods used to 
fabricate dissolving microstructures. Another limitation of the design of current dissolving 
microneedles was the relatively long time periods required for complete dissolution. The 
new advantages of my fabrication method and resulting dNPs when compared to the much 
larger dissolving microneedles were: 
 Ability to fabricate microstructures (< 200 m in size) with picolitre quantities, 
potentially reducing vaccine wastage, 
 mild fabrication conditions that maintained vaccine integrity, 
 much finer control over payload deposition within moulds, 
 ability to layer multiple payloads in a single array, 
 enhanced immunogenicity, 
 dose-sparing and,  
 rapid dissolution and diffusion. 
 
The above attributes listed distinguish dNPs from current dissolving/polymer 
microneedles in literature. In particular the rapid dissolution time of dNPs had not been 
observed with other forms of dissolving microneedles. I determined that the dNPs not only 
penetrated the skin, delivery of payload occurred within 5 seconds post administration. As 
stated, these findings were significant because they provided insight into the reason why 
much larger dissolving microneedles of similar composition required at least 1 hour for 
complete dissolution.  
 
The dissolution/diffusion properties of the dNPs were further analysed utilising the 
minimally invasive nature of the NP design to deposit payloads in the skin in conjunction 
with high resolution multiphoton and fluorescence confocal microscopy. I determined that 
approximately 52% of the vaccine was co-localised with APCs in the skin prior to any 
significant diffusion, which supported the theoretical probability analysis of 50%. However, 
immediately following administration the payload diffused rapidly within the skin resulting in 
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almost complete saturation of the patched area extending the probability of payload 
contacting the APCs in the skin to 75-100%.  
 
In quantifying the diffusion of payload post administration, it was determined that 
there was a correlation between the rate of diffusion and the layers of the skin. The tightly 
packed ‘brick and mortar’ structure of the SC resulted in very little diffusion. As depth 
increased, hydration also increased and the rate of diffusion increased in the VE. 
However, it wasn’t until the payload reached the dermis that the rate of diffusion increased 
significantly. This increased diffusion rate within the dermis compared to the VE had not 
been reported elsewhere due to limitations in skin delivery and high resolution microscopic 
analysis. These results had implications on all skin delivery technologies and provided 
insight into payload distribution and amounts required for targeted therapeutic delivery. 
Furthermore, the data obtained would benefit both direct (physically targeted) and indirect 
(topically applied) drug delivery to the skin providing insight into the distribution of 
payloads within the skin and also the impact of direct approaches on immune cell 
migration. 
 
Administration was also characterised in relation to the physical/mechanical 
properties of the dNP microprojections consisting of different sugar/polyol CMC 
formulations. No other works in literature had examined the failure profiles of individual 
microproejctions on this scale. By using nanoindentation, which examined the mechanical 
properties of materials using an extremely small probe (<40 m) or berkovich tip, I applied 
a force to individual dNP projections. This type of force analysis provided important insight 
into the interactions of micro-projections with surfaces (i.e. skin). It was determined that 
the majority of the formulations consisted of both partial brittle and ductile failure. However, 
the bulk of the failure for the examined projections was ductile. This was not surprising 
given that in general the dissolving polymers used were soft compared to the original 
silicon NP template.  A rigid crystalline material would fail in a far more brittle mode 
compared to the soft materials here, which could cause a failure to penetrate.  However, 
even where buckling had occurred, the projections maintained the ability to resist 
substantial forces (several millinewtons) indicating that even with slight buckling, the 
projections would still enter the skin. Even though the testing was done on dNP 
microprojections, the results could be extended to the larger dissolving/polymer 
microneedles providing insight into their mechanism of penetration. 
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Having confirmed and analysed dNP penetration into skin, perhaps the most 
significant part of this project was whether or not potent immune responses could be 
achieved from dNP immunisation. I validated the integrity of vaccines encapsulated within 
dNPs, by immunising mice in separate independent experiments using three antigens – 
ovalbumin protein, Fluvax2008® and Fluvax2010®. The dNP vaccination resulted in 
strong systemic immune responses in mice; with lower payloads required than the 
standard needle and syringe vaccination. More specifically, dNP immunisation resulted in 
antibody responses correlating to a 100-fold increase over IM (6 ng compared to 600 ng). 
The functional relevance of the antibody response produced in protection against influenza 
was also analysed using a haemagglutination-inhibitory assay. The 6 ng Fluvax2010® 
dNP immunised groups once again showed comparable results to the 600 ng IM groups. 
The significance of these results was that the HI data confirmed the integrity of the dNP 
encapsulated protein, verifying the fabrication method designed in Chapter 4. At the time 
of publication of these data, potent immune responses from skin targeted vaccinations had 
not been shown before using any form of dissolving microneedle or dNP. Overall the data 
in this chapter showed that the dNP was a potent and potential platform for vaccine 
delivery to the skin.  
 
In conclusion, the data obtained, both applied and fundamental would provide 
valuable insight into the development, delivery and dissolution of biological payloads using 
dNPs as an alternate platform for vaccine delivery. It would also benefit direct (physically 
targeted) and indirect (topically applied) drug delivery to the skin providing insight into the 
distribution of payloads within the skin and also the impact of direct approaches on 
immune cell migration. Overall, the data in this project would benefit the microfabrication, 
micro-mechanics, pharmaceutical and dermatology fields, and more specifically cutaneous 
drug/vaccine delivery. 
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Appendices 
 
Appendix One: Comparison of patent applications related to dissolving microneedles 
Senior 
Inventor 
Publication 
Type/Date 
Microneedle 
Composition 
Microneedle 
Length and 
Diameter 
No. of 
projections 
Mould and Casting 
Method 
Dissolution 
Time 
Comparisons 
ILLiescu 
WIPO 
Application 
2006 Sep. 
28 
Silicon microneedles, 
hollow or solid with 
porous silicon tips. Drug 
is in liquid formulation 
Length:100-
150µm. Tip 
diameter: 
<10µm. 
Aspect ratio 
10:1 to 2:1 
25-200 
with 100-
500µm 
spacing 
DRIE fabrication 
process to make 
silicon array. 
Biodegradable tips 
made from etching 
tips so that it 
becomes porous. 
Drug can be 
delivered as a fluid 
during or following 
application 
Tips 
biodegrade 
in 2-3 
weeks. 
Tips that can 
biodegrade 
Jung 
WIPO 
Application 
2008 Jan 24 
PLA, CMC, molten 
maltose 
Length:500-
2000µm. Tip 
diameter: 5-
40µm 
N/A 
Surface is coated 
with dissolving 
viscous material. 
Small pillars are 
placed on top and 
slowly withdrawn to 
form threads. 
Threads are cut at 
desired length. 
N/A 
Uses viscous 
CMC solution as 
excipient. 
Delivery in 
single 
application 
Jung 
US 
Application 
2008 May 
08 
PLA, CMC, molten 
maltose 
Length:500-
2000µm. Tip 
diameter: 5-
40µm 
N/A 
Surface is coated 
with dissolving 
viscous material. 
Small pillars are 
placed on top and 
N/A 
Uses viscous 
CMC solution as 
excipient. 
Delivery in 
single 
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Senior 
Inventor 
Publication 
Type/Date 
Microneedle 
Composition 
Microneedle 
Length and 
Diameter 
No. of 
projections 
Mould and Casting 
Method 
Dissolution 
Time 
Comparisons 
slowly withdrawn to 
form threads. 
Threads are cut at 
desired length. 
application 
Jung 
WIPO 
Application 
2008 June 
12 
PLA, CMC, molten 
maltose 
Length:500-
2000µm. 
Shaft 
diameter 
200µm. Tip 
diameter: 5-
10µm 
N/A 
(Images 
show 1-16) 
Surface is coated 
with dissolving 
viscous material. 
Small pillars are 
placed on top and 
slowly withdrawn to 
form threads. 
Threads are cut at 
desired length. 
N/A 
Uses viscous 
CMC solution as 
excipient. 
Delivery in 
single 
application 
Kwon 
WIPO 
Application 
2004 March 
25 
Slow dissolving porous 
needles made from 
sol/gel/drug. Sol is 
preferably a silicate 
Length:100-
1000µm. 
Shaft 
diameter: 10-
1000µm Tip 
diameter: 1-
100µm 
Aspect ratio 
at least 1 
1-200 per 
10cm2 
Master-mould 
prepared by MEMS. 
Sol/gel process-
silicate and 
methanol mixed with 
drug at 60oC. Force 
applied to 
gel/mould. Dried in 
shape at 60-100oC. 
At least 
95% 
remain for 
at least 6 
hours 
biodegradable 
needles 
Kwon 
WIPO 
Application 
2007 March 
15 
Drug particulate or drug 
absorbed particle 
concentrated to bottom 
quarter of microneedles. 
Inert particles- PLGA, 
Alum or aluminium 
hydroxide. Backing is 
CMC 
Length:100-
3000µm. 
Shaft 
diameter: 1-
2000µm Tip 
diameter: 1-
100µm 
Particle size 
0.01-100µm 
N/A 
Drug particulates or 
drug absorbed 
particles are forced 
into mould using 
centrifugation to 
move particulates to 
microneedle tips. 
Followed by drying 
and separating from 
mould. Compression 
10 minutes 
to 5 hours 
Dissolving 
microneedles 
with CMC as 
excipient. Active 
concentrated 
towards tip of 
needles. 
Centrifuge 
process of 
casting 
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Senior 
Inventor 
Publication 
Type/Date 
Microneedle 
Composition 
Microneedle 
Length and 
Diameter 
No. of 
projections 
Mould and Casting 
Method 
Dissolution 
Time 
Comparisons 
used for dried 
powder particulates. 
Potter 
WIPO 
Application 
2003 March 
20, 2004 
Feb 19, US 
Application 
2007 Nov. 
29 
<10mg therapeutic in 
volume <10mm3. 
Excipient is a 
crystalline/amorphous 
glassy material, which 
dissolves in body -
sugars. May include 
hardening agent PVP. 
Length: 
1.5mm-2mm. 
Shaft 
diameter: 
1mm-1.5mm. 
Aspect ratio 
1:1.5  
Single 
needle 
Hot sugar melt is 
moulded and cut. 
Drug paste/sol/gel is 
placed behind sugar 
splinter and injected. 
Mix of sugar 
powders and 
hardening agent 
forms splinter. Drug 
follows projectile. 
Minutes of 
hours 
Dissolving 
needle 
Prausnitz 
WIPO 
Application 
2007 Nov 8 
Combination of particles 
containing drug. PLA, 
PGA and PLGA 
copolymers. 
Length 
approx 
600µm 
(Obtained 
from Journal 
article) 
N/A 
Master moulds 
fabricated by MEMs 
techniques. PDMS 
female moulds 
created. Addition of 
particles by force. 
Particles are welded 
together using 
chemicals, 
ultrasonic energy, 
heat. Layering is 
achieved by forcing 
in particles and 
melting followed by 
addition of different 
particles with lower 
melting point than 
previous and 
melting. 
N/A 
Dissolving 
needles with 
dual layering 
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Appendix Two: Published dissolving microneedles patents prior to 2008 
Senior 
Inventor 
Publication 
Type/Date 
Microneedle 
Composition 
Microneedle 
Length and 
Diameter 
No. of 
projections 
Mould and Casting 
Method 
Dissolution 
Time 
Comparisons 
Kwon 
PUBLISHED 
US 2005 
Sep. 20 
Water-soluble 
carbohydrate 
derivative or 
polymer. Backing 
matrix acts as 
reservoir. Solvent in 
reservoir dissolves 
projections. 
Delivers at least 
one drug. 
Length:100-
1000µm Shaft 
diameter: 1-
1000µm Tip 
diameter: 10-
100µm 
20-200 per 
1cm3 
Master-mould prepared 
by MEMS. Liquid 
solution cast into mould 
and dried/photo cross-
linked. Under force - 
centrifuge, compression. 
Air dried, vacuum dried 
or freeze dried. After it is 
cut to shape and size. 
Powder also applied by 
heat or pressure. 
Seconds to 
hours 
Dissolving 
microneedles 
composed of 
carbohydrate 
derivative. Force 
(centrifuge) 
process of 
casting 
Kwon 
PUBLISHED 
US 2007 
May 01 
Water-soluble 
carbohydrate 
derivative or 
polymer. Backing 
matrix acts as 
reservoir. Solvent in 
reservoir dissolves 
projections. 
Delivers at least 
one drug. 
Length:100-
1000µm. Shaft 
diameter: 1-
1000µm Tip 
diameter: 10-
100µm 
20-200 per 
1cm2 
Master-mould prepared 
by MEMS. Liquid 
solution cast into mould 
and dried/photo cross-
linked. Under force - 
centrifuge, compression. 
Air dried, vacuum dried 
or freeze dried. After it is 
cut to shape and size. 
Powder also applied by 
heat or pressure. 
Seconds to 
hours 
Dissolving 
microneedles 
composed of 
carbohydrate 
derivative. Force 
(centrifuge) 
process of 
casting 
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Appendix Three: Matlab analysis of NP-delivered 70 kDa and 2 MDa 
rhodamine dextran 
 
Calculation of the average spatial fluorescence intensity of a deposition site 
The confocal data was processed with MATLAB. The hole axis was located for 16 
deposition sites per sample and 4 samples per time-point to crop stacks of 200 x 200-
pixel-slices (~80 m2) around it. The 64 3D-images of individual deposition sites were 
aligned along z using the skin reflectance signal to correct for skin morphology and sample 
tilt, and averaged to obtain mean and standard deviation of the 3D fluorescence 
distribution. The 2-dimensional fluorescence profiles were obtained calculating the 
average intensity distribution of the 4 radial sections (planes xz and yz) along the 
directions of the neighbouring projections. 
 
Elimination of the noise 
The 2D section profiles were padded to avoid filter edge-effects. We replicated the 
images laterally exploiting array periodicity and created margins extending the intensity 
values of the top and bottom rows. Then we convoluted the 2D-section images with disk-
averaging filters having different cut-off radii (10, 15, 20, 25, 30 pixels). 
 
Extrapolation of the diffusivity from the mean 2D intensity 
The diffusivity D can be calculated using Fick’s 2nd law of diffusion, 
  


D
t
,           (1) 
where =(x, y, z; t) is the dye concentration. The diffusivity is assumed to be isotropic, 
independent of the concentration and approximately constant within each voxel such that 
dD/D <<1 [188] so that Eq. 1 becomes 


2


 tD .           (2) 
If we approximate the concentration to be linearly proportional to the fluorescence intensity 
I, a 2D map of diffusivity of the skin section can be calculated from each pair of time-points 
(2-4, 2-7, 2-10, 4-7, 4-10, 7-10 minutes) using 
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where the derivatives are now discrete differences between the intensities of time and 
space-consecutive pixels. For example,  
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       (4) 
We assume that the diffusivity is constant in time and calculate the mean xz-map D(x, z) of 
the skin section (not shown) and standard deviation (x ,z) across all 6 time-point pairs. 
Note that we have 5 mean maps per molecular weight, from 5 different filters. 
 
Diffusivity as a function of depth through best filter selection 
The diffusivity as a function of depth z was found performing a weighted average of 
the values of D(x,z) along x, with weights w(x,z)=1/(x ,z). The weights allow to take into 
account the lower reliability of D(x, z) regions such as the image edges where the 
diffusivity value has high variance (x ,z). The formulas of the weighted mean and 
variance are respectively [189] 
 
                 (5) 
 
          (6) 
 
 
 
The pixels close to the hole that showed a consistent negative value with low 
deviation were not considered to exclude the mass-source effect of the coating dissolution. 
Note that a standard unweighted average gave similar results but this analysis allows the 
weighted error w(z) to propagate the uncertainty (x,z) across this new averaging step. 
Among the 5 curves Dw(z) from the different filters, the one that minimizes the standard 
deviation w(z) was chosen to represent the final diffusivity Dw(z) of each molecular 
weight. As a general rule the low-radius filters were accurate in shallow regions, whereas 
stronger filtering is needed in depth where the data are the noisiest.  
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A posterior verification of assumptions 
The assumption dD/D <<1 was proven a posteriori from the diffusivity results. The width of 
the error-bars in Figure 7.6 are the maximum between the propagated error and 
zDw(z)/Dw(z). The effect of skin light scattering and absorption on the relationship 
between fluorophore concentration and fluorescence intensity was investigated correcting 
the 2D images with a test attenuation factor = 100 m-1 [190, 191]. Diffusivity was 
recalculated from the new intensity I0, using the exponential decay law I = I0 e
-z
. The 
results showed negligible variation. 
 
